<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0082">
    <title>65 Mycoplasma and Ureaplasma</title>
    <sect1 id="ch0082s0001">
      <title>65 Mycoplasma and Ureaplasma</title>
      <anchor id="ch0082s0001a0001"/>
      <anchor id="ch0082s0000a0001"/>
      <para role="chapterAuthor"><phrase role="center">KEN B. WAITES AND CÉCILE BÉBÉAR</phrase>
      </para>
      <sect2 id="ch0082s0001s0001">
        <title>TAXONOMY</title>
        <anchor id="ch0082s0001a0002"/>
        <anchor id="ch0082s0000a0002"/>
        <para id="ch0082s0000p0001">Bacteria commonly referred to as mycoplasmas (“fungus-form”) are included within the class<emphasis>Mollicutes</emphasis> (“soft skin”), which is composed of 4 orders, 5 families, 8 genera, and about 200 known species (<anchor id="ch0082s0000a0003"/><link linkend="ch0082s0000a0011">Table 1</link>). New species, mainly in animals, are still being identified. <anchor id="ch0082s0000a0004"/><link linkend="ch0082s0000a0018">Table 2</link> lists the 16 species isolated from humans on multiple occasions, excluding species of animal origin which are detected occasionally in humans, usually in immunosuppressed hosts, but which are generally considered transient colonizers. <emphasis>Mycoplasma amphoriforme</emphasis> is the most recent species to have been recognized and has been recovered from the respiratory tracts of several patients with antibody deficiency and chronic bronchitis or bronchiectasis (<link linkend="ch0082s0000li0001">1</link>). <emphasis>Mollicutes</emphasis> are eubacteria that have evolved from <emphasis>Clostridium</emphasis>-like Gram-positive cells through genome reduction. The availability of species-specific PCR and next-generation sequencing (NGS) technology is ameliorating difficulties of both culture and identification for fastidious <emphasis>Mollicutes.</emphasis> Additional noncultivable, and thus presently unknown, species are likely to be discovered.</para>
      </sect2>
      <sect2 id="ch0082s0001s0002">
        <title>DESCRIPTION OF MOLLICUTES</title>
        <anchor id="ch0082s0001a0003"/>
        <anchor id="ch0082s0000a0005"/>
        <para id="ch0082s0000p0002">The term “mycoplasma” is often used in a trivial way to refer to any members of the class<emphasis>Mollicutes</emphasis>, irrespective of whether they actually belong to the genus <emphasis>Mycoplasma.</emphasis> It is more accurate to refer to the class with the trivial term “mollicute(s)” and to organisms within the individual genera as “mycoplasmas,” “ureaplasmas,” “acholeplasmas,” etc. <emphasis>Mollicutes</emphasis> are smaller than conventional bacteria, in cellular dimensions as well as genome size, making them the smallest free-living organisms known. <emphasis>Mollicutes</emphasis> associated with humans range from coccoid cells of about 0.2 to 0.3 μm in diameter, as in <emphasis>Ureaplasma</emphasis> spp. and <emphasis>Mycoplasma hominis</emphasis> (<link linkend="ch0082s0000li0002">2</link>), to tapered rods 1 to 2 μm in length and 0.1 to 0.2 μm in width, as in the case of <emphasis>Mycoplasma pneumoniae</emphasis> (<link linkend="ch0082s0000li0003">3</link>). Mollicutes are contained by a trilayered cell membrane and do not possess a cell wall. The permanent lack of a cell wall barrier makes them unique among prokaryotes and differentiates them from bacterial L forms, for which the lack of the cell wall is a temporary reflection of environmental conditions. Lack of a cell wall also renders them nonsusceptible to the activity of β-lactam antimicrobials, prevents them from staining with the Gram stain, and is largely responsible for their pleomorphic form. Extremely small genome sizes (&lt;600 kb in the case of <emphasis>Mycoplasma genitalium</emphasis>) and limited biosynthetic capabilities explain the parasitic or saprophytic existence of these organisms, their sensitivity to environmental conditions, and their fastidious growth requirements, which can complicate detection by culture.</para>
        <para id="ch0082s0000p0003"><emphasis>Mollicutes</emphasis> require enriched growth medium supplemented with nucleic acid precursors. Except for acholeplasmas, asteroleplasmas, and mesoplasmas, they require sterols in growth media, supplied by the addition of serum. Growth rates in culture medium vary among individual species, with generation times of approximately 1 h for <emphasis>Ureaplasma</emphasis> spp., 6 h for <emphasis>M. pneumoniae</emphasis>, and 16 h for <emphasis>M. genitalium</emphasis> (<link linkend="ch0082s0000li0004">4</link>).</para>
        <para id="ch0082s0000p0004">Typical colonies vary from 15 to 300 μm in diameter. Colonies of some species, such as<emphasis>M. hominis</emphasis>, often exhibit a “fried-egg” appearance owing to the contrast in deeper growth in the center of the colony with more shallow growth at the periphery (<anchor id="ch0082s0000a0006"/><link linkend="ch0082s0000a0027">Fig. 1</link>), while others, such as <emphasis>M. pneumoniae</emphasis>, produce spherical colonies (<anchor id="ch0082s0000a0007"/><link linkend="ch0082s0000a0028">Fig. 2</link>). Whereas colonies of <emphasis>Mycoplasma</emphasis> species may be observed with the naked eye, those produced by ureaplasmas are typically 15 to 60 μm in diameter and require low-power microscopic magnification for visualization (<anchor id="ch0082s0000a0008"/><link linkend="ch0082s0000a0029">Fig. 3</link>).</para>
        <para id="ch0082s0000p0005">Mycoplasmas and ureaplasmas of human origin can be classified according to whether they utilize glucose, arginine, or urea (<link linkend="ch0082s0000a0018">Table 2</link>). Except for utilization of urea for generation of metabolic energy, which is unique for ureaplasmas, these biochemical features are not sufficient for species distinction. Anaeroplasmas and asteroleplasmas, which occur in ruminants, are strictly anaerobic and oxygen sensitive, while most other <emphasis>Mollicutes</emphasis> are facultative anaerobes.</para>
        <para id="ch0082s0000p0006">Attachment of<emphasis>M. pneumoniae</emphasis> to host cells in the respiratory tract of humans is a prerequisite for colonization and infection. Cytoadherence, mediated by the P1 adhesin and other accessory proteins, described in detail in other publications (<link linkend="ch0082s0000li0005">5</link>, <link linkend="ch0082s0000li0006">6</link>) is followed by induction of chronic inflammation, and cytotoxicity mediated by hydrogen peroxide. <emphasis>M. pneumoniae</emphasis> stimulates B and T lymphocytes and induces formation of autoantibodies which react with a variety of host tissues and the I antigen on erythrocytes, which is responsible for production of cold agglutinins. An ADP-ribosylating toxin with significant sequence homology to the pertussis toxin S1 subunit, now known as the community-acquired respiratory distress syndrome (CARDS) toxin that causes vacuolation and ciliostasis in cultured host cells, has been described in <emphasis>M. pneumoniae</emphasis> (<link linkend="ch0082s0000li0007">7</link>). A murine model has shown that CARDS toxin concentrations in bronchoalveolar lavage fluid are directly linked to the ability of specific <emphasis>M. pneumoniae</emphasis> strains to colonize, replicate, and persist and to elicit lung histopathology. Variation among strains may predict the range in severity of pulmonary disease observed among patients (<link linkend="ch0082s0000li0008">8</link>). The CARDS toxin is also being studied as a gene target for PCR assays and as an antigen for use in serologic assays. <emphasis>M. genitalium</emphasis> also possesses a terminal structure, the MgPa adhesin, which facilitates its attachment to epithelial cells (<link linkend="ch0082s0000li0009">9</link>). Factors involved with <emphasis>Ureaplasma</emphasis> species and <emphasis>M. hominis</emphasis> attachment are not characterized to the same extent as for <emphasis>M. pneumoniae</emphasis>, and they do not have prominent attachment organelles. Henrich et al. (<link linkend="ch0082s0000li0010">10</link>) demonstrated the presence of the variable adherence-associated antigen (Vaa), which is believed to be a major adhesin of <emphasis>M. hominis</emphasis> and could also assist in evasion of host immune responses through antigenic variation. Ureaplasmas also attach to a variety of cell types, mediated by adhesin proteins expressed on the surface of the bacterial cell. The MB antigen contains serotype-specific and cross-reactive epitopes and is a prominent antigen recognized during human ureaplasmal infections (<link linkend="ch0082s0000li0011">11</link>). Ureaplasma<emphasis>s</emphasis> are known to produce IgA protease, even though genes encoding this protein have not been identified in their genome; they release ammonia through urealytic activity.</para>
        <anchor id="ch0082s0000a0009"/>
        <beginpage pagenum="1238"/>
        <anchor id="ch0082s0000a0010"/>
        <beginpage pagenum="1239"/>
        <table id="ch0082s0000t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0082s0000a0011"/><link linkend="ch0082s0000a0003">TABLE 1</link></phrase></emphasis> Classification and some distinguishing features of mycoplasmas (class <emphasis>Mollicutes</emphasis>)
</title>
          
          <tgroup cols="5">
            <tbody>
              <row>
                <entry><phrase role="center">Classification of class <emphasis>Mollicutes</emphasis> (no. of species)</phrase>
                </entry>
                <entry><phrase role="center">Distinguishing features</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="center">Sterol requirement</phrase>
                </entry>
                <entry><phrase role="center">Genome size (kbp)</phrase>
                </entry>
                <entry><phrase role="center">Mol% G+C of DNA</phrase>
                </entry>
                <entry><phrase role="left">Other</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Order I: <emphasis>Mycoplasmatales</emphasis></phrase>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry><phrase role="left">Vertebrate hosts</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Family I: <emphasis>Mycoplasmataceae</emphasis></phrase>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry><phrase role="left">Sterol requirement</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Genus I: <emphasis>Mycoplasma</emphasis> (119)<superscript><emphasis><anchor id="ch0082s0000a0012"/><link linkend="ch0082s0000a0015">a</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">Yes</phrase>
                </entry>
                <entry><phrase role="center">580–1,350</phrase>
                </entry>
                <entry><phrase role="center">23–40</phrase>
                </entry>
                <entry/>
              </row>
              <row>
                <entry><phrase role="left">Genus II: <emphasis>Ureaplasma</emphasis> (7)<superscript><emphasis><anchor id="ch0082s0000a0013"/><link linkend="ch0082s0000a0016">b</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">Yes</phrase>
                </entry>
                <entry><phrase role="center">730–1,170</phrase>
                </entry>
                <entry><phrase role="center">25–32</phrase>
                </entry>
                <entry><phrase role="left">Hydrolyzes urea</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Order II: <emphasis>Entomoplasmatales</emphasis></phrase>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry><phrase role="left">Plant/insect hosts</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Family I: <emphasis>Entomoplasmataceae</emphasis></phrase>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry><phrase role="left">Nonhelical structure</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Genus I: <emphasis>Entomoplasma</emphasis> (6)</phrase>
                </entry>
                <entry><phrase role="center">Yes</phrase>
                </entry>
                <entry><phrase role="center">870–900</phrase>
                </entry>
                <entry><phrase role="center">27–34</phrase>
                </entry>
                <entry><phrase role="left">Sterol requirement</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Genus II: <emphasis>Mesoplasma</emphasis> (11)</phrase>
                </entry>
                <entry><phrase role="center">No</phrase>
                </entry>
                <entry><phrase role="center">825–930</phrase>
                </entry>
                <entry><phrase role="center">26–32</phrase>
                </entry>
                <entry><phrase role="left">Sterol requirement +/−</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Family II: <emphasis>Spiroplasmataceae</emphasis></phrase>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry><phrase role="left">Helical structure</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Genus I: <emphasis>Spiroplasma</emphasis> (38)</phrase>
                </entry>
                <entry><phrase role="center">Yes</phrase>
                </entry>
                <entry><phrase role="center">780–2,200</phrase>
                </entry>
                <entry><phrase role="center">24–31</phrase>
                </entry>
                <entry><phrase role="left">Sterol requirement +/−</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Order III: <emphasis>Acholeplasmatales</emphasis><superscript><emphasis><anchor id="ch0082s0000a0014"/><link linkend="ch0082s0000a0017">c</link></emphasis></superscript></phrase>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><phrase role="left">Family I: <emphasis>Acholeplasmataceae</emphasis></phrase>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><phrase role="left">Genus I: <emphasis>Acholeplasma</emphasis> (18)</phrase>
                </entry>
                <entry><phrase role="center">No</phrase>
                </entry>
                <entry><phrase role="center">1,500–1,650</phrase>
                </entry>
                <entry><phrase role="center">26–36</phrase>
                </entry>
                <entry><phrase role="left">Sterols not required</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Order IV: <emphasis>Anaeroplasmatales</emphasis></phrase>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry><phrase role="left">Obligate anaerobes</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Family I: <emphasis>Anaeroplasmataceae</emphasis></phrase>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><phrase role="left">Genus I: <emphasis>Anaeroplasma</emphasis> (4)</phrase>
                </entry>
                <entry><phrase role="center">Yes</phrase>
                </entry>
                <entry><phrase role="center">1,500–1,600</phrase>
                </entry>
                <entry><phrase role="center">29–33</phrase>
                </entry>
                <entry><phrase role="left">Sterol requirement</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Genus II: <emphasis>Asteroleplasma</emphasis> (1)</phrase>
                </entry>
                <entry><phrase role="center">No</phrase>
                </entry>
                <entry><phrase role="center">1,500</phrase>
                </entry>
                <entry><phrase role="center">40</phrase>
                </entry>
                <entry><phrase role="left">Sterols not required</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">“<emphasis>Candidatus</emphasis> Phytoplasma”<superscript><emphasis><link linkend="ch0082s0000a0017">c</link></emphasis></superscript> (41)</phrase>
                </entry>
                <entry><phrase role="center">Unknown</phrase>
                </entry>
                <entry><phrase role="center">530–1,350</phrase>
                </entry>
                <entry><phrase role="center">23–29</phrase>
                </entry>
                <entry/>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0015"/><link linkend="ch0082s0000a0012">a</link></emphasis></superscript>The total number includes subspecies. The genus <emphasis>Mycoplasma</emphasis> also includes several <emphasis>Candidatus</emphasis> species of cell wall-less uncultivated parasitic bacteria. Some were previously classified in the genera <emphasis>Haemobartonella</emphasis> and <emphasis>Eperythrozoon.</emphasis> Their guanine-plus-cytosine content and sterol requirements are unknown.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0016"/><link linkend="ch0082s0000a0013">b</link></emphasis></superscript><emphasis>U. urealyticum</emphasis> and <emphasis>U. parvum</emphasis>, formerly considered biovars of <emphasis>U. urealyticum</emphasis>, were reclassified as two separate species and are the only ureaplasmas of human origin.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0017"/><link linkend="ch0082s0000a0014">c</link></emphasis></superscript>Phytoplasmas are <emphasis>Candidatus</emphasis> species of mollicutes of plants and insects genetically related to the <emphasis>Acholeplasmatales.</emphasis></para>
        <table id="ch0082s0000t0002"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0082s0000a0018"/><link linkend="ch0082s0000a0004">TABLE 2</link></phrase></emphasis> <emphasis>Mycoplasma</emphasis> species isolated from humans on multiple occasions<superscript><emphasis><anchor id="ch0082s0000a0019"/><link linkend="ch0082s0000a0023">a</link></emphasis></superscript>
</title>
          
          <tgroup cols="6">
            <tbody>
              <row>
                <entry><phrase role="center">Species</phrase>
                </entry>
                <entry><phrase role="center">Primary site of colonization</phrase>
                </entry>
                <entry><phrase role="center">Metabolism of:</phrase>
                </entry>
                <entry><phrase role="center">Pathogenicity</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="center">Respiratory tract</phrase>
                </entry>
                <entry><phrase role="center">Genitourinary tract</phrase>
                </entry>
                <entry><phrase role="center">Glucose</phrase>
                </entry>
                <entry><phrase role="center">Arginine</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>M. salivarium</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>M. orale</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>M. buccale</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>M. faucium</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>M. lipophilum</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>M. amphoriforme</emphasis>
                    <superscript>
                      <emphasis>
                        <anchor id="ch0082s0000a0020"/>
                        <link linkend="ch0082s0000a0024">b</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
                <entry><phrase role="center">?+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">?</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>M. pneumoniae</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>M. hominis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>M. genitalium</emphasis>
                    <superscript>
                      <emphasis>
                        <anchor id="ch0082s0000a0021"/>
                        <link linkend="ch0082s0000a0025">c</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>M. fermentans</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>M. primatum</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>M. spermatophilum</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>M. pirum</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">?</phrase>
                </entry>
                <entry><phrase role="center">?</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>M. penetrans</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">?</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>U. parvum</emphasis>
                    <superscript>
                      <emphasis>
                        <anchor id="ch0082s0000a0022"/>
                        <link linkend="ch0082s0000a0026">d</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>U. urealyticum</emphasis>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0082s0000a0026">d</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>A. laidlawii</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0023"/><link linkend="ch0082s0000a0019">a</link></emphasis></superscript>+ indicates positive for trait; − indicates negative for trait; ? indicates unknown.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0024"/><link linkend="ch0082s0000a0020">b</link></emphasis></superscript>All isolates reported to date have been from the lower respiratory tract, but no other sites have been sampled.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0025"/><link linkend="ch0082s0000a0021">c</link></emphasis></superscript>This organism has been found in the oropharynx, but it seems unlikely that this is a common or primary location.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0026"/><link linkend="ch0082s0000a0022">d</link></emphasis></superscript>Metabolizes urea.</para>
        <figure id="ch0082s0000f0001"><title><phrase role="figureLabel"><anchor id="ch0082s0000a0027"/><link linkend="ch0082s0000a0006">FIGURE 1</link></phrase> Fried-egg-type colonies of <emphasis>Mycoplasma hominis</emphasis> up to 110 μm in diameter. Magnification, ×132.</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0082f04.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <figure id="ch0082s0000f0002"><title><phrase role="figureLabel"><anchor id="ch0082s0000a0028"/><link linkend="ch0082s0000a0007">FIGURE 2</link></phrase> Spherical colonies of <emphasis>Mycoplasma pneumoniae</emphasis> up to 100 μm in diameter. Magnification, ×126.</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0082f05.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <figure id="ch0082s0000f0003"><title><phrase role="figureLabel"><anchor id="ch0082s0000a0029"/><link linkend="ch0082s0000a0008">FIGURE 3</link></phrase> Granular brown urease-positive colonies of <emphasis>Ureaplasma</emphasis> species 15 to 60 μm in diameter from a vaginal specimen growing on A8 agar. Magnification, ×100.</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0082f03.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
      </sect2>
      <sect2 id="ch0082s0001s0003">
        <title>EPIDEMIOLOGY AND TRANSMISSION</title>
        <anchor id="ch0082s0001a0004"/>
        <anchor id="ch0082s0000a0030"/>
        <para id="ch0082s0000p0007"><emphasis>Mollicutes</emphasis> are common in practically all mammalian species, as well as many other vertebrates in which they have been sought. Although most have species-specific host-organism associations, some mycoplasmas and acholeplasmas of animal origin occur in a wide variety of different animal hosts. <emphasis>Mollicutes</emphasis> in the genera <emphasis>Spiroplasma, Mesoplasma, Entomoplasma</emphasis>, and <emphasis>Acholeplasma</emphasis> can be isolated from insects and plants.</para>
        <para id="ch0082s0000p0008">In humans, mycoplasmas and ureaplasmas are associated with mucosal surfaces, residing predominantly in the respiratory or urogenital tracts and rarely penetrating the submucosa, except in cases of immunosuppression or instrumentation, when they can invade the bloodstream and disseminate to many different organs and tissues throughout the body. Many exist as commensals in the oropharynx or urogenital tract (<link linkend="ch0082s0000a0018">Table 2</link>) and have been associated with invasive disease only in rare circumstances. <emphasis>M. fermentans</emphasis> has been detected by culture and PCR assays in various body sites, including the urogenital tract, throat, lower respiratory tract and other body locations, including joints, but its primary site of colonization and true disease potential are incompletely understood (<link linkend="ch0082s0000li0011">11</link>). Oral commensal mycoplasmas can occasionally spread to the lower respiratory tract and show up in cultures, but they should not cause diagnostic confusion with <emphasis>M. pneumoniae</emphasis> if appropriate means of organism identification are employed.</para>
        <para id="ch0082s0000p0009">Urogenital mycoplasmas of clinical importance include<emphasis>Mycoplasma genitalium</emphasis>, a sexually transmitted pathogen, and <emphasis>Mycoplasma hominis</emphasis> and <emphasis>Ureaplasma</emphasis> spp., commensals of the human urogenital tract. Frequent occurrence of <emphasis>M. hominis</emphasis> and ureaplasmas in the lower urogenital tract in healthy men and women has complicated understanding of their disease-producing capabilities. Various investigations found that <emphasis>M. genitalium</emphasis> is much less common in the lower urogenital tracts of healthy males and females than <emphasis>M. hominis</emphasis> and <emphasis>Ureaplasma</emphasis> spp., with a prevalence ranging from 1 to 3.3% in the general European and U.S. population (<link linkend="ch0082s0000li0012">12</link>–<link linkend="ch0082s0000li0014">14</link>). In a recent meta-analysis from the general population, the summary prevalence of <emphasis>M. genitalium</emphasis> was 1.3% in countries with higher levels of development and 3.9% in countries with lower levels (<link linkend="ch0082s0000li0015">15</link>). Other species, as shown in <link linkend="ch0082s0000a0018">Table 2</link>, can also occur in the lower urogenital tract but are not known to be associated with disease. PCR assays demonstrate the frequent occurrence of <emphasis>M. genitalium</emphasis> in the urogenital tract in men with urethritis and in women with cervicitis.</para>
        <anchor id="ch0082s0000a0031"/>
        <beginpage pagenum="1240"/>
        <para id="ch0082s0000p0010">Generally considered to be extracellular organisms, intracellular localization is now appreciated for<emphasis>Mycoplasma fermentans, M. penetrans, M. genitalium, M. hominis</emphasis> and <emphasis>M. pneumoniae</emphasis> (<link linkend="ch0082s0000li0016">16</link>). Intracellular localization may be responsible for protecting the organisms from antibodies and antibiotics, as well as contributing to disease chronicity and difficulty in cultivation in some cases. Variation in surface antigens of <emphasis>M. hominis</emphasis> and <emphasis>Ureaplasma</emphasis> spp. can be related to persistence at invasive sites. In humans, mycoplasmas and ureaplasmas can be transmitted by direct contact between hosts, i.e., sexually through genital-genital or oral-genital contact, vertically from mother to offspring either at birth or <emphasis>in utero</emphasis>, by respiratory aerosols or fomites in the case of <emphasis>M. pneumoniae</emphasis>, or even by nosocomial acquisition through transplanted tissues for urogenital <emphasis>Mollicutes</emphasis> (<link linkend="ch0082s0000li0011">11</link>, <link linkend="ch0082s0000li0017">17</link>, <link linkend="ch0082s0000li0018">18</link>).</para>
      </sect2>
      <sect2 id="ch0082s0001s0004">
        <title>CLINICAL SIGNIFICANCE</title>
        <anchor id="ch0082s0001a0005"/>
        <anchor id="ch0082s0000a0032"/>
      </sect2>
    </sect1>
    <sect1 id="ch0082s0002">
      <title>Respiratory Infections</title>
      <anchor id="ch0082s0002a0001"/>
      <anchor id="ch0082s0000a0033"/>
      <para id="ch0082s0000p0011"><emphasis>M. pneumoniae</emphasis> was first identified and described in the early 1960s. It causes approximately 4 to 8% of community-acquired pneumonias in the general population during periods of endemicity and up to 20 to 40% during periods of epidemicity, as well as up to 70% of pneumonias in certain confined groups (<link linkend="ch0082s0000li0006">6</link>). Although <emphasis>M. pneumoniae</emphasis> has long been associated with pneumonias in school-aged children, adolescents, and young adults, in recent years this organism was shown to cause disease in older persons, as well as children under 5 years of age (<link linkend="ch0082s0000li0006">6</link>). The most typical clinical syndrome is tracheobronchitis, often accompanied by upper respiratory tract manifestations, such as acute pharyngitis. Pneumonia develops in about one-third of those infected. The incubation period is generally 2 to 3 weeks, and spread throughout households is common. <emphasis>M. pneumoniae</emphasis> was recently found to be carried in the upper respiratory tracts of 21% of asymptomatic children (<link linkend="ch0082s0000li0019">19</link>). The organism can persist in the respiratory tract for several months after initial infection and sometimes for years in hypogammaglobulinemic patients, possibly because it attaches strongly to and invades epithelial cells. Subclinical infections are common, and the disease is ordinarily mild. However, severe infections requiring hospitalization and even deaths are known to occur (<link linkend="ch0082s0000li0006">6</link>, <link linkend="ch0082s0000li0020">20</link>).</para>
      <para id="ch0082s0000p0012">Extrapulmonary complications of<emphasis>M. pneumoniae</emphasis> infections include meningoencephalitis, ascending paralysis, transverse myelitis, Bell palsy, myocarditis, endocarditis, pericarditis, hemolytic anemia, arthritis, glomerular diseases, and mucocutaneous lesions (<link linkend="ch0082s0000li0006">6</link>, <link linkend="ch0082s0000li0021">21</link>). An autoimmune response is thought to play a role in some extrapulmonary complications. However, <emphasis>M. pneumoniae</emphasis> has been isolated directly from cerebrospinal, pericardial, and synovial fluids, as well as other extrapulmonary sites, and additional evidence of direct invasion by the use of PCR is documented (<link linkend="ch0082s0000li0021">21</link>).</para>
      <para id="ch0082s0000p0013">Clinical manifestations are not sufficiently unique to allow differentiation from infections caused by other common bacteria, particularly<emphasis>Chlamydia pneumoniae.</emphasis> Data from animal models as well as clinical studies have suggested a potential role for <emphasis>M. pneumoniae</emphasis> as an etiologic or exacerbating factor in bronchial asthma, and clinical studies have linked this organism to stable as well as exacerbating disease (<link linkend="ch0082s0000li0005">5</link>, <link linkend="ch0082s0000li0006">6</link>, <link linkend="ch0082s0000li0022">22</link>, <link linkend="ch0082s0000li0023">23</link>).</para>
      <para id="ch0082s0000p0014"><emphasis>Mycoplasma amphoriforme</emphasis> was initially detected in the lower respiratory tract in a series of patients with antibody deficiency and chronic bronchitis or bronchiectasis (<link linkend="ch0082s0000li0001">1</link>). Its biochemical reactivity, colonial appearance, growth characteristics, and gliding motility are like those of <emphasis>M. pneumoniae</emphasis>, but it is genetically distinct. Repeated isolations over time and clinical improvement after antimicrobial therapy with elimination of the microorganism suggest a possible pathogenic role in lower respiratory tract infections, but more work must be done to determine the extent of disease that may be due to this organism. Most reports of this species from persons with lower respiratory infections have come from various European countries over the past 2 decades (<link linkend="ch0082s0000li0024">24</link>).</para>
    </sect1>
    <sect1 id="ch0082s0003">
      <title>Genitourinary Infections</title>
      <anchor id="ch0082s0003a0001"/>
      <anchor id="ch0082s0000a0034"/>
      <para id="ch0082s0000p0015">Following puberty,<emphasis>Ureaplasma</emphasis> spp. and <emphasis>M. hominis</emphasis> may occur as commensals in the lower genital tract in many healthy sexually active adults, but there is evidence that these organisms play etiologic roles in some genital tract diseases. Results of human and animal inoculation studies and observations of immunocompromised persons are supportive of ureaplasmas being a cause of nonchlamydial, nongonococcal urethritis (NGU) in men (<link linkend="ch0082s0000li0025">25</link>). <emphasis>Ureaplasma urealyticum</emphasis> in high bacterial loads might cause a small proportion of male NGU, but most men and women infected/colonized with <emphasis>U. urealyticum</emphasis> do not develop disease.</para>
      <para id="ch0082s0000p0016">Since the identification of two distinct biovars of<emphasis>U. urealyticum</emphasis>, now considered as separate species, biovar 2 (<emphasis>U. urealyticum</emphasis>) has been implicated in NGU, whereas biovar 1 (<emphasis>Ureaplasma parvum</emphasis>) has not been implicated in this manner in most studies (<link linkend="ch0082s0000li0026">26</link>–<link linkend="ch0082s0000li0029">29</link>). There have been attempts to link various disease conditions with individual <emphasis>Ureaplasma</emphasis> serovars. However, recent evidence suggests that individual serovars rarely occur alone and horizontal gene transfer among the various serovars occurs to a significant extent, making the individual distinct serovar concept no longer tenable (<link linkend="ch0082s0000li0026">26</link>).</para>
      <para id="ch0082s0000p0017">Evidence that<emphasis>M. hominis</emphasis> causes NGU is lacking, but <emphasis>M. genitalium</emphasis> has been detected by PCR technology significantly more often in urethral specimens from men with acute NGU than from those without urethritis and is now considered one of the causes of the disease. Following puberty, <emphasis>Ureaplasma</emphasis> spp. and <emphasis>M. hominis</emphasis> may occur as commensals in the lower genital tract in healthy sexually active adults; there is evidence that these organisms play etiologic roles in some genital tract diseases. Evidence that <emphasis>M. hominis</emphasis> causes NGU is lacking. <emphasis>M. genitalium</emphasis> has been detected by PCR significantly more often in urethral specimens from men with acute disease (<link linkend="ch0082s0000li0030">30</link>). <emphasis>M. genitalium-</emphasis>positive men have been found to have symptomatic urethritis significantly more often than those infected with <emphasis>Chlamydia trachomatis</emphasis> (<link linkend="ch0082s0000li0031">31</link>). The prevalence of <emphasis>M. genitalium</emphasis> in men with NGU ranges from 10 to 35% (<link linkend="ch0082s0000li0014">14</link>). Moreover, <emphasis>M. genitalium</emphasis> could be responsible for up to 30% of male persistent urethritis (<link linkend="ch0082s0000li0032">32</link>). Antibody responses have been detected in some men with acute disease and this mycoplasma has also produced urethritis in nonhuman primates (<link linkend="ch0082s0000li0030">30</link>). <emphasis>M. genitalium</emphasis> also may be a rare cause of conjunctivitis associated with urethritis as a result of direct invasion of both sites, as documented by PCR (<link linkend="ch0082s0000li0033">33</link>). Thus, in symptomatic men with NGU, sexually transmitted pathogens such as <emphasis>Neisseria gonorrhoeae, C. trachomatis</emphasis>, and <emphasis>M. genitalium</emphasis> should be excluded prior to <emphasis>U. urealyticum</emphasis> testing (<link linkend="ch0082s0000li0034">34</link>). In a recent U.S. study, <emphasis>M. penetrans</emphasis> was involved in some cases of urethritis in men who have sex with men (<link linkend="ch0082s0000li0035">35</link>).</para>
      <anchor id="ch0082s0000a0035"/>
      <beginpage pagenum="1241"/>
      <para id="ch0082s0000p0018"><emphasis>M. hominis</emphasis> and <emphasis>Ureaplasma</emphasis> spp. have not been detected by culture of prostatic biopsy samples from patients with chronic abacterial prostatitis (<link linkend="ch0082s0000li0036">36</link>), but <emphasis>M. genitalium</emphasis> has been rarely found using PCR (<link linkend="ch0082s0000li0037">37</link>). In contrast, ureaplasmas have been recovered from an epididymal aspirate from a patient with nonchlamydial, nongonococcal acute epididymo-orchitis accompanied by a specific antibody response (<link linkend="ch0082s0000li0038">38</link>) and could be an infrequent cause of the disease. <emphasis>Ureaplasma</emphasis> spp. produce urease and induce crystallization of struvite and calcium phosphates in urine <emphasis>in vitro</emphasis> and calculi in animal models, and they have been found in urinary calculi of patients with infection-type stones more frequently than those with metabolic-type stones, suggesting a possible causal association (<link linkend="ch0082s0000li0039">39</link>). <emphasis>M. hominis</emphasis> has been isolated from bladder urine and the upper urinary tracts of patients with symptoms of acute or chronic pyelonephritis, significantly more often than from patients with noninfectious urinary tract diseases, often with an antibody response (<link linkend="ch0082s0000li0040">40</link>–<link linkend="ch0082s0000li0042">42</link>). In one study, <emphasis>M. hominis</emphasis> was isolated from the upper urinary tract of 7 of 80 patients (8.8%) with acute pyelonephritis and 0 of 60 patients with noninfectious diseases of the urinary tract (<link linkend="ch0082s0000li0042">42</link>). Additional studies are needed to confirm the frequency of <emphasis>M. hominis</emphasis> as a pathogen in upper urinary tract disease since <emphasis>Mollicutes</emphasis> are rarely sought routinely in patients with kidney disease of suspected infectious origin. Obstruction or instrumentation of the urinary tract are predisposing factors. Ureaplasmas have not been associated in the same way.</para>
      <para id="ch0082s0000p0019"><emphasis>Mollicutes</emphasis> do not cause vaginitis but are among various microorganisms that proliferate in patients with bacterial vaginosis (BV). Some studies suggest that <emphasis>M. hominis</emphasis> contributes to BV (<link linkend="ch0082s0000li0043">43</link>), but evidence is lacking for an association with ureaplasmas (<link linkend="ch0082s0000li0011">11</link>, <link linkend="ch0082s0000li0025">25</link>). A recent study showed that, in women with BV, <emphasis>M. hominis</emphasis> colonization appeared to accentuate symptoms, but no association with signs or symptoms could be found in women without BV (<link linkend="ch0082s0000li0044">44</link>). The independent association of <emphasis>M. genitalium</emphasis> with BV is controversial, as in some studies an association has been shown (<link linkend="ch0082s0000li0013">13</link>), while in others a relationship has not been demonstrated (<link linkend="ch0082s0000li0043">43</link>, <link linkend="ch0082s0000li0045">45</link>). BV has been associated with cervicitis, endometritis, salpingitis, and tubal factor infertility (<link linkend="ch0082s0000li0046">46</link>), and <emphasis>M. hominis</emphasis> has been isolated from the endometrium and fallopian tubes of about 10% of women with salpingitis diagnosed by laparoscopy, accompanied by a specific antibody response (<link linkend="ch0082s0000li0047">47</link>). The significance of this microorganism is difficult to assess in an individual case when several microorganisms are present. Nevertheless, serological evidence suggests that <emphasis>M. hominis</emphasis> could be an independent factor in tubal factor infertility (<link linkend="ch0082s0000li0048">48</link>). <emphasis>Ureaplasma</emphasis> spp. have been isolated from affected fallopian tubes, but not in pure culture. Moreover, negative results of serologic tests, inoculation of nonhuman primates, and fallopian tube organ cultures do not support a causal role for ureaplasmas as sole pathogens in pelvic inflammatory disease (PID) (<link linkend="ch0082s0000li0025">25</link>). <emphasis>M. genitalium</emphasis> can, however, play a role in PID, as indicated by its association with cervicitis (<link linkend="ch0082s0000li0045">45</link>, <link linkend="ch0082s0000li0059">59</link>, <link linkend="ch0082s0000li0050">50</link>) and endometritis (<link linkend="ch0082s0000li0051">51</link>). In a recent meta-analysis (<link linkend="ch0082s0000li0052">52</link>), significant associations were found between <emphasis>M. genitalium</emphasis> and cervicitis and PID. In addition, serologic and direct evidence has also shown an association with increased risk of <emphasis>M. genitalium</emphasis> infection and tubal infertility (<link linkend="ch0082s0000li0052">52</link>). That ureaplasmas might cause infertility still remains speculative (<link linkend="ch0082s0000li0053">53</link>).</para>
      <para id="ch0082s0000p0020">In cross-sectional and longitudinal studies, an association between<emphasis>M. genitalium</emphasis> and HIV infection has been found. This microorganism is found more frequently at both urethral and rectal sites of HIV-positive men who have sex with men than those who are HIV negative (<link linkend="ch0082s0000li0054">54</link>), and <emphasis>M. genitalium</emphasis>-induced cervicitis (<link linkend="ch0082s0000li0055">55</link>) occurs more often in HIV-positive than -negative women. Women who have a high burden of <emphasis>M. genitalium</emphasis> were more likely to shed HIV-1 than were <emphasis>M. genitalium</emphasis>-negative women, an observation in keeping with the ability of mycoplasmas to stimulate HIV replication (<link linkend="ch0082s0000li0056">56</link>) and possibly enhance viral transmission. The significant positive association between <emphasis>M. genitalium</emphasis> and HIV infection is also strongly supported by the result of a meta-analysis, in particular in studies from sub-Saharan Africa (<link linkend="ch0082s0000li0057">57</link>).</para>
      <para id="ch0082s0000p0021">Ureaplasmas have been isolated from internal organs of spontaneously aborted fetuses and from stillborn and premature infants more often than from induced abortions or normal full-term infants (<link linkend="ch0082s0000li0011">11</link>). Results from some serologic and therapeutic studies support a role for these organisms in fetal morbidity (<link linkend="ch0082s0000li0011">11</link>). BV is a possible confounding factor which must be considered in the association between ureaplasmas in the chorioamnion and low birth weight. Ureaplasmas at this site are directly associated with inflammation and may invade the amniotic sac early in pregnancy in the presence of intact fetal membranes, causing persistent infection and adverse pregnancy outcomes (<link linkend="ch0082s0000li0058">58</link>).</para>
      <para id="ch0082s0000p0022">The notion that<emphasis>M. hominis</emphasis> causes fever in some women after abortion, or after normal delivery, is based on their isolation from the blood of about 10% of such women but not from afebrile women who have had abortions or from healthy pregnant women (<link linkend="ch0082s0000li0025">25</link>). In addition, antibody responses have been detected in about half of febrile aborting women but in few of those who remain afebrile (<link linkend="ch0082s0000li0025">25</link>). Similar observations have been made regarding isolation of <emphasis>Ureaplasma</emphasis> spp. which could be responsible for a few cases of postpartum endometritis (<link linkend="ch0082s0000li0059">59</link>). The ability of <emphasis>U. parvum</emphasis> and <emphasis>M. hominis</emphasis> to induce amniotic fluid leukocyte infiltrates, proinflammatory cytokines, prostaglandins, metalloproteinases, and uterine activity, resulting in chorioamnionitis and a systemic fetal inflammatory response, and to contribute to preterm labor and fetal lung injury is supported by experimental studies in rhesus macaques (<link linkend="ch0082s0000li0060">60</link>). However, it is difficult to determine whether they have a role independent from other bacteria occurring in BV, a condition associated with preterm labor and birth. In addition, there are conflicting opinions about the importance of <emphasis>U. urealyticum</emphasis> compared to <emphasis>U. parvum</emphasis> in premature delivery, a situation that needs to be resolved. While there are fewer data regarding pregnancy, <emphasis>M. genitalium</emphasis> has been associated with preterm birth and spontaneous abortion (<link linkend="ch0082s0000li0052">52</link>).</para>
    </sect1>
    <sect1 id="ch0082s0004">
      <title>Neonatal Infections</title>
      <anchor id="ch0082s0004a0001"/>
      <anchor id="ch0082s0000a0036"/>
      <para id="ch0082s0000p0023">Colonization of infants by genital<emphasis>Mollicutes</emphasis> can occur by ascension from the lower genital tract of the mother at the time of delivery or <emphasis>in utero</emphasis> earlier in gestation and can be transient and without sequelae. The rate of vertical transmission is 18 to 55% among infants born to colonized mothers (<link linkend="ch0082s0000li0011">11</link>). <emphasis>Ureaplasma</emphasis> spp. and <emphasis>M. hominis</emphasis> can be isolated from neonates born to mothers with intact membranes and delivered by cesarean section (<link linkend="ch0082s0000li0011">11</link>). Congenital pneumonia, bacteremia, progression to chronic lung disease of prematurity with development of inflammatory cytokines in tracheal aspirates, and even death have occurred in very-low-birth-weight infants due to ureaplasmal infection of the lower respiratory tract (<link linkend="ch0082s0000li0011">11</link>). Meta-analyses of the literature accumulated since the 1980s support an association of ureaplasmal infection with development of chronic lung disease, but so far there has been no evidence of a reduction in the incidence of chronic lung disease or death when preterm infants are treated with macrolides (<link linkend="ch0082s0000li0061">61</link>). Both <emphasis>M. hominis</emphasis> and <emphasis>Ureaplasma</emphasis> spp. have been isolated from maternal and umbilical cord blood, as well as the blood of neonates. Both species can also invade the cerebrospinal fluid of neonates (<link linkend="ch0082s0000li0011">11</link>). Either mild, subclinical meningitis without sequelae or neurological damage with permanent deficits can ensue. Colonization of healthy full-term infants declines after 3 months of age, and fewer than 10% of older children and sexually inexperienced adults are colonized with genital <emphasis>Mollicutes</emphasis> (<link linkend="ch0082s0000li0011">11</link>).</para>
      <anchor id="ch0082s0000a0037"/>
      <beginpage pagenum="1242"/>
      <para id="ch0082s0000p0024">Routine screening of neonates for genital<emphasis>Mollicutes</emphasis> is not clinically justified based on the available evidence that many healthy neonates are colonized without consequence. However, if there is clinical, radiological, or laboratory evidence of pneumonia, meningitis, or overall instability, particularly in preterm neonates in whom there are no obvious alternative etiologies, infection with <emphasis>M. hominis</emphasis> or <emphasis>Ureaplasma</emphasis> spp. should be considered and culture or PCR assays of respiratory tract secretions and/or cerebrospinal fluid obtained, depending on the clinical condition.</para>
    </sect1>
    <sect1 id="ch0082s0005">
      <title>Systemic Infections and Immunosuppressed Hosts</title>
      <anchor id="ch0082s0005a0001"/>
      <anchor id="ch0082s0000a0038"/>
      <para id="ch0082s0000p0025">Extrapulmonary and extragenital mycoplasmal infections probably occur more often than currently recognized.<emphasis>M. hominis</emphasis> is alone among pathogenic mycoplasmas of human origin which are occasionally detected in routine bacteriologic cultures, so that there have been many instances of accidental discovery when mycoplasmas were not specifically sought. The number of published case reports implicating <emphasis>Mycoplasma</emphasis> and <emphasis>Ureaplasma</emphasis> spp. in a variety of systemic infections involving persons with and without impaired host defenses has increased in recent years because of more widespread utilization of 16S rRNA gene PCR/sequencing when infection is suspected and no conventional microbes are detected by culture.</para>
      <para id="ch0082s0000p0026"><emphasis>Mollicutes</emphasis> can cause invasive disease of the joints following dissemination from the genital or respiratory tracts in immunosuppressed persons, especially individuals with hypogammaglobulinemia, and should be considered as a potential cause of septic arthritis in the setting of antibody deficiency. <emphasis>M. hominis</emphasis> bacteremia has been demonstrated after renal transplantation, trauma, and genitourinary manipulations, and <emphasis>M. hominis</emphasis> has also been found in brain abscesses, osteomyelitis lesions, and wound infections (<link linkend="ch0082s0000li0062">62</link>, <link linkend="ch0082s0000li0063">63</link>). Numerous mycoplasmal species have been detected—mainly by PCR—in synovial fluid of persons with rheumatoid arthritis and other arthritides, although the precise contribution of these organisms to disease remains uncertain (<link linkend="ch0082s0000li0064">64</link>–<link linkend="ch0082s0000li0066">66</link>). The significance of <emphasis>M. fermentans</emphasis> and other mycoplasmas as possible agents of Gulf War Syndrome received a great deal of attention several years ago, but there is no credible evidence supporting either an association or a causal role (<link linkend="ch0082s0000li0067">67</link>).</para>
      <para id="ch0082s0000p0027"><emphasis>Ureaplasma</emphasis> species have been shown to cause systemic and sometimes fatal infections leading to hyperammonemia in immunosuppressed persons who have undergone lung transplantation (associated with donor transmission of <emphasis>Ureaplasma</emphasis> species) (<link linkend="ch0082s0000li0068">68</link>, <link linkend="ch0082s0000li0069">69</link>). There have been occasional reports of systemic infections with oral commensal <emphasis>Mycoplasma</emphasis> spp. such as <emphasis>M. salivarium</emphasis> or <emphasis>M. orale</emphasis> as well as a variety of species of animal origin causing zoonotic infections in persons with various types of immunodeficiencies. Usually, these infections are detected after an extensive search for other pathogens has failed and specimens are submitted for <emphasis>Mycoplasma</emphasis> culture or 16S rRNA gene PCR/sequencing to aid in their detection. There are also reports of various <emphasis>Spiroplasma</emphasis> spp. rarely causing ocular infections in neonates and bacteremia in adults with hypogammaglobulinemia from whom these organisms were recovered in blood cultures and identified by PCR (<link linkend="ch0082s0000li0070">70</link>, <link linkend="ch0082s0000li0071">71</link>). Spiroplasmas have also been implicated as potential pathogens in transmissible spongiform encephalopathies in humans, but it is not yet clear what precise role they may play in such conditions (<link linkend="ch0082s0000li0072">72</link>).</para>
      <sect2 id="ch0082s0005s0001">
        <title>COLLECTION, TRANSPORT, AND STORAGE OF SPECIMENS</title>
        <anchor id="ch0082s0005a0002"/>
        <anchor id="ch0082s0000a0039"/>
      </sect2>
    </sect1>
    <sect1 id="ch0082s0006">
      <title>Specimen Type and Collection</title>
      <anchor id="ch0082s0006a0001"/>
      <anchor id="ch0082s0000a0040"/>
      <para id="ch0082s0000p0028">Body fluids appropriate for<emphasis>Mollicutes</emphasis> culture or detection by noncultural methods include blood, synovial fluid, amniotic fluid, cerebrospinal fluid, urine, prostatic secretions, semen, wound aspirates, sputum, pleural fluid, bronchoalveolar lavage fluid, and other tracheobronchial secretions, depending on the clinical condition and organisms of interest. Swabs from the nasopharynx, throat, cervix/vagina, wounds, and urethra are also acceptable. Tissue from biopsy or autopsy, including placenta, endometrium, bone, and urinary calculi, can also be used. When swabs are used, care must be taken to sample the desired site vigorously to obtain as many cells as possible, since <emphasis>Mollicutes</emphasis> are mainly cell associated. Urine specimens could prove more sensitive than urethral swabs in males for detection of fastidious species such as <emphasis>M. genitalium</emphasis> by PCR (<link linkend="ch0082s0000li0073">73</link>). If determination of the localization of <emphasis>Mollicutes</emphasis> in the genitourinary tract is desired, urine specimens can be obtained at various stages during urination or after prostatic massage. Care should be taken to avoid collection of specimens that are contaminated by lubricants or antiseptics commonly used in gynecologic practice. Dacron or polyester swabs with aluminum or plastic shafts are preferred. Wooden-shaft cotton swabs should be avoided because of potential inhibitory effects on organism viability.</para>
      <para id="ch0082s0000p0029">Successful isolation of<emphasis>Mollicutes</emphasis> from blood can be achieved by inoculating blood, free of anticoagulant, into liquid mycoplasmal growth medium at the bedside in a 1:5 to 1:10 ratio, using as much blood as possible (at least 10 mL is desirable in adults). <emphasis>Mollicutes</emphasis> are inhibited by sodium polyanethol sulfonate, the anticoagulant used in most commercial blood culture media, but the inhibitory effect can be overcome by addition of gelatin (1% [wt/vol]) (<link linkend="ch0082s0000li0074">74</link>). Use of commercial blood culture media with automated blood culture instruments is not recommended for detection of <emphasis>Mollicutes.</emphasis> None of the newer continuously monitored, automated blood culture systems will flag bottles containing <emphasis>M. hominis</emphasis>, even when additional metabolic substrate and gelatin are added. However, <emphasis>M. hominis</emphasis> may survive in these media for several days (<link linkend="ch0082s0000li0075">75</link>).</para>
      <anchor id="ch0082s0000a0041"/>
      <beginpage pagenum="1243"/>
    </sect1>
    <sect1 id="ch0082s0007">
      <title>Transport and Storage</title>
      <anchor id="ch0082s0007a0001"/>
      <anchor id="ch0082s0000a0042"/>
      <para id="ch0082s0000p0030"><emphasis>Mollicutes</emphasis> are extremely sensitive to adverse environmental conditions, particularly drying and heat. Specimens should be inoculated at the bedside whenever possible, using appropriate transport and/or culture media. Liquid growth media, such as commercially prepared SP4 and 10B broths (Thermo Fisher [Waltham, MA] or Hardy Diagnostics [Santa Maria, CA]), can also serve as transport media. 2-SP (10% [vol/vol] heat-inactivated fetal calf serum with 0.2 M sucrose in 0.02 M phosphate buffer, pH 7.2) and Trypticase soy broth with 0.5% (vol/vol) bovine albumin (Thermo Fisher) are also acceptable transport media. Specialized liquid transport media such as A3B (Thermo Fisher, Waltham, MA) have been designed by deletion of some growth supplements present in other growth media so that an increase in pH caused by urealytic activity of ureaplasmas will be delayed and result in less toxicity to the organisms during transport. Laboratories can choose to stock a single universal transport medium for mycoplasmas, ureaplasmas, chlamydiae, and viruses. Most universal transport media contain inhibitors to prevent bacterial or fungal overgrowth in specimens obtained from nonsterile sites that have their own indigenous microbial flora. M4, M5, and M6 (Thermo Fisher, Waltham, MA), UTM (Copan Diagnostics, Murrieta, CA), and BD UVT medium (Becton Dickinson, Franklin Lakes, NJ) are examples of universal transport systems suitable for transport of specimens from which mycoplasmas and/or ureaplasmas will be sought by culture.</para>
      <para id="ch0082s0000p0031">Liquid specimens do not require special transport media if cultures can be inoculated within 1 h. Tissues can be placed in sterile containers which are tightly closed and delivered to the laboratory immediately. Otherwise, tissue specimens should be placed in transport media if delay in culture inoculation is anticipated. Specimens should be refrigerated if immediate transportation to the laboratory is not possible. If specimens must be shipped and/or if the storage time is likely to exceed 24 h prior to processing, the specimen in transport medium should be frozen at −80°C to prevent loss of viability and to minimize bacterial overgrowth.<emphasis>Mollicutes</emphasis> can be stored for long periods in appropriate growth or transport media at −80°C or in liquid nitrogen. Frozen specimens can be shipped with dry ice to a reference laboratory if necessary. Storage at 20°C is deleterious to detection, even by nonculture methods. When frozen specimens are to be examined, they should be thawed rapidly in a water bath at 37°C.</para>
      <sect2 id="ch0082s0007s0001">
        <title>DIRECT EXAMINATION</title>
        <anchor id="ch0082s0007a0002"/>
        <anchor id="ch0082s0000a0043"/>
      </sect2>
    </sect1>
    <sect1 id="ch0082s0008">
      <title>Microscopy</title>
      <anchor id="ch0082s0008a0001"/>
      <anchor id="ch0082s0000a0044"/>
      <para id="ch0082s0000p0032"><emphasis>Mollicutes</emphasis>, like chlamydiae and rickettsiae, cannot be clearly visualized by routine light microscopy. Lack of a cell wall precludes visualization by Gram staining, but this procedure can prove useful to exclude contaminating bacteria. <emphasis>M. hominis</emphasis> occasionally appears as pinpoint colonies on bacteriologic media such as Columbia agar, and the lack of a Gram stain reaction by these colonies gives a clue as to their possible identity, warranting further specific evaluation and subculture to mycoplasmal media. A DNA fluorochrome or acridine orange stain can be useful to visualize the microorganism in body fluids, but it is not specific for <emphasis>Mollicutes</emphasis>.</para>
    </sect1>
    <sect1 id="ch0082s0009">
      <title>Antigen Detection</title>
      <anchor id="ch0082s0009a0001"/>
      <anchor id="ch0082s0000a0045"/>
      <para id="ch0082s0000p0033">Although culture is appropriate for species which can be isolated easily and rapidly from clinical specimens, such as<emphasis>M. hominis</emphasis> and <emphasis>Ureaplasma</emphasis> spp., it is not ideal for detection of fastidious and/or extremely slow-growing organisms such as <emphasis>M. genitalium</emphasis> and, to a considerable degree, <emphasis>M. pneumoniae.</emphasis> Therefore, alternate non-culture-based methods of detection should be employed even if culture is attempted for these organisms. Rapid methods for antigenic detection of <emphasis>M. pneumoniae</emphasis> were developed in the 1980s, but these techniques were hampered by low sensitivity and cross-reactivity with other commensal mycoplasmas. This approach for rapid diagnosis has now been abandoned in favor of nucleic acid amplification tests (NAATs).</para>
    </sect1>
    <sect1 id="ch0082s0010">
      <title>Nucleic Acid Detection</title>
      <anchor id="ch0082s0010a0001"/>
      <anchor id="ch0082s0000a0046"/>
      <para id="ch0082s0000p0034">DNA hybridization techniques for diagnosis of<emphasis>M. pneumoniae</emphasis> infection using 16S rRNA genes as targets were developed in the early 1980s, but because probes were insensitive, NAATs have supplanted them. NAATs have been developed for all clinically important <emphasis>Mycoplasma</emphasis> spp. that infect humans, largely because of the advantages they have over culture and serology, such as the ability to complete the procedure in one day utilizing a single specimen containing organisms that do not have to be viable, as well as the ability to detect nucleic acid in preserved tissues. NAATs also detect the organisms earlier in the course of illness than serology, since development of measurable antibodies can require several days or more. Real-time PCR assays are now the preferred PCR method for detection of mycoplasmas and ureaplasmas. The advantages include rapid turnaround times, less handling of amplification product, and improved diagnostic sensitivity over the traditional PCR techniques (<link linkend="ch0082s0000li0076">76</link>). Analytical sensitivity is high, with some assays capable of detecting a single organism when purified DNA is used. Details of various NAATs and their applications for detection of mycoplasmas and ureaplasmas are discussed in depth elsewhere (<link linkend="ch0082s0000li0076">76</link>, <link linkend="ch0082s0000li0077">77</link>).</para>
      <para id="ch0082s0000p0035">Gene targets for PCR assays for detection of<emphasis>M. pneumoniae</emphasis> in clinical specimens have included the 16S rRNA gene, <emphasis>P1, tuf, parE, dnak, pdhA</emphasis>, ATPase operon, CARDS toxin gene (<emphasis>mpn372</emphasis>), and the noncoding repetitive element <emphasis>repMp1</emphasis> (<link linkend="ch0082s0000li0005">5</link>, <link linkend="ch0082s0000li0078">78</link>–<link linkend="ch0082s0000li0081">81</link>). Both conventional and real-time nucleic acid sequence-based amplification (NASBA) have also been used to detect <emphasis>M. pneumoniae</emphasis> RNA (<link linkend="ch0082s0000li0082">82</link>). NASBA can provide rapid results with sensitivity as good as that of PCR (<link linkend="ch0082s0000li0082">82</link>, <link linkend="ch0082s0000li0083">83</link>). There have been few side-by-side comparisons to determine whether one assay format or gene target is better than another. Many comparisons of PCR using culture or serology as a reference method yielded disparate results. Commercial NAATs are available in Europe for detection of <emphasis>M. pneumoniae</emphasis> alone or in combination with other respiratory tract bacteria or viruses (<link linkend="ch0082s0000li0077">77</link>). Limited evaluations show performance comparable to that of noncommercial assays (<link linkend="ch0082s0000li0084">84</link>–<link linkend="ch0082s0000li0086">86</link>).</para>
      <para id="ch0082s0000p0036">There are now several FDA-cleared molecular assays for detection of<emphasis>M. pneumoniae</emphasis> sold in the United States that have been evaluated in comparison to one another. Some of these are automated multianalyte PCR platforms targeting various respiratory viruses and other bacterial pathogens obtained from nasopharyngeal swabs (<anchor id="ch0082s0000a0047"/><link linkend="ch0082s0000a0049">Table 3</link>). The BioFire FilmArray respiratory panel (RP) (BioFire Diagnostics, Salt Lake City, UT) is performed on nasopharyngeal swabs and detects 20 respiratory pathogens, including <emphasis>M. pneumoniae</emphasis> in about an hour, performing nucleic acid extraction, reverse transcription, DNA amplification, nested PCR, and melt curve analysis using the CARDS toxin as its target. The BioFire RP EZ is now FDA cleared and is classified as a waived test under the Clinical Laboratory Improvement Amendment (CLIA) regulations. The GenMark ePlex RP (GenMarkDx, Carlsbad, CA) uses electrowetting microfluidic technology and detects 17 viral and bacterial pathogens within 1.5 h, targeting the <emphasis>M. pneumoniae</emphasis> P1 adhesin. The Luminex NxTAG RPP (Luminex Corp., Austin, TX) detects 20 respiratory pathogens by multiplex PCR amplification, bead hybridization, and fluorescence imaging using a 96-well plate format, enabling the evaluation of up to 96 samples in 4 h. The target for <emphasis>M. pneumoniae</emphasis> is the P1 adhesin. In a comparative study of 428 specimens, 212 of which were confirmed to be positive for <emphasis>M. pneumoniae</emphasis>, the FilmArray had the best overall performance and detected significantly more confirmed positive specimens than the ePlex and NxTAG tests (<link linkend="ch0082s0000li0087">87</link>).</para>
      <anchor id="ch0082s0000a0048"/>
      <beginpage pagenum="1244"/>
      <table id="ch0082s0000t0003"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0082s0000a0049"/><link linkend="ch0082s0000a0047">TABLE 3</link></phrase></emphasis> Examples of commercial NAATs for detection of <emphasis>M. pneumoniae</emphasis><superscript><emphasis><anchor id="ch0082s0000a0050"/><link linkend="ch0082s0000a0051">a</link></emphasis></superscript>
</title>
        
        <tgroup cols="7">
          <tbody>
            <row>
              <entry><phrase role="center">Product</phrase>
              </entry>
              <entry><phrase role="center">Manufacturer, platform</phrase>
              </entry>
              <entry><phrase role="center">Method</phrase>
              </entry>
              <entry><phrase role="center">Pathogen(s) detected (no.)</phrase>
              </entry>
              <entry><phrase role="center">MP gene target</phrase>
              </entry>
              <entry><phrase role="center">Time to result (h); sample throughput</phrase>
              </entry>
              <entry><phrase role="center">Regulatory status</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">FilmArray RP</phrase>
              </entry>
              <entry><phrase role="left">bioMérieux/BioFire Diagnostics (Salt Lake City, UT)</phrase>
              </entry>
              <entry><phrase role="left">PCR</phrase>
              </entry>
              <entry><phrase role="left">MP, <emphasis>C. pneumoniae, Bordetella pertussis</emphasis>, several respiratory viruses (20)</phrase>
              </entry>
              <entry><phrase role="left">CARDS toxin</phrase>
              </entry>
              <entry><phrase role="left">~1; cartridge assay, 12 per tower</phrase>
              </entry>
              <entry><phrase role="left">FDA cleared, CE-IVD</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">ePlex RPP</phrase>
              </entry>
              <entry><phrase role="left">GenMark Diagnostics (Austin. TX), ePlex instrument</phrase>
              </entry>
              <entry><phrase role="left">PCR</phrase>
              </entry>
              <entry><phrase role="left">MP, <emphasis>C. pneumoniae</emphasis>, several respiratory viruses (17)</phrase>
              </entry>
              <entry><phrase role="left">P1 adhesin</phrase>
              </entry>
              <entry><phrase role="left">~1.5; cartridge assay, 6 per tower</phrase>
              </entry>
              <entry><phrase role="left">FDA cleared, CE-IVD</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">NxTAG RP</phrase>
              </entry>
              <entry><phrase role="left">Luminex Corp. (Carlsbad, CA), Magpix</phrase>
              </entry>
              <entry><phrase role="left">PCR</phrase>
              </entry>
              <entry><phrase role="left">MP, <emphasis>C. pneumoniae</emphasis>, several respiratory viruses (20)</phrase>
              </entry>
              <entry><phrase role="left">P1 adhesin</phrase>
              </entry>
              <entry><phrase role="left">~4; 96 well plate</phrase>
              </entry>
              <entry><phrase role="left">FDA cleared, CE-IVD</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Alethia Mycoplasma direct</phrase>
              </entry>
              <entry><phrase role="left">Meridian Bioscience, Inc. (Cincinnati, OH)</phrase>
              </entry>
              <entry><phrase role="left">LAMP</phrase>
              </entry>
              <entry><phrase role="left">MP (1)</phrase>
              </entry>
              <entry><phrase role="left">RepMp4</phrase>
              </entry>
              <entry><phrase role="left">~1; 10 per run</phrase>
              </entry>
              <entry><phrase role="left">FDA cleared, CE-IVD</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">MGB Alert <emphasis>Mycoplasma pneumoniae</emphasis></phrase>
              </entry>
              <entry><phrase role="left">ELITechGroup (Puteaux, France), InGenius</phrase>
              </entry>
              <entry><phrase role="left">PCR</phrase>
              </entry>
              <entry><phrase role="left">MP (1)</phrase>
              </entry>
              <entry><phrase role="left">Protease-like protein</phrase>
              </entry>
              <entry><phrase role="left">~3; 12 per run</phrase>
              </entry>
              <entry><phrase role="left">RUO</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0051"/><link linkend="ch0082s0000a0050">a</link></emphasis></superscript>LAMP, loop-mediated isothermal amplification; MP, <emphasis>M. pneumoniae</emphasis>; RUO, research use only; CE-IVD, approved Communauté Européenne marking on <emphasis>in vitro</emphasis> diagnostic medical devices.</para>
      <para id="ch0082s0000p0037">The Alethia Illumigene<emphasis>Mycoplasma</emphasis> direct assay (Meridian Bioscience, Inc., Cincinnati, OH) is an automated single-analyte loop-mediated isothermal amplification (LAMP) assay detecting only <emphasis>M. pneumoniae</emphasis> that has been shown to produce acceptable results in comparison to culture (<link linkend="ch0082s0000li0088">88</link>). The target of this assay is a 208-bp DNA sequence found in the intracellular protease-like protein gene. The specimen for this assay is a throat swab. This relatively simple, low-cost, single-analyte rapid detection system, which is FDA cleared, is the closest thing currently available to a true point-of-care test for detection of <emphasis>M. pneumoniae</emphasis> in an ambulatory care setting in the United States.</para>
      <para id="ch0082s0000p0038">Several NAATs based on real-time PCR or transcription-mediated amplification (TMA) are described for the molecular detection of<emphasis>M. genitalium.</emphasis> They utilize targets such as the MgPa operon, 16S rRNA genes, the 115-kDa gene, and <emphasis>gap</emphasis> (encoding glyceraldehyde-3-phosphate dehydrogenase) (<link linkend="ch0082s0000li0089">89</link>–<link linkend="ch0082s0000li0095">95</link>). Several commercial NAATs have been developed, some of them FDA cleared, with excellent sensitivity and specificity. Furthermore, several of these assays can detect <emphasis>M. genitalium</emphasis> and its macrolide resistance-associated mutations, although no assays capable of resistance detection are currently FDA cleared (<anchor id="ch0082s0000a0052"/><link linkend="ch0082s0000a0054">Table 4</link>) (<link linkend="ch0082s0000li0096">96</link>).</para>
      <para id="ch0082s0000p0039">Hologic, Inc. (Marlborough, MA), developed a TMA assay for detection of<emphasis>M. genitalium</emphasis> that has been commercialized in Europe and is FDA cleared in the United States (<link linkend="ch0082s0000li0097">97</link>). The Aptima <emphasis>Mycoplasma genitalium</emphasis> assay for <emphasis>in vitro</emphasis> diagnosis is available on Hologic’s Panther platform. The Cobas TV/MG (Roche Molecular Systems, Pleasanton, CA) is a commercial PCR that detects <emphasis>M. genitalium</emphasis> and <emphasis>Trichomonas vaginalis.</emphasis> This assay is FDA cleared (<link linkend="ch0082s0000li0098">98</link>).</para>
      <para id="ch0082s0000p0040">Various companies have commercialized CE-marked multiplex PCR panels for detection of nonviral sexually transmitted pathogens, including<emphasis>M. genitalium</emphasis>, in Europe (<link linkend="ch0082s0000li0099">99</link>–<link linkend="ch0082s0000li0102">102</link>). A recent study evaluated the clinical performance of four multiplex real-time PCR kits and described poor performance for the detection of <emphasis>M. genitalium</emphasis> and <emphasis>Trichomonas vaginalis</emphasis> (<link linkend="ch0082s0000li0102">102</link>).</para>
      <para id="ch0082s0000p0041">PCR assays for<emphasis>M. hominis</emphasis> mainly utilize the 16S rRNA gene as a target (<link linkend="ch0082s0000li0103">103</link>). Since some heterogeneity has been reported in the 16S rRNA gene of <emphasis>M. hominis</emphasis> (<link linkend="ch0082s0000li0104">104</link>), assays that target other genes, including <emphasis>gap, fstY, yidC, rpo</emphasis>, and <emphasis>tuf</emphasis>, have been developed (<link linkend="ch0082s0000li0105">105</link>–<link linkend="ch0082s0000li0108">108</link>). PCR assays can be used to detect as well as differentiate species of <emphasis>Ureaplasma.</emphasis> Gel-based conventional PCR assays target sequences of the 16S rRNA gene, 16S rRNA-23S rRNA intergenic spacer regions, the urease gene, and <emphasis>mba</emphasis> (<link linkend="ch0082s0000li0109">109</link>–<link linkend="ch0082s0000li0113">113</link>), while real-time PCR assays have mainly targeted urease genes and their subunits or <emphasis>mba</emphasis> (<link linkend="ch0082s0000li0094">94</link>, <link linkend="ch0082s0000li0108">108</link>, <link linkend="ch0082s0000li0114">114</link>, <link linkend="ch0082s0000li0118">118</link>). The UAB Diagnostic Mycoplasma Laboratory developed a real-time PCR assay for detection and differentiation of <emphasis>Ureaplasma</emphasis> spp. based on <emphasis>UU063</emphasis>, which encodes a conserved hypothetical protein identical in 4 <emphasis>U. parvum</emphasis> strains and a 15,072-bp open reading frame (ORF), and on <emphasis>UUR10_0680</emphasis>, which is conserved (&gt;99.97%) in <emphasis>U. urealyticum</emphasis> (<link linkend="ch0082s0000li0115">115</link>). This assay detected more positive clinical specimens than a conventional PCR assay based on a urease gene target in intralaboratory method evaluations. Some molecular assays are multiplexed and detect <emphasis>Ureaplasma</emphasis> spp. and <emphasis>M. hominis</emphasis> with other sexually transmitted pathogens (<emphasis>C. trachomatis, N. gonorrhoeae, M. genitalium</emphasis>, and <emphasis>T. vaginalis</emphasis>). No multiplex assays have been FDA cleared, but some are CE-IVD marked (i.e., they have an approved Communauté Européenne marking for <emphasis>in vitro</emphasis> diagnostic medical devices) (<link linkend="ch0082s0000li0077">77</link>). However, <emphasis>Ureaplasma</emphasis> spp. and <emphasis>M. hominis</emphasis> should not be included in these kits for lower urogenital tract specimens, as they are commensals in this location.</para>
      <anchor id="ch0082s0000a0053"/>
      <beginpage pagenum="1245"/>
      <table id="ch0082s0000t0004"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0082s0000a0054"/><link linkend="ch0082s0000a0052">TABLE 4</link></phrase></emphasis> Examples of commercial NAATs for detection of <emphasis>M. genitalium</emphasis><superscript><emphasis><anchor id="ch0082s0000a0055"/><link linkend="ch0082s0000a0058">a</link></emphasis></superscript>
</title>
        
        <tgroup cols="8">
          <tbody>
            <row>
              <entry><phrase role="left">Product</phrase>
              </entry>
              <entry><phrase role="left">Manufacturer, platform</phrase>
              </entry>
              <entry><phrase role="left">Method</phrase>
              </entry>
              <entry><phrase role="left">Pathogen(s) detected</phrase>
              </entry>
              <entry><phrase role="left">MG gene target</phrase>
              </entry>
              <entry><phrase role="left">Detection of macrolide resistance<superscript><emphasis><anchor id="ch0082s0000a0056"/><link linkend="ch0082s0000a0059">b</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">Sample throughput</phrase>
              </entry>
              <entry><phrase role="left">Regulatory status</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Aptima <emphasis>Mycoplasma genitalium</emphasis></phrase>
              </entry>
              <entry><phrase role="left">Hologic (Marlborough, MA), Panther</phrase>
              </entry>
              <entry><phrase role="left">TMA<superscript><emphasis><link linkend="ch0082s0000a0059">b</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">MG</phrase>
              </entry>
              <entry><phrase role="left">16S rRNA</phrase>
              </entry>
              <entry><phrase role="left">No</phrase>
              </entry>
              <entry><phrase role="left">Batched, 120 per run</phrase>
              </entry>
              <entry><phrase role="left">FDA cleared, CE-IVD</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Cobas TV/MG detection</phrase>
              </entry>
              <entry><phrase role="left">Roche Molecular Systems (Pleasanton, CA), Cobas 6800/8800</phrase>
              </entry>
              <entry><phrase role="left">PCR</phrase>
              </entry>
              <entry><phrase role="left">MG, <emphasis>T. vaginalis</emphasis></phrase>
              </entry>
              <entry><phrase role="left">16S rRNA</phrase>
              </entry>
              <entry><phrase role="left">No</phrase>
              </entry>
              <entry><phrase role="left">Batched, 96-well plates</phrase>
              </entry>
              <entry><phrase role="left">FDA cleared, CE-IVD</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Alinity mSTI</phrase>
              </entry>
              <entry><phrase role="left">Abbott Molecular Diagnostics (Des Plaines, IL), Alinity m</phrase>
              </entry>
              <entry><phrase role="left">PCR</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>C. trachomatis, N. gonorrhoeae</emphasis>, MG, <emphasis>T. vaginalis</emphasis></phrase>
              </entry>
              <entry><phrase role="left">rRNA</phrase>
              </entry>
              <entry><phrase role="left">No</phrase>
              </entry>
              <entry><phrase role="left">Random access, up to 20 assays on board at any one time</phrase>
              </entry>
              <entry><phrase role="left">FDA cleared CE-IVD</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">STI PLUS ELITe MGB</phrase>
              </entry>
              <entry><phrase role="left">ELITechGroup (Puteaux, France), InGenius</phrase>
              </entry>
              <entry><phrase role="left">PCR</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>C. trachomatis, N. gonorrhoeae</emphasis>, MG, <emphasis>T. vaginalis</emphasis></phrase>
              </entry>
              <entry><phrase role="left">23S rRNA</phrase>
              </entry>
              <entry><phrase role="left">No</phrase>
              </entry>
              <entry><phrase role="left">Batched, 12 per run</phrase>
              </entry>
              <entry><phrase role="left">CE-IVD</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Allplex® STI Essential</phrase>
              </entry>
              <entry><phrase role="left">Seegene (Seoul, South Korea), Cfx96 (Bio-Rad)</phrase>
              </entry>
              <entry><phrase role="left">PCR</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>C. trachomatis, N. gonorrhoeae</emphasis>, MG, <emphasis>T. vaginalis, M. hominis, U. parvum, U. urealyticum</emphasis></phrase>
              </entry>
              <entry><phrase role="left">
                  <superscript>
                    <emphasis>mgpA</emphasis>
                  </superscript>
                </phrase>
              </entry>
              <entry><phrase role="left">No</phrase>
              </entry>
              <entry><phrase role="left">Batched, 96-well plates</phrase>
              </entry>
              <entry><phrase role="left">CE-IVD</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">ResistancePlus MG FleXible</phrase>
              </entry>
              <entry><phrase role="left">SpeeDx/Cepheid (Sydney, Australia), GeneXpert</phrase>
              </entry>
              <entry><phrase role="left">PCR</phrase>
              </entry>
              <entry><phrase role="left">MG</phrase>
              </entry>
              <entry><phrase role="left">MgPa adhesin gene</phrase>
              </entry>
              <entry><phrase role="left">Yes, 4 mutations A2058G/C/T, A2059G<superscript><emphasis><anchor id="ch0082s0000a0057"/><link linkend="ch0082s0000a0060">c</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">Cartridge assay, 2, 4, or 16 per tower</phrase>
              </entry>
              <entry><phrase role="left">CE-IVD</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">ResistancePlus MG</phrase>
              </entry>
              <entry><phrase role="left">SpeeDx (Sydney, Australia)</phrase>
              </entry>
              <entry><phrase role="left">PCR</phrase>
              </entry>
              <entry><phrase role="left">MG</phrase>
              </entry>
              <entry><phrase role="left">MgPa adhesin gene</phrase>
              </entry>
              <entry><phrase role="left">Yes, 4 mutations A2058G/C/T, A2059G<superscript><emphasis><link linkend="ch0082s0000a0060">c</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">Batched, up to 96-well plates</phrase>
              </entry>
              <entry><phrase role="left">CE-IVD</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Macrolide-R/MG ELITe MGB</phrase>
              </entry>
              <entry><phrase role="left">ELITechGroup (Puteaux, France), InGenius</phrase>
              </entry>
              <entry><phrase role="left">PCR</phrase>
              </entry>
              <entry><phrase role="left">MG</phrase>
              </entry>
              <entry><phrase role="left">23S rRNA</phrase>
              </entry>
              <entry><phrase role="left">Yes, 5 mutations A2058G/C/T, A2059G/C<superscript><emphasis><link linkend="ch0082s0000a0060">c</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">Batched, 12 per run</phrase>
              </entry>
              <entry><phrase role="left">CE-IVD</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Allplex MG &amp; AziR</phrase>
              </entry>
              <entry><phrase role="left">Seegene (Seoul, South Korea), Cfx 96 (Bio-Rad)</phrase>
              </entry>
              <entry><phrase role="left">PCR</phrase>
              </entry>
              <entry><phrase role="left">MG</phrase>
              </entry>
              <entry><phrase role="left">
                  <superscript>
                    <emphasis>mgpA</emphasis>
                  </superscript>
                </phrase>
              </entry>
              <entry><phrase role="left">Yes, 6 mutations A2058G/C/T, A2059G/C/T<superscript><emphasis><link linkend="ch0082s0000a0060">c</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">Batched, 12 per run</phrase>
              </entry>
              <entry><phrase role="left">CE-IVD</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">S-DiaMGRes</phrase>
              </entry>
              <entry><phrase role="left">Diagenode (Denville, NJ)</phrase>
              </entry>
              <entry><phrase role="left">PCR</phrase>
              </entry>
              <entry><phrase role="left">MG</phrase>
              </entry>
              <entry><phrase role="left">
                  <superscript>
                    <emphasis>mg219</emphasis>
                  </superscript>
                </phrase>
              </entry>
              <entry><phrase role="left">Yes, 5 mutations A2058G/C/T, A2059G/C<superscript><emphasis><link linkend="ch0082s0000a0060">c</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">Batched, up to 96-well plates</phrase>
              </entry>
              <entry><phrase role="left">CE-IVD</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">RealAccurateTVMGres</phrase>
              </entry>
              <entry><phrase role="left">Pathofinder (Maastricht, Netherlands)</phrase>
              </entry>
              <entry><phrase role="left">PCR</phrase>
              </entry>
              <entry><phrase role="left">MG, <emphasis>T. vaginalis</emphasis></phrase>
              </entry>
              <entry><phrase role="left">MgPa adhesin gene</phrase>
              </entry>
              <entry><phrase role="left">Yes, 4 mutations A2058G/C/T, A2059G<superscript><emphasis><link linkend="ch0082s0000a0060">c</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">Batched</phrase>
              </entry>
              <entry><phrase role="left">CE-IVD</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0058"/><link linkend="ch0082s0000a0055">a</link></emphasis></superscript>TMA, transcription-mediated amplification; CE-IVD, approved Communauté Européenne marking on <emphasis>in vitro</emphasis> diagnostic medical devices; Mg, <emphasis>M. genitalium.</emphasis></para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0059"/><link linkend="ch0082s0000a0056">b</link></emphasis></superscript>Kits detecting macrolide resistance associated mutations also amplify 23S rRNA.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0060"/><link linkend="ch0082s0000a0057">c</link></emphasis></superscript><emphasis>E. coli</emphasis> numbering.</para>
      <para id="ch0082s0000p0042">Comparison of<emphasis>M. pneumoniae</emphasis> PCR with culture and/or serology has yielded varied results that are not always in agreement. PCR is more sensitive than serology in the diagnosis of early <emphasis>M. pneumoniae</emphasis> infection (<link linkend="ch0082s0000li0119">119</link>). However, NAATs are unable to differentiate between asymptomatic carriage and acute symptomatic infection. Positive PCR results for <emphasis>M. pneumoniae</emphasis> in culture-negative persons without evidence of respiratory disease suggests inadequate assay specificity, persistence of the organism after infection or asymptomatic carriage. Positive PCR results in serologically negative persons could be due to an inadequate immune response or collection of specimens before specific antibody synthesis occurs. Negative PCR results in culture or serologically proven infections raise the possibility of inhibitors or other technical problems with the assay. Use of a second PCR assay with a different gene target can help resolve such discrepancies. This is particularly important in the setting of a positive PCR assay when culture and/or serology is negative. If mycoplasmacidal antibiotics have been administered, PCR results can be negative, even though serology is positive. There is some evidence suggesting that PCR inhibition occurs more commonly with nasopharyngeal specimens than throat swabs being assayed for <emphasis>M. pneumoniae</emphasis> (<link linkend="ch0082s0000li0120">120</link>). Commercial reagents available for purification of nucleic acids can be helpful in overcoming PCR inhibition.</para>
      <anchor id="ch0082s0000a0061"/>
      <beginpage pagenum="1246"/>
      <para id="ch0082s0000p0043">Screening the lower urogenital tract specimens of adults for<emphasis>M. hominis</emphasis> or <emphasis>Ureaplasma</emphasis> spp. by NAATs is not recommended, as asymptomatic carriage of these species is common and most colonized individuals do not develop disease (<link linkend="ch0082s0000li0034">34</link>). However, NAATs from sterile body fluids or blood can be valuable in the diagnosis of upper genital and extragenital infections due to <emphasis>M. hominis</emphasis> and <emphasis>Ureaplasma</emphasis> spp. Molecular detection of <emphasis>Mollicutes</emphasis> is now the diagnostic method of choice for detection of <emphasis>M. pneumoniae</emphasis> and <emphasis>M. genitalium</emphasis> in clinical specimens. NAATs are being used much more frequently now that FDA-cleared commercially sold rapid kits are becoming more widely available. Specific real-time PCR assays and Sanger sequencing-based approaches can also be used for identification of unknown <emphasis>Mollicutes</emphasis> previously obtained by culture and has replaced cumbersome biochemical and immunological methods formerly used for this purpose.</para>
      <sect2 id="ch0082s0010s0001">
        <title>ISOLATION PROCEDURES</title>
        <anchor id="ch0082s0010a0002"/>
        <anchor id="ch0082s0000a0062"/>
      </sect2>
    </sect1>
    <sect1 id="ch0082s0011">
      <title>Biosafety Considerations</title>
      <anchor id="ch0082s0011a0001"/>
      <anchor id="ch0082s0000a0063"/>
      <para id="ch0082s0000p0044"><emphasis>M. pneumoniae, M. genitalium, M. hominis</emphasis>, and ureaplasmas are biosafety level 2 (BSL-2) pathogens. Work with these microorganisms and other <emphasis>Mollicutes</emphasis> of human origin can be undertaken on the laboratory bench and/or in a class 2 biosafety cabinet.</para>
    </sect1>
    <sect1 id="ch0082s0012">
      <title>Growth Media and Inoculation</title>
      <anchor id="ch0082s0012a0001"/>
      <anchor id="ch0082s0000a0064"/>
      <para id="ch0082s0000p0045">Growth of<emphasis>Mollicutes</emphasis> pathogenic to humans requires the presence of serum, growth factors such as yeast extract, and a metabolic substrate. No single formulation is ideal for all pertinent species due to different properties, optimum pH, and substrate requirements. SP4 broth and agar (pH 7.5) are the best media overall and can be used for <emphasis>M. pneumoniae</emphasis> and <emphasis>M. hominis</emphasis>, provided that arginine is added for the latter. Shepard’s 10B broth (pH 6.0) can be used for <emphasis>M. hominis</emphasis> and <emphasis>Ureaplasma</emphasis> spp., with A8 as the corresponding solid medium. Penicillin G or another broad-spectrum β-lactam should be added to minimize bacterial overgrowth. Addition of a pH indicator, such as phenol red, is important for detection, because <emphasis>Mollicutes</emphasis> usually do not produce turbidity in broth culture owing to their small cell size. Medium compositions are provided elsewhere (<link linkend="ch0082s0000li0121">121</link>).</para>
      <para id="ch0082s0000p0046">For self-prepared media, quality control is crucial for each of the main components. These controls must consist of the quantitative growth of a<emphasis>Mollicutes</emphasis> strain(s) in two media that differ only in the component to be tested. New lots or batches of broth are considered satisfactory if the numbers of organisms that grow are within one 10-fold dilution of that in the reference batch. Agar plates should ideally support growth of at least 90% of colonies supported by the reference medium. Sterility of commercially purchased medium components, such as horse serum, must be confirmed prior to use. If a reference laboratory is to be used for testing, inquiry should be made of whether the medium used is self-prepared or purchased from a manufacturer, and there should also be verification of the type of quality control procedures performed. Quality control test organisms should include type strains and low-passage-number clinical isolates of the species of interest. When testing ureaplasmas, it is recommended to include at least one representative of each species. Testing inhibitory properties of media against growth of various other organisms likely present in specimens from nonsterile sites could be worthwhile to prevent loss of <emphasis>Mollicutes</emphasis> due to overgrowth of contaminating organisms.</para>
      <para id="ch0082s0000p0047">Specimens should always be mixed well before media are inoculated. Fluids should be centrifuged (600 ×<emphasis>g</emphasis> for 15 min) and the pellet inoculated. Urine can be filtered through a 0.45-μm filter if bacterial contamination is suspected. Furthermore, it is wise to mince, not grind, tissues in broth prior to diluting to prevent release of mycoplasmacidal inhibitors that may be present in the tissue (<link linkend="ch0082s0000li0122">122</link>). Serial dilution of specimens in broth to at least 10<superscript>−3</superscript> with subculture of each dilution onto agar is an extremely important step in the cultivation process, since it will help overcome possible interference by antibiotics, antibodies, and other inhibitors, including other bacteria that can be present in clinical specimens. Omission of this critical dilution step can be one reason why some laboratories have difficulty in recovering the organisms. Dilution also helps to overcome the problem of rapid decline in culture viability, which is particularly common with ureaplasmas, and it also provides information about the number of organisms present.</para>
    </sect1>
    <sect1 id="ch0082s0013">
      <title>Incubation Conditions and Subcultures</title>
      <anchor id="ch0082s0013a0001"/>
      <anchor id="ch0082s0000a0065"/>
      <para id="ch0082s0000p0048">Broths should be incubated at 37°C under atmospheric conditions. Agar plates yield the best growth if they are incubated in an atmosphere of room air supplemented with 5 to 10% CO<subscript>2</subscript> or in an anaerobic environment of 95% N<subscript>2</subscript> plus 5% CO<subscript>2.</subscript> An anaerobe jar with GasPak catalyst is adequate if dedicated incubators are not available. The relatively rapid growth of <emphasis>M. hominis</emphasis> and <emphasis>Ureaplasma</emphasis> spp. makes identification of most positive cultures possible within 2 to 4 days, whereas <emphasis>M. pneumoniae</emphasis> usually requires 21 days or more. Several <emphasis>Mycoplasma</emphasis> species can produce similar biochemical reactions, and identification can be accomplished only by specific tests on organisms once they are isolated. Broths that change color should be subcultured into a fresh tube of the corresponding broth (0.1 ml into 0.9 ml) and onto agar (0.02 ml). Subcultures must be performed soon after the color change occurs, particularly for <emphasis>Ureaplasma</emphasis> spp., because the culture can lose viability within a few hours. Subculture also increases diagnostic yield, since some strains may not grow sufficiently from the original specimen inoculated onto solid media. Blind subculture periodically during incubation may improve the yield of <emphasis>M. pneumoniae</emphasis> and other mycoplasmas, since a color change is not always evident, even if growth occurs. Cultures should be incubated for at least 7 days before being designated negative for genital <emphasis>Mollicutes</emphasis> and 6 weeks for <emphasis>M. pneumoniae. M. genitalium</emphasis> is seldom cultured in axenic medium from clinical specimens. Some investigators have recommended inclusion of a cell culture step in Vero cells before attempting growth on agar (<link linkend="ch0082s0000li0030">30</link>). PCR assays have made improvement of culture techniques for slow-growing and fastidious organisms, such as <emphasis>M. genitalium</emphasis> and <emphasis>M. fermentans</emphasis>, relatively unimportant clinically.</para>
    </sect1>
    <sect1 id="ch0082s0014">
      <title>Development of Colonies</title>
      <anchor id="ch0082s0014a0001"/>
      <anchor id="ch0082s0000a0066"/>
      <para id="ch0082s0000p0049">Broth cultures for<emphasis>Ureaplasma</emphasis> spp. should be examined for color changes resulting from hydrolysis of urea twice daily for up to 7 days because of the steep death phase of this organism in culture. This is less critical for <emphasis>Mycoplasma</emphasis> spp., for which once-daily inspection of broth cultures suffices. Agar plates should be examined using a stereomicroscope at a magnification of ×20 to ×60 daily for <emphasis>Ureaplasma</emphasis> spp., at 1- to 3-day intervals for <emphasis>M. hominis</emphasis>, and every 3 to 5 days for <emphasis>M. pneumoniae</emphasis> and other slower-growing species. <emphasis>Ureaplasma</emphasis> colonies (<link linkend="ch0082s0000a0029">Fig. 3</link>) can be identified on A8 agar by urease production in the presence of a CaCl<subscript>2</subscript> indicator contained in the medium. The larger <emphasis>M. hominis</emphasis> colonies are urease negative and often have the typical fried-egg appearance (<link linkend="ch0082s0000a0027">Fig. 1</link>). Other species, such as <emphasis>M. pneumoniae</emphasis> and <emphasis>M. genitalium</emphasis>, produce smaller spherical colonies which may or may not demonstrate a fried-egg appearance (<link linkend="ch0082s0000a0028">Fig. 2</link>). Methylene blue stain applied directly to the agar plate to turn the colonies blue is useful if there is uncertainty about whether colonies are present. <emphasis>M. hominis</emphasis> is the only pathogenic member of the <emphasis>Mollicutes</emphasis> of humans cultivable on bacteriological media such as chocolate agar and blood agar. However, the pinpoint translucent colonies are easily overlooked, and routine bacterial cultures may be discarded sooner than the time needed for <emphasis>M. hominis</emphasis> colonies to develop, which may be 4 days or more in some cases. Occurrence of suspicious colonies warrants subculture to appropriate media or molecular techniques for identification.</para>
      <anchor id="ch0082s0000a0067"/>
      <beginpage pagenum="1247"/>
    </sect1>
    <sect1 id="ch0082s0015">
      <title>Commercial Media and Culture Kits</title>
      <anchor id="ch0082s0015a0001"/>
      <anchor id="ch0082s0000a0068"/>
      <para id="ch0082s0000p0050">In response to the growing desires of many independent or hospital-based clinical laboratories to offer<emphasis>Mollicutes</emphasis> cultures on site, numerous companies have developed transport and growth media. A variety of kits for detection, quantitation, identification, and antimicrobial susceptibility testing of <emphasis>Ureaplasma</emphasis> spp. and <emphasis>M. hominis</emphasis> from urogenital specimens have been available in Europe for several years. Two products, Mycoscreen Plus and Mycofast US (ELITech Group, Puteaux, France), are available in the United States. Specimens are placed in a suspension transport medium and used to inoculate wells containing specific dried or lyophilized substrates and inhibitors. Identification and quantitation of organisms are based on color changes of specific wells containing substrates and antibiotics.</para>
      <para id="ch0082s0000p0051">Some kits and other commercial products and media sold in various countries have been evaluated by independent investigators (<link linkend="ch0082s0000li0077">77</link>, <link linkend="ch0082s0000li0123">123</link>, <link linkend="ch0082s0000li0124">124</link>). Commercial products and kits can be of value if the need to detect <emphasis>Mollicutes</emphasis> arises infrequently in laboratories which do not specialize in detection of <emphasis>Mollicutes</emphasis>, but users should be aware of the potential limitations of existing products. If commercially prepared media are utilized, laboratories must perform internal quality control tests.</para>
      <sect2 id="ch0082s0015s0001">
        <title>IDENTIFICATION</title>
        <anchor id="ch0082s0015a0002"/>
        <anchor id="ch0082s0000a0069"/>
        <para id="ch0082s0000p0052">Even though the numerous large-colony<emphasis>Mycoplasma</emphasis> species which can be isolated from humans cannot be identified based on colonial morphology or a particular biochemical profile, the body site of origin and rate of growth, in conjunction with biochemical features, provide clues. Biochemical properties such as glucose, arginine, or urea utilization are determined based on color changes in the absence of turbidity in appropriate broths. Utilization of glucose in SP4 broth produces an acidic shift (red to yellow), whereas utilization of arginine produces a red to deeper-red color change in the presence of a phenol red pH indicator. Urea or arginine utilization in 10B broth causes an alkaline shift of orange to deep red. Thus, a slow-growing glycolytic organism from the respiratory tract that produces spherical colonies on SP4 agar after approximately 5 to 20 days of incubation and exhibits hemolytic activity and hemadsorption with guinea pig erythrocytes is most likely to be <emphasis>M. pneumoniae.</emphasis> Oral commensal <emphasis>Mycoplasma</emphasis> spp. that can be present alone or simultaneously with <emphasis>M. pneumoniae</emphasis> usually result in an alkaline shift (pink to deep red) in SP4 medium and produce fried-egg-type colonies on agar. An alkaline color change which occurs after overnight incubation without turbidity in 10B broth containing urea is likely <emphasis>Ureaplasma</emphasis> spp., whereas a urogenital specimen that produces an alkaline reaction within 24 to 72 h in broth supplemented with arginine is likely to contain <emphasis>M. hominis.</emphasis> Examination of colonial morphology on agar containing urea and an indicator such as CaCl<subscript>2</subscript> is sufficient to identify <emphasis>Ureaplasma</emphasis> spp.; it is important to keep in mind that these organisms often coexist with <emphasis>M. hominis</emphasis> in urogenital specimens.</para>
        <para id="ch0082s0000p0053">To identify a large-colony<emphasis>Mycoplasma</emphasis> organism to the species level, several techniques are available, although they are more appropriately performed by a reference laboratory rather than a hospital microbiology laboratory because of their complexity and the lack of commercial availability of the reagents required. PCR is the best overall choice for species identification, since it is much simpler to perform than other methods and it does not require immunological reagents that are not readily available. PCR assays are also less subjective to interpret than older methods such as epi-immunofluorescence. An alternative for bacterial species identification, matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) has been applied by Pereyre and colleagues to the identification and subtyping of human <emphasis>Mollicutes</emphasis> (<link linkend="ch0082s0000li0125">125</link>). Following broth culture and protein extraction, MALDI-TOF MS accurately identified most human species, including <emphasis>M. pneumoniae, M. hominis</emphasis>, and <emphasis>Ureaplasma</emphasis> spp., and clustered <emphasis>M. pneumoniae</emphasis> isolates by their adhesin P1 type. However, 1 ml, 30 ml, and 100 ml of <emphasis>M. hominis, M. pneumoniae</emphasis>, and <emphasis>Ureaplasma</emphasis> sp. cultures were required for MALDI-TOF MS identification, limiting its routine use.</para>
      </sect2>
      <sect2 id="ch0082s0015s0002">
        <title>TYPING SYSTEMS</title>
        <anchor id="ch0082s0015a0003"/>
        <anchor id="ch0082s0000a0070"/>
        <para id="ch0082s0000p0054">Several methods for typing<emphasis>Mollicutes</emphasis> to study epidemiology in the case of <emphasis>M. pneumoniae</emphasis> and differential pathogenicity for the <emphasis>Ureaplasma</emphasis> serotypes have been described. Results of early studies attempting to study <emphasis>Ureaplasma</emphasis> pathogenicity were varied and inconsistent due to the inefficient and imprecise methods available, the occurrence of multiple cross-reactions, and the fact that many individuals harbor more than one species in their urogenital tract. Development of monoclonal antibodies enabled identification of multiple band antigens responsible for <emphasis>Ureaplasma</emphasis> serotype specificity on cell surfaces. PCR assays have enabled accurate characterization of the two <emphasis>Ureaplasma</emphasis> spp. Pulsed-field gel electrophoresis (PFGE) has been applied to <emphasis>Ureaplasma</emphasis> spp. to determine the size of the genome, and this technique can distinguish among most of the 14 <emphasis>Ureaplasma</emphasis> serotypes and detect differences within them (<link linkend="ch0082s0000li0126">126</link>, <link linkend="ch0082s0000li0127">127</link>). In view of the recent findings of extensive horizontal gene transfer among <emphasis>Ureaplasma</emphasis> serotypes and lack of association at the serovar level with any disease condition, serotyping is not recommended for diagnostic purposes (<link linkend="ch0082s0000li0026">26</link>). Multilocus sequence typing (MLST) has also been described for typing <emphasis>Ureaplasma</emphasis> spp. (<link linkend="ch0082s0000li0128">128</link>).</para>
        <anchor id="ch0082s0000a0071"/>
        <beginpage pagenum="1248"/>
        <para id="ch0082s0000p0055">Restriction fragment length polymorphism (RFLP) analysis, multiple-locus variable-number tandem-repeat analysis (MLVA), MLST, single nucleotide polymorphism (SNP) genotyping using SNaPshot technology, Western blotting, PCR assays, whole-genome sequencing, and various other techniques have been used to characterize<emphasis>M. pneumoniae</emphasis> clinical isolates (<link linkend="ch0082s0000li0129">129</link>–<link linkend="ch0082s0000li0135">135</link>). Most evaluations determined that there are two major genomic groups or subtypes distinguishable by analysis of the P1 adhesin gene, ORF6 gene, P65 gene and typical DNA restriction fragment pattern. MLVA is the most discriminant and frequently used method for <emphasis>M. pneumoniae</emphasis> typing, with more than 50 MLVA types identified and guidelines for interpretation proposed (<link linkend="ch0082s0000li0136">136</link>). Several typing methods have been developed for <emphasis>M. hominis.</emphasis> Most recently, these have included MLVA and MLST (<link linkend="ch0082s0000li0137">137</link>, <link linkend="ch0082s0000li0138">138</link>). The lack of clinical isolates for <emphasis>M. genitalium</emphasis> limits typing methods primarily to non-culture-based techniques. Analysis of SNPs in the <emphasis>mgpB</emphasis> adhesin gene or rRNA operon, short tandem repeat (STR) analysis of the putative lipoprotein gene MG309, and RFLP analysis of <emphasis>mgpC</emphasis> have been described (<link linkend="ch0082s0000li0139">139</link>–<link linkend="ch0082s0000li0141">141</link>). Facilities for typing of human mycoplasmas or ureaplasmas for epidemiological purposes are generally unavailable except in specialized research or reference laboratories. Strain typing is not normally utilized for clinical diagnostic purposes.</para>
      </sect2>
      <sect2 id="ch0082s0015s0003">
        <title>SEROLOGIC TESTS</title>
        <anchor id="ch0082s0015a0004"/>
        <anchor id="ch0082s0000a0072"/>
      </sect2>
    </sect1>
    <sect1 id="ch0082s0016">
      <title>M. pneumoniae Respiratory Disease</title>
      <anchor id="ch0082s0016a0001"/>
      <anchor id="ch0082s0000a0073"/>
      <para id="ch0082s0000p0056">Historically, serology has been the most common laboratory means for diagnosis of<emphasis>M. pneumoniae</emphasis> respiratory tract infections. Although culture and PCR are also used to detect the presence of <emphasis>M. pneumoniae</emphasis> in respiratory specimens, persistence of the organism for variable lengths of time following acute infection makes it difficult in some cases to assess the significance of a positive culture or PCR assay without additional confirmatory tests, such as seroconversion.</para>
      <para id="ch0082s0000p0057"><emphasis>M. pneumoniae</emphasis> has both lipid and protein antigens which elicit antibody responses that can be detected after about 1 week of illness, peaking at 3 to 6 weeks, followed by a gradual decline, allowing several types of serological assays, based on different antigens and technologies, to be used. Serology is a useful epidemiologic tool in circumstances where the likelihood of mycoplasmal disease is high but is less suited for assessment of individual patients in a timely manner. Its main disadvantage is the need for paired acute- and convalescent-phase serum samples collected 2 to 3 weeks apart that are tested simultaneously for IgM and IgG to confirm seroconversion. This is especially important in adults over 40 years of age who may not mount an IgM response, presumably because of reinfection (<link linkend="ch0082s0000li0142">142</link>). Moreover, IgM antibodies can persist for several weeks to months, making it risky to base diagnosis of acute infection on a single assay for IgM (<link linkend="ch0082s0000li0142">142</link>). Antibody production may also be delayed in some infections or may even be absent if patients are immunosuppressed. False-negative IgM results can also occur if serum is collected too soon after onset of illness. Since <emphasis>M. pneumoniae</emphasis> is a mucosal pathogen, IgA is typically produced early in the course of infection. Measurement of serum IgA may therefore be a better approach for diagnosis of acute infection because of its rapid rise and decline, but very few commercial assays include reagents for its detection. <anchor id="ch0082s0000a0074"/><link linkend="ch0082s0000a0076">Table 5</link> provides examples of various serological assays used to detect <emphasis>M. pneumoniae</emphasis> infection in the United States.</para>
      <para id="ch0082s0000p0058">Complement fixation (CF) was the primary method for serological testing for<emphasis>M. pneumoniae</emphasis> in the past. Although CF measures mainly early IgM response and to a lesser extent IgG, the test does not differentiate among antibody classes. Cross reactions with other organisms, most notably <emphasis>M. genitalium</emphasis>, are well recognized, and false-positive results due to cross-reactive autoantibodies induced by acute inflammation from other unrelated causes may occur. In most clinical laboratories, CF has been replaced by alternative techniques.</para>
      <para id="ch0082s0000p0059">Immunofluorescent antibody (IFA) assays, direct and indirect hemagglutination using IgM capture, and other particle agglutination antibody assays (PAs) have been developed to detect antibody to<emphasis>M. pneumonia</emphasis>e (<link linkend="ch0082s0000li0143">143</link>–<link linkend="ch0082s0000li0145">145</link>). IFA assays consist of <emphasis>M. pneumoniae</emphasis> antigen affixed to microscope slides that allow separate measurements of IgM and IgG. This assay is technically simple to perform but subjective in interpretation and requires a fluorescent microscope; moreover, the presence of <emphasis>M. pneumoniae</emphasis>-specific IgG may interfere with IgM results. Qualitative and semiquantitative PAs using either latex beads or gelatin that detect IgM and IgG simultaneously can be technically easy to perform but do not offer significant advantages over enzyme immunoassays (EIAs). Though commonly used in some countries because of their ease and simplicity of performance, PAs have not been widely used for serological diagnosis of <emphasis>M. pneumoniae</emphasis> infections in the United States.</para>
      <para id="ch0082s0000p0060">EIAs, developed in the 1970s, have become the most widely used methods for detection of<emphasis>M. pneumoniae</emphasis> antibody in the United States. They are classified as having either moderate or high complexity according to CLIA. They are qualitative or quantitative and may or may not require specialized equipment. EIAs are more sensitive than CF or culture and can be performed with small volumes of serum. The need for acute- and convalescent-phase serum samples has limited their utility for prompt diagnosis. A membrane-based EIA specific for IgM, the ImmunoCard (Meridian Bioscience, Inc., Cincinnati, OH), was developed for rapid detection of acute <emphasis>M. pneumoniae</emphasis> infection using a single serum specimen. However, in one study, this EIA had a sensitivity of only 31.8% when single serum samples from seropositive children with pneumonia were analyzed, increasing to 88% when paired sera were analyzed (<link linkend="ch0082s0000li0146">146</link>). The Remel EIA (Thermo Fisher, Waltham, MA) is another rapid point-of care qualitative serologic assay that detects both IgM and IgG simultaneously in an easy-to-read format without the need for instrumentation. This test has shown good sensitivity and specificity compared to other EIAs, IFA assays, and CF tests.</para>
      <para id="ch0082s0000p0061">Several comparison studies have been performed, evaluating each of the EIA kits listed in<link linkend="ch0082s0000a0076">Table 5</link> and various others (<link linkend="ch0082s0000li0143">143</link>–<link linkend="ch0082s0000li0145">145</link>, <link linkend="ch0082s0000li0147">147</link>–<link linkend="ch0082s0000li0152">152</link>). A comprehensive evaluation of 12 commercial EIAs and PAs was performed in the Netherlands using PCR as a reference standard. The authors found that most assays had problems with sensitivity and specificity, limiting their use in diagnosis of acute infection, affirming the necessity of testing both IgM and IgG in paired sera from adults, and suggesting that PCR assays are the preferred diagnostic approach (<link linkend="ch0082s0000li0150">150</link>). Another evaluation of 10 serological kits used in Europe found considerable variation in sensitivity and specificity (<link linkend="ch0082s0000li0153">153</link>). In another study (<link linkend="ch0082s0000li0154">154</link>), sera from a substantial proportion of healthy blood donors had measurable antibody against <emphasis>M. pneumoniae</emphasis>, suggesting cross-reactivity of the antigens used in some of the commercial EIAs and the likelihood of overdiagnosis of <emphasis>M. pneumoniae</emphasis> infections if used.</para>
      <anchor id="ch0082s0000a0075"/>
      <beginpage pagenum="1249"/>
      <table id="ch0082s0000t0005"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0082s0000a0076"/><link linkend="ch0082s0000a0074">TABLE 5</link></phrase></emphasis> Examples of test kits for detection of serum antibodies to <emphasis>M. pneumoniae</emphasis> sold in the United States<superscript><emphasis><anchor id="ch0082s0000a0077"/><link linkend="ch0082s0000a0078">a</link></emphasis></superscript>
</title>
        
        <tgroup cols="8">
          <tbody>
            <row>
              <entry><phrase role="center">Product name</phrase>
              </entry>
              <entry><phrase role="center">Manufacturer</phrase>
              </entry>
              <entry><phrase role="center">Antibodies measured</phrase>
              </entry>
              <entry><phrase role="center">Assay format and description</phrase>
              </entry>
              <entry><phrase role="center">No. tests/kit</phrase>
              </entry>
              <entry><phrase role="center">Specimen throughput</phrase>
              </entry>
              <entry><phrase role="center">Assay time</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Start to finish</phrase>
              </entry>
              <entry><phrase role="center">Hands on</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>M. pneumoniae</emphasis> antibody test system</phrase>
              </entry>
              <entry><phrase role="left">Zeus Scientific Inc., Branchburg, NJ</phrase>
              </entry>
              <entry><phrase role="left">IgM and IgG separately</phrase>
              </entry>
              <entry><phrase role="left">Indirect immunofluorescence assay available as a slurry of <emphasis>M. pneumoniae</emphasis> antigenic substrate or a CrownTitre of <emphasis>M. pneumoniae</emphasis> colonies affixed to microscope slides</phrase>
              </entry>
              <entry><phrase role="left">100</phrase>
              </entry>
              <entry><phrase role="left">Each slide contains 10 wells</phrase>
              </entry>
              <entry><phrase role="left">2.5 h</phrase>
              </entry>
              <entry><phrase role="left">30 min</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">ImmunoCard</phrase>
              </entry>
              <entry><phrase role="left">Meridian Bioscience, Cincinnati, OH</phrase>
              </entry>
              <entry><phrase role="left">IgM only</phrase>
              </entry>
              <entry><phrase role="left">Qualitative, membrane-based, enzyme immunoassay in a single sample card format consisting of a test port containing <emphasis>M. pneumoniae</emphasis> antigen and a control port containing immobilized human IgM</phrase>
              </entry>
              <entry><phrase role="left">30</phrase>
              </entry>
              <entry><phrase role="left">1 specimen/card</phrase>
              </entry>
              <entry><phrase role="left">12 min</phrase>
              </entry>
              <entry><phrase role="left">10 min</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>M. pneumoniae</emphasis> IgG/IgM antibody test system</phrase>
              </entry>
              <entry><phrase role="left">Thermo Fisher (Remel), Lenexa, KS</phrase>
              </entry>
              <entry><phrase role="left">IgM and IgG simultaneously</phrase>
              </entry>
              <entry><phrase role="left">Qualitative, membrane-based, enzyme immunobinding assay consisting of a single sample test containing inactivated <emphasis>M. pneumoniae</emphasis> cytadhesin protein</phrase>
              </entry>
              <entry><phrase role="left">10 or 40</phrase>
              </entry>
              <entry><phrase role="left">1 specimen/card</phrase>
              </entry>
              <entry><phrase role="left">10 min</phrase>
              </entry>
              <entry><phrase role="left">2–3 min</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Mycoplasma</emphasis> IgG and IgM ELISA test system</phrase>
              </entry>
              <entry><phrase role="left">Zeus Scientific, Inc., Branchburg, NJ</phrase>
              </entry>
              <entry><phrase role="left">IgM and IgG separately</phrase>
              </entry>
              <entry><phrase role="left">Qualitative enzyme immunoassay in multiwell breakaway strips containing partially purified inactivated <emphasis>M. pneumoniae</emphasis></phrase>
              </entry>
              <entry><phrase role="left">96</phrase>
              </entry>
              <entry><phrase role="left">Strips of 8 wells</phrase>
              </entry>
              <entry><phrase role="left">50 min</phrase>
              </entry>
              <entry><phrase role="left">5–10 min</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">GenBio ImmunoWell <emphasis>Mycoplasma pneumoniae</emphasis> IgM and IgG</phrase>
              </entry>
              <entry><phrase role="left">GenBio, San Diego, CA</phrase>
              </entry>
              <entry><phrase role="left">IgM and IgG separately</phrase>
              </entry>
              <entry><phrase role="left">Enzyme immunoassay in a 96-well microtiter plate format coated with purified glycolipid <emphasis>M. pneumoniae</emphasis> antigen</phrase>
              </entry>
              <entry><phrase role="left">96</phrase>
              </entry>
              <entry><phrase role="left">Strips of 8 wells</phrase>
              </entry>
              <entry><phrase role="left">IgG 2.35 h, IgM 2.75 h</phrase>
              </entry>
              <entry><phrase role="left">15–20 min</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0078"/><link linkend="ch0082s0000a0077">a</link></emphasis></superscript>This table does not include all commercially available test kits for serological diagnosis of <emphasis>M. pneumoniae</emphasis> infections sold in the United States. It provides descriptions of tests representing various formats and is limited to products which have been evaluated in independent studies.</para>
      <para id="ch0082s0000p0062">Selection of the best commercial EIA for individual patient diagnosis depends on the age of the patient being tested, timing of serum collection, whether paired sera are available, equipment available, and experience of the laboratory personnel who will perform the test. However, maintaining a large variety of different assays within one laboratory is not practical or cost-effective. A combination of IgM serology and PCR might be an optimum diagnostic approach, but it could be less useful in adults who do not mount an IgM response and would add considerable cost to laboratory testing. Cold agglutinins, detected by agglutination of type O Rh-negative erythrocytes at 4°C, occur in association with<emphasis>M. pneumoniae</emphasis> infection, but only in about 50% of cases, and are not specific; therefore, detection of cold agglutinins is not recommended for diagnosis of <emphasis>M. pneumoniae</emphasis> infection.</para>
    </sect1>
    <sect1 id="ch0082s0017">
      <title>Infections Due to Genital Mollicutes</title>
      <anchor id="ch0082s0017a0001"/>
      <anchor id="ch0082s0000a0079"/>
      <para id="ch0082s0000p0063">Serological tests for<emphasis>M. hominis</emphasis> and <emphasis>Ureaplasma</emphasis> spp. using the techniques of microimmunofluorescence, metabolism inhibition, and EIA have been described (<link linkend="ch0082s0000li0155">155</link>–<link linkend="ch0082s0000li0157">157</link>). A microimmunofluorescence assay for <emphasis>M. genitalium</emphasis> has also been developed (<link linkend="ch0082s0000li0158">158</link>) and shown to detect antibody responses in men with NGU (<link linkend="ch0082s0000li0159">159</link>) and women with salpingitis (<link linkend="ch0082s0000li0160">160</link>). This method is rapid, reproducible, and sensitive and specific, with less cross-reactivity with <emphasis>M. pneumoniae</emphasis> than other methods. A sensitive and specific serological assay for <emphasis>M. genitalium</emphasis> using lipid-associated membrane proteins as antigens has also been developed, and this technique has been used in combination with Western blotting to assess immunoreactivity of women who were culture positive for <emphasis>M. genitalium</emphasis> (<link linkend="ch0082s0000li0161">161</link>). No serological tests for genital mycoplasmas have been standardized and made commercially available for diagnostic use in the United States. Overall, serologic tests for genital <emphasis>Mollicutes</emphasis> infections cannot be recommended for routine diagnostic purposes.</para>
      <sect2 id="ch0082s0017s0001">
        <title>ANTIMICROBIAL SUSCEPTIBILITIES</title>
        <anchor id="ch0082s0017a0002"/>
        <anchor id="ch0082s0000a0080"/>
      </sect2>
    </sect1>
    <sect1 id="ch0082s0018">
      <title>Methods</title>
      <anchor id="ch0082s0018a0001"/>
      <anchor id="ch0082s0000a0081"/>
      <para id="ch0082s0000p0064">Several methods of susceptibility testing used for conventional bacteria have been employed for testing<emphasis>Mollicutes.</emphasis> Agar dilution has been used as a reference method (<link linkend="ch0082s0000li0162">162</link>). It has the advantage of a relatively stable endpoint over time, the inoculum size does not have a great effect, and it allows detection of mixed cultures readily. However, this technique is not practical for testing small numbers of strains or occasional isolates encountered in diagnostic laboratories. Agar disk diffusion is not useful, since there has been no correlation between inhibitory zones and MICs, and the relatively slow growth of these organisms limits application of this technology. Studies using the agar gradient diffusion technique (Etest; bioMérieux, Marcy-l’Etoile, France) for detection of tetracycline and fluoroquinolone susceptibilities of <emphasis>M. hominis</emphasis> and <emphasis>Ureaplasma</emphasis> spp. yielded results comparable to those of broth microdilution and agar dilution, though procedures for performing Etest MIC testing are not standardized (<link linkend="ch0082s0000li0163">163</link>–<link linkend="ch0082s0000li0165">165</link>). Staining plates with Dienes stain helps visualize the ellipse on the agar plate. Etest advantages include the simplicity of agar-based testing, an endpoint that does not shift over time, no large inoculum effect, and ease of use for testing single isolates. This technique is adaptable for laboratories not specializing in <emphasis>Mollicutes</emphasis> diagnosis that encounter isolates needing susceptibility tests only on an occasional basis. Etests are commercially available, can be maintained frozen for 3 to 5 years, and work well with commercial SP4 broth and agar. Broth microdilution is the most practical and widely used method to determine MICs. It is economical and allows several antimicrobials to be tested in the same microtiter plate, but it has disadvantages in that preparation of antimicrobial dilutions is labor intense and endpoints tend to shift over time (<link linkend="ch0082s0000li0121">121</link>).</para>
      <anchor id="ch0082s0000a0082"/>
      <beginpage pagenum="1250"/>
      <para id="ch0082s0000p0065">Standardized consensus-based methods, designated quality control reference strains with defined MIC ranges, medium formulations for broth microdilution and agar dilution, and MIC breakpoints for selected antimicrobial agents have been published for human mycoplasmas and ureaplasmas by the Clinical and Laboratory Standards Institute (CLSI) (<link linkend="ch0082s0000li0166">166</link>). Since standardized methods for MIC determination and quality control are available, these procedures should be used when MIC testing is needed. Bactericidal activity can be tested directly from the wells in broth microdilution MIC assays that have not changed color by removing the mixture of organisms and antibiotic, diluting it to subinhibitory concentrations in fresh medium, and observing it for a color change as evidence of growth. This method is described in more detail in another publication (<link linkend="ch0082s0000li0121">121</link>).</para>
      <para id="ch0082s0000p0066">Susceptibility testing kits using the broth microdilution technique, such as Mycoplasma IST3 (bioMérieux, Marcy-l’Etoile, France), Mycofast RevolutioN (ELItech Group, Puteaux, France), and the Myco Well D-One assay (CPM SAS, Rome, Italy), are sold in Europe. Some of these kits combine detection and identification in the same product. They consist of microwells containing dried antimicrobials, generally in one or two concentrations corresponding to the thresholds proposed for conventional bacteria to classify the strains as susceptible, intermediate, or resistant. They can have design limitations, such as an inappropriate choice of antibiotic or concentration, the inability to provide an antibiotic susceptibility profile in case of a mixed infection with<emphasis>Ureaplasma</emphasis> spp. and <emphasis>M. hominis</emphasis>, and the inability with some kits to calculate the bacterial inoculum required for CLSI-recommended antibiotic susceptibility testing (<link linkend="ch0082s0000li0167">167</link>). The three devices cited above are the only assays available that evaluate antimicrobial susceptibilities separately for <emphasis>Ureaplasma</emphasis> spp. and <emphasis>M. hominis</emphasis> using CLSI-defined antimicrobial concentrations (<link linkend="ch0082s0000li0166">166</link>).</para>
      <para id="ch0082s0000p0067">Molecular assays to detect mutations in 23S rRNA that confer macrolide resistance directly from clinical specimens without the need to isolate the organisms in culture have been developed for the fastidious species,<emphasis>M. pneumoniae</emphasis> (<link linkend="ch0082s0000li0168">168</link>–<link linkend="ch0082s0000li0170">170</link>) and <emphasis>M. genitalium</emphasis> (<link linkend="ch0082s0000li0171">171</link>–<link linkend="ch0082s0000li0175">175</link>) in which macrolide resistance is problematic. Currently, there are two assays that detect <emphasis>M. pneumoniae</emphasis> and/or 23S rRNA macrolide resistance-associated mutations, the Genecube <emphasis>Mycoplasma pneumoniae</emphasis> assay (Toyobo Co., Ltd., Osaka, Japan), which is newly approved in Japan (<link linkend="ch0082s0000li0176">176</link>), and the Lightmix Mycoplasma macrolide assay (TibMolBiol, Berlin, Germany) available for research use only in Europe (<link linkend="ch0082s0000li0177">177</link>).</para>
      <para id="ch0082s0000p0068">Several commercial NAATs which can detect<emphasis>M. genitalium</emphasis> and its macrolide resistance-associated mutations have been CE marked and are sold in Europe, the United Kingdom, and Australia, although no assays capable of resistance detection in <emphasis>M. genitalium</emphasis> are currently FDA cleared. These assays can detect 4 to 6 mutations in the 23S rRNA gene responsible for macrolide resistance in <emphasis>M. genitalium</emphasis> (<link linkend="ch0082s0000a0054">Table 4</link>). The Allplex MG &amp; AziR (Seegene, Seoul, South Korea), the Macrolide-R/MG ELITe MGB (ELITechGroup, Puteaux, France), the ResistancePlus MG FleXible (SpeeDx-Cepheid, Sunnyvale, CA), the ResistancePlus MG (SpeeDx, Ltd., Sydney, Australia), the S-DiaMGRes (Diagenode S.A., Denville, NJ), and the RealAccurate TVMGres (PathoFinder B.V., Maastricht, Netherlands) assays performed well in comparison to laboratory-developed procedures for <emphasis>M. genitalium</emphasis> detection and melting curve analysis or Sanger sequencing to determine 23S rRNA gene mutations (<link linkend="ch0082s0000li0178">178</link>–<link linkend="ch0082s0000li0180">180</link>).</para>
    </sect1>
    <sect1 id="ch0082s0019">
      <title>Susceptibility Profiles and Treatment</title>
      <anchor id="ch0082s0019a0001"/>
      <anchor id="ch0082s0000a0083"/>
      <para id="ch0082s0000p0069">A comparison of MICs for several antimicrobial agents is shown in<anchor id="ch0082s0000a0084"/><link linkend="ch0082s0000a0086">Table 6</link>. <emphasis>Mollicutes</emphasis> are innately resistant to all β-lactams, sulfonamides, trimethoprim, and rifampin. Resistance to macrolides and lincosamides is variable by species, with <emphasis>M. hominis</emphasis> being resistant to erythromycin and other 14- and 15-membered macrolides but susceptible to clindamycin. For <emphasis>Ureaplasma</emphasis> spp., the reverse is true. Newer macrolides and ketolides have <emphasis>in vitro</emphasis> activity comparable to or better than that of erythromycin for <emphasis>M. pneumoniae</emphasis> and <emphasis>M. genitalium</emphasis>.</para>
      <para id="ch0082s0000p0070"><emphasis>M. pneumoniae</emphasis> has historically been predictably susceptible to fluoroquinolones, tetracyclines, and macrolides, so that susceptibility testing has not been recommended except for the <emphasis>in vitro</emphasis> evaluation of new and previously untested agents. However, studies from Japan, China, Europe, and the United States show that high-level macrolide resistance in <emphasis>M. pneumoniae</emphasis> due to mutations in domain V of the 23S rRNA gene have been spreading worldwide since 2000 in children and adults with acute respiratory infections. The prevalence of macrolide resistance in <emphasis>M. pneumoniae</emphasis> is now as high as 26% in some countries in Europe, 30% in Israel, and 90 to 100% in Asia (<link linkend="ch0082s0000li0006">6</link>). A national surveillance study performed in the United States between 2015 and 2018 found that macrolide resistance ranged from 2.1% in the western U.S. to 18.3% in the southern and eastern regions of the country (<link linkend="ch0082s0000li0181">181</link>). A more recent study reported a 10% rate of macrolide resistance in the midwestern region of the United States (<link linkend="ch0082s0000li0182">182</link>). In a recent study investigating the global <emphasis>M. pneumoniae</emphasis> incidence after implementation of nonpharmaceutical interventions (NPIs) against COVID-19, macrolide resistance in <emphasis>M. pneumoniae</emphasis> was reported from seven sites (Europe, Asia, and the United States) and detected in 4.6% of investigated cases during the period from April 2020 to March 2021 and 23.1% during the period from April 2017 to March 2020 (<emphasis>P</emphasis> = 0.04) (<link linkend="ch0082s0000li0183">183</link>).</para>
      <anchor id="ch0082s0000a0085"/>
      <beginpage pagenum="1251"/>
      <table id="ch0082s0000t0006"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0082s0000a0086"/><link linkend="ch0082s0000a0084">TABLE 6</link></phrase></emphasis> MIC ranges of various antimicrobials for <emphasis>M. pneumoniae, M. hominis, M. fermentans, M. genitalium</emphasis>, and <emphasis>Ureaplasma</emphasis> spp.<superscript><emphasis><anchor id="ch0082s0000a0087"/><link linkend="ch0082s0000a0093">a</link></emphasis></superscript>
</title>
        
        <tgroup cols="6">
          <tbody>
            <row>
              <entry><phrase role="left">Antimicrobial</phrase>
              </entry>
              <entry><phrase role="center">MIC range (μg/ml) for:</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">
                  <superscript>
                    <emphasis>M. pneumoniae</emphasis>
                  </superscript>
                </phrase>
              </entry>
              <entry><phrase role="center">
                  <superscript>
                    <emphasis>M. hominis</emphasis>
                  </superscript>
                </phrase>
              </entry>
              <entry><phrase role="center">
                  <superscript>
                    <emphasis>M. genitalium</emphasis>
                  </superscript>
                </phrase>
              </entry>
              <entry><phrase role="center">
                  <superscript>
                    <emphasis>M. fermentans</emphasis>
                  </superscript>
                </phrase>
              </entry>
              <entry><phrase role="center"><emphasis>Ureaplasma</emphasis> spp.</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Tetracycline</phrase>
              </entry>
              <entry><phrase role="center">0.06 to 0.25</phrase>
              </entry>
              <entry><phrase role="center">0.2 to 2<superscript><emphasis><anchor id="ch0082s0000a0088"/><link linkend="ch0082s0000a0094">b</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">≤0.01 to 0.05</phrase>
              </entry>
              <entry><phrase role="center">0.1 to 1</phrase>
              </entry>
              <entry><phrase role="center">0.05 to 2<superscript><emphasis><link linkend="ch0082s0000a0094">b</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Doxycycline</phrase>
              </entry>
              <entry><phrase role="center">0.02 to 0.5</phrase>
              </entry>
              <entry><phrase role="center">0.1 to 2<superscript><emphasis><link linkend="ch0082s0000a0094">b</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">≤0.01 to 0.3</phrase>
              </entry>
              <entry><phrase role="center">0.05 to 1</phrase>
              </entry>
              <entry><phrase role="center">0.02 to 1<superscript><emphasis><link linkend="ch0082s0000a0094">b</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Eravacycline</phrase>
              </entry>
              <entry><phrase role="center">0.004-0.008</phrase>
              </entry>
              <entry><phrase role="center">0.002 to 0.008<superscript><emphasis><anchor id="ch0082s0000a0089"/><link linkend="ch0082s0000a0095">c</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">0.002 to 2<superscript><emphasis><link linkend="ch0082s0000a0095">c</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">0.032 to 0.25<superscript><emphasis><link linkend="ch0082s0000a0095">c</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Minocycline</phrase>
              </entry>
              <entry><phrase role="center">0.06 to 0.5</phrase>
              </entry>
              <entry><phrase role="center">0.03 to 1<superscript><emphasis><link linkend="ch0082s0000a0094">b</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center"><emphasis role="underline">&lt;</emphasis>0.01 to 0.2</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">0.06 to 1<superscript><emphasis><link linkend="ch0082s0000a0094">b</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Omadacycline</phrase>
              </entry>
              <entry><phrase role="center">0.125 to 0.25</phrase>
              </entry>
              <entry><phrase role="center">0.016 to 0.125<superscript><emphasis><link linkend="ch0082s0000a0095">c</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">0.063 to 0.25<superscript><emphasis><link linkend="ch0082s0000a0095">c</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">0.25 to 2<superscript><emphasis><link linkend="ch0082s0000a0095">c</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Tigecycline</phrase>
              </entry>
              <entry><phrase role="center">0.06 to 0.25</phrase>
              </entry>
              <entry><phrase role="center">0.125 to 0.5<superscript><emphasis><link linkend="ch0082s0000a0095">c</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">1 to 16<superscript><emphasis><link linkend="ch0082s0000a0095">c</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Erythromycin</phrase>
              </entry>
              <entry><phrase role="center">≤0.004 to 0.06<superscript><emphasis><anchor id="ch0082s0000a0090"/><link linkend="ch0082s0000a0096">d</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">32 to &gt;1,000</phrase>
              </entry>
              <entry><phrase role="center">≤0.01<superscript><emphasis><link linkend="ch0082s0000a0096">d</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">0.5 to 64</phrase>
              </entry>
              <entry><phrase role="center">0.02 to 4<superscript><emphasis><link linkend="ch0082s0000a0096">d</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Clarithromycin</phrase>
              </entry>
              <entry><phrase role="center">≤0.004 to 0.125<superscript><emphasis><link linkend="ch0082s0000a0096">d</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">16 to &gt;256</phrase>
              </entry>
              <entry><phrase role="center">≤0.01<superscript><emphasis><link linkend="ch0082s0000a0096">d</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">1 to 64</phrase>
              </entry>
              <entry><phrase role="center">≤0.004 to 2<superscript><emphasis><link linkend="ch0082s0000a0096">d</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Azithromycin</phrase>
              </entry>
              <entry><phrase role="center">≤0.004 to 0.01<superscript><emphasis><link linkend="ch0082s0000a0096">d</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">4 to 64</phrase>
              </entry>
              <entry><phrase role="center">≤0.01<superscript><emphasis><link linkend="ch0082s0000a0096">d</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">≤0.003 to 0.05</phrase>
              </entry>
              <entry><phrase role="center">0.5 to 4<superscript><emphasis><link linkend="ch0082s0000a0096">d</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Telithromycin</phrase>
              </entry>
              <entry><phrase role="center"><emphasis role="underline">&lt;</emphasis>0.008 to 0.06<superscript><emphasis><link linkend="ch0082s0000a0096">d</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">2 to 32</phrase>
              </entry>
              <entry><phrase role="center"><emphasis role="underline">&lt;</emphasis>0.015<superscript><emphasis><link linkend="ch0082s0000a0096">d</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">0.06 to 0.25</phrase>
              </entry>
              <entry><phrase role="center"><emphasis role="underline">&lt;</emphasis>0.015 to 0.25<superscript><emphasis><link linkend="ch0082s0000a0096">d</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Solithromycin</phrase>
              </entry>
              <entry><phrase role="center">&lt;0.000000063 to 0.5<superscript><emphasis><anchor id="ch0082s0000a0091"/><link linkend="ch0082s0000a0097">e</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">0.002 to 0.008</phrase>
              </entry>
              <entry><phrase role="center">&lt;0.000032</phrase>
              </entry>
              <entry><phrase role="center">&lt;0.008</phrase>
              </entry>
              <entry><phrase role="center">0.002 to 0.063</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Clindamycin</phrase>
              </entry>
              <entry><phrase role="center">≤0.008 to 2</phrase>
              </entry>
              <entry><phrase role="center">≤0.008 to 2</phrase>
              </entry>
              <entry><phrase role="center">0.2 to 1</phrase>
              </entry>
              <entry><phrase role="center">0.01 to 0.25</phrase>
              </entry>
              <entry><phrase role="center">0.2 to 64</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Chloramphenicol</phrase>
              </entry>
              <entry><phrase role="center">2</phrase>
              </entry>
              <entry><phrase role="center">2 to 25</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">0.5 to 10</phrase>
              </entry>
              <entry><phrase role="center">0.4 to 8</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Gentamicin</phrase>
              </entry>
              <entry><phrase role="center">4</phrase>
              </entry>
              <entry><phrase role="center">2 to 16</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">0.25 to &gt;500</phrase>
              </entry>
              <entry><phrase role="center">0.1 to 13</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Ciprofloxacin</phrase>
              </entry>
              <entry><phrase role="center">0.5 to 2</phrase>
              </entry>
              <entry><phrase role="center">0.1 to 4</phrase>
              </entry>
              <entry><phrase role="center">2</phrase>
              </entry>
              <entry><phrase role="center">0.02 to &gt;64</phrase>
              </entry>
              <entry><phrase role="center">0.1 to 16</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Levofloxacin</phrase>
              </entry>
              <entry><phrase role="center">0.5 to 1</phrase>
              </entry>
              <entry><phrase role="center">0.1 to 2<superscript><emphasis><anchor id="ch0082s0000a0092"/><link linkend="ch0082s0000a0098">f</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">0.5 to 1</phrase>
              </entry>
              <entry><phrase role="center">0.05 to 1</phrase>
              </entry>
              <entry><phrase role="center">0.2 to 2<superscript><emphasis><link linkend="ch0082s0000a0098">f</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Moxifloxacin</phrase>
              </entry>
              <entry><phrase role="center">0.06 to 0.125</phrase>
              </entry>
              <entry><phrase role="center">0.06 to 0.125<superscript><emphasis><link linkend="ch0082s0000a0098">f</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">0.03 to 0.06</phrase>
              </entry>
              <entry><phrase role="center">≤0.015 to 0.06</phrase>
              </entry>
              <entry><phrase role="center">0.125 to 1<superscript><emphasis><link linkend="ch0082s0000a0098">f</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Garenoxacin</phrase>
              </entry>
              <entry><phrase role="center"><emphasis role="underline">&lt;</emphasis>0.008 to 0.125</phrase>
              </entry>
              <entry><phrase role="center"><emphasis role="underline">&lt;</emphasis>0.008 to 0.063<superscript><emphasis><link linkend="ch0082s0000a0098">f</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">0.06 to 0.125</phrase>
              </entry>
              <entry><phrase role="center"><emphasis role="underline">&lt;</emphasis>0.008 to 0.015</phrase>
              </entry>
              <entry><phrase role="center">0.016 to 1<superscript><emphasis><link linkend="ch0082s0000a0098">f</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Gemifloxacin</phrase>
              </entry>
              <entry><phrase role="center">0.05 to 0.125</phrase>
              </entry>
              <entry><phrase role="center">0.0025 to 0.01<superscript><emphasis><link linkend="ch0082s0000a0098">f</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">0.05 to 0.125</phrase>
              </entry>
              <entry><phrase role="center">0.001 to 0.01</phrase>
              </entry>
              <entry><phrase role="center">0.03 to 0.5<superscript><emphasis><link linkend="ch0082s0000a0098">f</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Delafloxacin</phrase>
              </entry>
              <entry><phrase role="center">0.063 to 0.5</phrase>
              </entry>
              <entry><phrase role="center">0.008 to 0.016</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center"><emphasis role="underline">&lt;</emphasis>0.001 to 0.016</phrase>
              </entry>
              <entry><phrase role="center"><emphasis role="underline">&lt;</emphasis>0.008 to 1</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Gepotidacin</phrase>
              </entry>
              <entry><phrase role="center">0.032 to 0.125</phrase>
              </entry>
              <entry><phrase role="center">0.5 to 2</phrase>
              </entry>
              <entry><phrase role="center"><emphasis role="underline">&lt;</emphasis>0.016 to 0.5</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">1 to 8</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Rifampin</phrase>
              </entry>
              <entry><phrase role="center">&gt;8</phrase>
              </entry>
              <entry><phrase role="center">&gt;1000</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">25 to &gt;50</phrase>
              </entry>
              <entry><phrase role="center">&gt;1,000</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Quinupristin/dalfopristin</phrase>
              </entry>
              <entry><phrase role="center">0.008 to 0.06</phrase>
              </entry>
              <entry><phrase role="center">0.03 to 8</phrase>
              </entry>
              <entry><phrase role="center">0.05</phrase>
              </entry>
              <entry><phrase role="center">0.1 to 0.5</phrase>
              </entry>
              <entry><phrase role="center">0.03 to 0.5</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Pristinamycin</phrase>
              </entry>
              <entry><phrase role="center">0.02 to 0.05</phrase>
              </entry>
              <entry><phrase role="center">0.1 to 0.5</phrase>
              </entry>
              <entry><phrase role="center">&lt;0.01 to 0.02</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">0.1 to 1</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Linezolid</phrase>
              </entry>
              <entry><phrase role="center"><emphasis role="underline">&gt;</emphasis>64</phrase>
              </entry>
              <entry><phrase role="center">2 to 8</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">&gt;64</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Lefamulin</phrase>
              </entry>
              <entry><phrase role="center"><emphasis role="underline">&lt;</emphasis>0.001 to 0.008<superscript><emphasis><link linkend="ch0082s0000a0097">e</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center"><emphasis role="underline">&lt;</emphasis>0.001 to 0.063<superscript><emphasis><link linkend="ch0082s0000a0097">e</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0093"/><link linkend="ch0082s0000a0087">a</link></emphasis></superscript>Data were compiled from multiple publications in which different methodologies and often different antimicrobial concentrations were used. ND, no data available.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0094"/><link linkend="ch0082s0000a0088">b</link></emphasis></superscript>Tetracycline-susceptible isolates only. Tetracycline MICs for resistant isolates containing <emphasis>tetM</emphasis> are 2 to &gt;64 μg/ml.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0095"/><link linkend="ch0082s0000a0089">c</link></emphasis></superscript>Includes tetracycline-resistant isolates.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0096"/><link linkend="ch0082s0000a0090">d</link></emphasis></superscript>Macrolide-susceptible isolates only. Macrolide MICs for resistant isolates containing mutations in the rRNA gene are <emphasis role="underline">&gt;</emphasis>16 μg/ml.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0097"/><link linkend="ch0082s0000a0091">e</link></emphasis></superscript>Includes macrolide-resistant strains.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0082s0000a0098"/><link linkend="ch0082s0000a0092">f</link></emphasis></superscript>Fluoroquinolone-susceptible strains only. Levofloxacin MICs for resistant isolates containing mutations in quinolone resistance-determining regions are 4 to 32 μg/ml.</para>
      <para id="ch0082s0000p0071">High-level resistance can be clinically significant, sometimes necessitating changes to alternative treatments such as tetracyclines or fluoroquinolones (<link linkend="ch0082s0000li0006">6</link>, <link linkend="ch0082s0000li0168">168</link>, <link linkend="ch0082s0000li0184">184</link>). The new pleuromutilin lefamulin demonstrates activity <emphasis>in vitro</emphasis> against <emphasis>M. pneumoniae</emphasis> isolates with high-level macrolide resistance and may be another alternative for treatment of macrolide-resistant <emphasis>M. pneumoniae</emphasis> (<link linkend="ch0082s0000li0185">185</link>). Molecular methods to detect 23S rRNA gene mutations directly in clinical specimens by PCR enables monitoring of resistance trends without having to isolate <emphasis>M. pneumoniae</emphasis> in culture and can provide rapid diagnostic information, though no assays are yet FDA cleared. Some isolates of <emphasis>Ureaplasma</emphasis> spp. contain ribosomal mutations conferring high-level macrolide resistance (<link linkend="ch0082s0000li0186">186</link>, <link linkend="ch0082s0000li0187">187</link>). However, such resistance is believed to be uncommon in the United States.</para>
      <para id="ch0082s0000p0072">Tetracycline resistance has been well documented in<emphasis>M. hominis</emphasis> and <emphasis>Ureaplasma</emphasis> spp. since the mid-1980s, mediated by the <emphasis>tet</emphasis>(M) determinant, which codes for a protein that binds to the ribosomes, protecting them from the actions of these drugs. The extent to which tetracycline resistance occurs in <emphasis>M. hominis</emphasis> and <emphasis>Ureaplasma</emphasis> spp. varies geographically and according to prior antimicrobial exposure in different populations, but it approaches 40 to 50% in some locations in the United States (<link linkend="ch0082s0000li0011">11</link>). In France, 7.5% and 14.8% of <emphasis>Ureaplasma</emphasis> spp. and <emphasis>M. hominis</emphasis> isolates, respectively, were reported to be tetracycline resistant between 2010 and 2015. All resistant strains harbored the <emphasis>tet</emphasis>(M) gene (<link linkend="ch0082s0000li0188">188</link>).</para>
      <para id="ch0082s0000p0073">While the first clinical isolates of<emphasis>M. genitalium</emphasis> identified appeared to be fully susceptible to tetracyclines, macrolides, and fluoroquinolones, much has changed over the past several years, as resistance, accompanied by treatment failures of first-line drugs, has become widespread. <emphasis>M. genitalium-</emphasis>positive men with NGU and women with cervicitis respond better to azithromycin than they do to a tetracycline, possibly because of the lower macrolide MICs. Data from Europe, Australia, and Japan indicate that macrolide resistance mutations in the 23S rRNA gene are now detected in 30 to 100% of cases of <emphasis>M. genitalium</emphasis> (<link linkend="ch0082s0000li0032">32</link>, <link linkend="ch0082s0000li0178">178</link>, <link linkend="ch0082s0000li0189">189</link>). In a recent meta-analysis, the summary prevalence of mutations associated with azithromycin resistance in <emphasis>M. genitalium</emphasis> increased from 10% before 2010 to 51% in 2016-2017. This estimate was higher in the Western Pacific (68%) and Americas (67%) than in the European region (<link linkend="ch0082s0000li0190">190</link>). A prevalence of 48% for macrolide resistance was reported for <emphasis>M. genitalium</emphasis> in a multicenter clinical study in the United States (<link linkend="ch0082s0000li0191">191</link>). A study from Alabama found 23S rRNA gene mutations known to confer macrolide resistance in urogenital or rectal samples in 20 of 27 (74.1%) mostly asymptomatic HIV-positive men who were PCR positive for <emphasis>M. genitalium</emphasis> (<link linkend="ch0082s0000li0175">175</link>). A prevalence of 67.6% for <emphasis>M. genitalium</emphasis> macrolide resistance was reported in men who have sex with men using on-demand tenofovir disoproxil fumarate/emtricitabine for HIV prevention in France (<link linkend="ch0082s0000li0192">192</link>).</para>
      <anchor id="ch0082s0000a0099"/>
      <beginpage pagenum="1252"/>
      <para id="ch0082s0000p0074">Treatment failure with the third-line treatment pristinamycin, a streptogramin combination available in Europe and Australia, in a French patient was recently described. This was probably caused by a 23S rRNA gene mutation at position 2062 (<emphasis>Escherichia coli</emphasis> numbering) (<link linkend="ch0082s0000li0193">193</link>).</para>
      <para id="ch0082s0000p0075">Fluoroquinolones such as levofloxacin and moxifloxacin are usually active against human mycoplasmal and ureaplasmal species. However, fluoroquinolone-resistant strains<emphasis>of M. hominis</emphasis> and <emphasis>Ureaplasma</emphasis> spp. with mutations in the DNA gyrase and/or topoisomerase IV genes have been reported over the past 2 decades (<link linkend="ch0082s0000li0188">188</link>, <link linkend="ch0082s0000li0194">194</link>–<link linkend="ch0082s0000li0196">196</link>). Moxifloxacin treatment failures of <emphasis>M. genitalium</emphasis> infections have been reported and are typically associated with mutations in <emphasis>parC</emphasis> (<link linkend="ch0082s0000li0197">197</link>). In the meta-analysis by Machalek et al. (<link linkend="ch0082s0000li0190">190</link>), the overall prevalence of mutations associated with moxifloxacin resistance was 8% and was associated with treatment failure in up to 30% of inpatients from the Asia-Pacific region (<link linkend="ch0082s0000li0189">189</link>). Recent data from the Alabama study mentioned above (<link linkend="ch0082s0000li0175">175</link>) also demonstrated the presence of <emphasis>parC</emphasis> mutations known to be associated with fluoroquinolone resistance in 8 of 27 (29.6%) men who were PCR positive for <emphasis>M. genitalium.</emphasis> Samples from 6 of 25 (24%) men had evidence of multidrug resistance involving both macrolides and fluoroquinolones.</para>
      <para id="ch0082s0000p0076">Because of escalating resistance and treatment failures with first-line drugs in<emphasis>M. genitalium</emphasis> infections, the 2021 CDC guidelines for treatment of sexually transmitted infections (<link linkend="ch0082s0000li0198">198</link>) state that men with recurrent NGU and women with recurrent cervicitis should be tested for <emphasis>M. genitalium</emphasis> using an FDA-cleared test. If testing to detect rRNA gene mutations conferring macrolide resistance is available, this should also be done, and the results should be used to guide therapy. Testing should also be considered for women with PID. Resistance testing for persons who test positive for <emphasis>M. genitalium</emphasis> was also recommended by the European guidelines in 2021 (<link linkend="ch0082s0000li0189">189</link>). Various molecular methods for detecting 23S rRNA gene mutations conferring macrolide resistance based on real-time PCR or pyrosequencing have been described, including the commercial assay sold in some countries described in the section above (<link linkend="ch0082s0000li0171">171</link>–<link linkend="ch0082s0000li0174">174</link>, <link linkend="ch0082s0000li0180">180</link>, <link linkend="ch0082s0000li0191">191</link>). Unfortunately, resistance testing in the United States is rarely performed due to very limited availability and lack of FDA-cleared assays, so even if <emphasis>M genitalium</emphasis> is confirmed in a symptomatic person by a molecular test, treatment will likely still be empiric. The current CDC guidelines for treatment of <emphasis>M. genitalium</emphasis> infections describe various regimens of doxycycline, azithromycin, and moxifloxacin, depending on whether resistance has been documented and on the nature of the illness (<link linkend="ch0082s0000li0198">198</link>). Though not specifically recommended by the CDC, minocycline has been shown to eradicate multidrug-resistant <emphasis>M. genitalium</emphasis> (<link linkend="ch0082s0000li0199">199</link>) and is recommended as a third-line treatment in the current European guideline (<link linkend="ch0082s0000li0189">189</link>). Pristinamycin and the aminocyclitol spectinomycin have been used successfully to treat infections caused by antimicrobial-resistant <emphasis>M. genitalium</emphasis> in a limited number of cases (<link linkend="ch0082s0000li0200">200</link>). Pristinamycin is the best evaluated third-line treatment with an approximately 75% cure rate (<link linkend="ch0082s0000li0189">189</link>).</para>
      <para id="ch0082s0000p0077">Other agents, such as streptogramins, aminoglycosides, and chloramphenicol, may show<emphasis>in vitro</emphasis> inhibitory activity against some <emphasis>Mollicutes</emphasis>, but these agents are rarely used to treat these infections. Oxazolidinones such as linezolid are inactive <emphasis>in vitro</emphasis> against <emphasis>Mollicutes</emphasis>.</para>
      <para id="ch0082s0000p0078">Extragenital infections, often in immunocompromised hosts, can be caused by multidrug-resistant<emphasis>Mollicutes</emphasis>, making guidance of chemotherapy by <emphasis>in vitro</emphasis> susceptibility tests important in this clinical setting. Eradication of infection under these circumstances can be difficult, requiring prolonged therapy, even when the organisms are susceptible to the expected agents. This difficulty highlights the facts that these bacteria are inhibited but not killed by most commonly bacteriostatic antimicrobial agents at concentrations achievable <emphasis>in vivo</emphasis> and that a functioning immune system plays an integral part in their eradication. Treatment of mycoplasmal and ureaplasmal infections has been described in greater depth elsewhere (<link linkend="ch0082s0000li0201">201</link>).</para>
      <sect2 id="ch0082s0019s0001">
        <title>EVALUATION, INTERPRETATION, AND REPORTING OF RESULTS</title>
        <anchor id="ch0082s0019a0002"/>
        <anchor id="ch0082s0000a0100"/>
        <para id="ch0082s0000p0079">Tests offered through diagnostic microbiology laboratories should focus on the species known to cause human disease and for which cultivation techniques are best defined. Unusual organisms, or those for which cultivation conditions are not established, may be detectable by PCR technology offered through a few specialized research or reference laboratories. Such organisms should be sought only after consultation with clinicians and personnel from the reference laboratory. Except for<emphasis>Ureaplasma</emphasis> spp., which can be identified by urease production and distinct colonial morphology, until species identification can be confirmed, a preliminary report of “large-colony <emphasis>Mycoplasma</emphasis> species” is appropriate.</para>
        <para id="ch0082s0000p0080">Screening the lower urogenital tract of asymptomatic adults for<emphasis>Ureaplasma</emphasis> spp. and <emphasis>M. hominis</emphasis> is not recommended, as asymptomatic carriage of these species is common. Screening of asymptomatic <emphasis>M. genitalium</emphasis> infection among women and men and extragenital testing for <emphasis>M. genitalium</emphasis> are not recommended (<link linkend="ch0082s0000li0189">189</link>, <link linkend="ch0082s0000li0198">198</link>, <link linkend="ch0082s0000li0202">202</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0082s0020">
      <title>M. pneumoniae</title>
      <anchor id="ch0082s0020a0001"/>
      <anchor id="ch0082s0000a0101"/>
      <para id="ch0082s0000p0081">Detection of<emphasis>M. pneumoniae</emphasis> in culture is time consuming and not overly sensitive. However, isolation of the organism from respiratory tract specimens is clinically significant in most instances, although asymptomatic carriers exist. <emphasis>Mollicutes</emphasis> isolated by culture from the respiratory tract or from a sterile site suspected of being <emphasis>M. pneumoniae</emphasis> should always have species identification confirmed due to the possibility that they represent one of several commensal species inhabiting the upper respiratory tract. Detection of <emphasis>M. pneumoniae</emphasis> by PCR or other molecular methods is becoming widely available; positive results should be correlated with clinical events. A fourfold rise in antibody titer between acute- and convalescent-phase sera is considered diagnostic of acute infection. In children, adolescents, and young adults, a single positive IgM result using appropriate immunoglobulin class-specific reagents can be considered diagnostic of acute infection in some but not necessarily all cases, because of the possibility of prolonged IgM elevation, which sometimes occurs. Mild respiratory infections due to <emphasis>M. pneumoniae</emphasis> may not merit a costly and time-consuming microbiological workup, since empiric treatment will be effective in most instances. However, the emergence of clinically significant macrolide resistance may influence choices of empiric antimicrobial agents.</para>
      <anchor id="ch0082s0000a0102"/>
      <beginpage pagenum="1253"/>
    </sect1>
    <sect1 id="ch0082s0021">
      <title>M. hominis</title>
      <anchor id="ch0082s0021a0001"/>
      <anchor id="ch0082s0000a0103"/>
      <para id="ch0082s0000p0082"><emphasis>M. hominis</emphasis> can be detected in culture within a few days. It may occasionally be discovered from appropriate clinical material in or on routine bacteriologic media, but this should not be relied upon. Its isolation in any quantity from normally sterile body fluids or tissues is significantly associated with disease, and complete species identification is necessary.</para>
    </sect1>
    <sect1 id="ch0082s0022">
      <title>Ureaplasma species</title>
      <anchor id="ch0082s0022a0001"/>
      <anchor id="ch0082s0000a0104"/>
      <para id="ch0082s0000p0083">Ureaplasmas can be detected in culture within 24 to 48 h. The characteristic colonial morphology and urease production in the presence of suitable indicators in agar media are sufficient for identification at the genus level. Isolation in any quantity from normally sterile body fluids or tissues is significantly associated with disease and can indicate serious infection in neonates or other immunosuppressed persons. Ureaplasmas in the female lower genital tract and fewer than 10<superscript>4</superscript> organisms in the male urethra or in first-void urine are unlikely to be significant. Distinguishing between the 2 species of <emphasis>Ureaplasma, U. urealyticum</emphasis> and <emphasis>U. parvum</emphasis>, by PCR assay could eventually become more important in view of possible differences in pathogenicity in some circumstances, but this is not currently recommended for routine diagnostic purposes.</para>
    </sect1>
    <sect1 id="ch0082s0023">
      <title>M. genitalium</title>
      <anchor id="ch0082s0023a0001"/>
      <anchor id="ch0082s0000a0105"/>
      <para id="ch0082s0000p0084">Growing evidence for the role of<emphasis>M. genitalium</emphasis> as a urogenital pathogen has generated interest in the development of diagnostic methods for its detection, and it is now possible to obtain such information in the United States using FDA-cleared molecular testing. Even though cultivation techniques for <emphasis>M. genitalium</emphasis> have been described (<link linkend="ch0082s0000li0004">4</link>, <link linkend="ch0082s0000li0030">30</link>, <link linkend="ch0082s0000li0203">203</link>), relatively few clinical isolates have been obtained since the initial description of this species in the early 1980s. The slow growth, requiring 6 weeks or longer even in enriched SP4 medium or Vero cells, and poor sensitivity make culture impractical. The potential importance of this organism in sexually transmitted urogenital infections underscores the need for improved and standardized methods for its detection. When <emphasis>M. genitalium</emphasis> is detected in clinical specimens from the urogenital tract, such as the male urethra or female cervix, in persons with clinical evidence of urethritis, cervicitis, or PID, it should be considered medically significant.</para>
      <sect2 id="ch0082s0023s0001">
        <title>REFERENCES</title>
        <anchor id="ch0082s0023a0002"/>
        <anchor id="ch0082s0000a0106"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0082s0000li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Webster D, Windsor H, Ling C, Windsor D, Pitcher D.</emphasis> 2003. Chronic bronchitis in immunocompromised patients: association with a novel <citetitle><emphasis>Mycoplasma</emphasis></citetitle> species. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">22</emphasis><emphasis role="strong">:</emphasis>530–534.</para>
          </listitem>
          <listitem id="ch0082s0000li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Robertson JA, Alfa M, Boatman ES.</emphasis> 1983. Morphology of the cells and colonies of <citetitle><emphasis>Mycoplasma hominis. Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">10</emphasis>(Suppl)<emphasis role="strong">:</emphasis>232–239.</para>
          </listitem>
          <listitem id="ch0082s0000li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Wilson MH, Collier AM.</emphasis> 1976. Ultrastructural study of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> in organ culture. <citetitle><emphasis>J Bacteriol</emphasis></citetitle> <emphasis role="strong">125</emphasis><emphasis role="strong">:</emphasis>332–339.</para>
          </listitem>
          <listitem id="ch0082s0000li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Jensen JS, Hansen HT, Lind K.</emphasis> 1996. Isolation of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> strains from the male urethra. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">34</emphasis><emphasis role="strong">:</emphasis>286–291.</para>
          </listitem>
          <listitem id="ch0082s0000li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Waites KB, Balish MF, Atkinson TP.</emphasis> 2008. New insights into the pathogenesis and detection of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> infections. <citetitle><emphasis>Future Microbiol</emphasis></citetitle> <emphasis role="strong">3</emphasis><emphasis role="strong">:</emphasis>635–648.</para>
          </listitem>
          <listitem id="ch0082s0000li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP.</emphasis> 2017. <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> from the respiratory tract and beyond. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">30</emphasis><emphasis role="strong">:</emphasis>747–809.</para>
          </listitem>
          <listitem id="ch0082s0000li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Kannan TR, Baseman JB.</emphasis> 2006. ADP-ribosylating and vacuolating cytotoxin of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> represents unique virulence determinant among bacterial pathogens. <citetitle><emphasis>Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">103:</emphasis>6724–6729.</para>
          </listitem>
          <listitem id="ch0082s0000li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Techasaensiri C, Tagliabue C, Cagle M, Iranpour P, Katz K, Kannan TR, Coalson JJ, Baseman JB, Hardy RD.</emphasis> 2010. Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> strains. <citetitle><emphasis>Am J Respir Crit Care Med</emphasis></citetitle> <emphasis role="strong">182</emphasis><emphasis role="strong">:</emphasis>797–804.</para>
          </listitem>
          <listitem id="ch0082s0000li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Hu PC, Schaper U, Collier AM, Clyde WA Jr, Horikawa M, Huang YS, Barile MF.</emphasis> 1987. A <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> protein resembling the <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> attachment protein. <citetitle><emphasis>Infect Immun</emphasis></citetitle> <emphasis role="strong">55:</emphasis>1126–1131.</para>
          </listitem>
          <listitem id="ch0082s0000li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Henrich B, Feldmann RC, Hadding U.</emphasis> 1993. Cytoadhesins of <citetitle><emphasis>Mycoplasma hominis. Infect Immun</emphasis></citetitle> <emphasis role="strong">61:</emphasis>2945–2951.</para>
          </listitem>
          <listitem id="ch0082s0000li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Waites KB, Katz B, Schelonka RL.</emphasis> 2005. Mycoplasmas and ureaplasmas as neonatal pathogens. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">18</emphasis><emphasis role="strong">:</emphasis>757–789.</para>
          </listitem>
          <listitem id="ch0082s0000li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Andersen B, Sokolowski I, Østergaard L, Kjølseth Møller J, Olesen F, Jensen JS.</emphasis> 2007. <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle>: prevalence and behavioural risk factors in the general population. <citetitle><emphasis>Sex Transm Infect</emphasis></citetitle> <emphasis role="strong">83</emphasis><emphasis role="strong">:</emphasis>237–241.</para>
          </listitem>
          <listitem id="ch0082s0000li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Oakeshott P, Aghaizu A, Hay P, Reid F, Kerry S, Atherton H, Simms I, Taylor-Robinson D, Dohn B, Jensen JS.</emphasis> 2010. Is <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> in women the “new chlamydia?” A community-based prospective cohort study. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1160–1166.</para>
          </listitem>
          <listitem id="ch0082s0000li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Manhart LE, Holmes KK, Hughes JP, Houston LS, Totten PA.</emphasis> 2007. <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> among young adults in the United States: an emerging sexually transmitted infection. <citetitle><emphasis>Am J Public Health</emphasis></citetitle> <emphasis role="strong">97:</emphasis>1118–1125.</para>
          </listitem>
          <listitem id="ch0082s0000li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Baumann L, Cina M, Egli-Gany D, Goutaki M, Halbeisen FS, Lohrer GR, Ali H, Scott P, Low N.</emphasis> 2018. Prevalence of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> in different population groups: systematic review and meta-analysis. <citetitle><emphasis>Sex Transm Infect</emphasis></citetitle> <emphasis role="strong">94</emphasis><emphasis role="strong">:</emphasis>255–262.</para>
          </listitem>
          <listitem id="ch0082s0000li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Dallo SF, Baseman JB.</emphasis> 2000. Intracellular DNA replication and long-term survival of pathogenic mycoplasmas. <citetitle><emphasis>Microb Pathog</emphasis></citetitle> <emphasis role="strong">29</emphasis><emphasis role="strong">:</emphasis>301–309.</para>
          </listitem>
          <listitem id="ch0082s0000li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Sampath R, Patel R, Cunningham SA, Arif S, Daly RC, Badley AD, Wylam ME.</emphasis> 2017. Cardiothoracic transplant recipient <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle>: an uncommon infection with probable donor transmission. <citetitle><emphasis>EBioMedicine</emphasis></citetitle> <emphasis role="strong">19:</emphasis>84–90.</para>
          </listitem>
          <listitem id="ch0082s0000li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Fernandez R, Chi M, Ison MG, Waites KB, Crabb DM, Ratliff AE, Cajigas H, DeCamp MM, Odell D, Budinger GR, Bharat A.</emphasis> 2017. Sequelae of donor-derived Mollicutes transmission in lung recipients. <citetitle><emphasis>Am J Respir Crit Care Med</emphasis></citetitle> <emphasis role="strong">195</emphasis><emphasis role="strong">:</emphasis>687–689.</para>
          </listitem>
          <listitem id="ch0082s0000li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Spuesens EB, Fraaij PL, Visser EG, Hoogenboezem T, Hop WC, van Adrichem LN, Weber F, Moll HA, Broekman B, Berger MY, van Rijsoort-Vos T, van Belkum A, Schutten M, Pas SD, Osterhaus AD, Hartwig NG, Vink C, van Rossum AM.</emphasis> 2013. Carriage of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. <citetitle><emphasis>PLoS Med</emphasis></citetitle> <emphasis role="strong">10:</emphasis>e1001444.</para>
          </listitem>
          <listitem id="ch0082s0000li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Kannan TR, Hardy RD, Coalson JJ, Cavuoti DC, Siegel JD, Cagle M, Musatovova O, Herrera C, Baseman JB.</emphasis> 2012. Fatal outcomes in family transmission of <citetitle><emphasis>Mycoplasma pneumoniae. Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">54</emphasis><emphasis role="strong">:</emphasis>225–231.</para>
          </listitem>
          <listitem id="ch0082s0000li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Talkington DF, Waites KB, Schwartz SB, Besser RE.</emphasis> 2001. Emerging from obscurity: understanding pulmonary and exrrapulmonary syndromes, pathogenesis, and epidemiology of human <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> infections, p 57–84. <citetitle><emphasis>In</emphasis></citetitle> Scheld WM, Craig WA, Hughes JM (ed), <citetitle><emphasis>Emerging Infections 5.</emphasis></citetitle> American Society for Microbiology, Washington, DC.</para>
          </listitem>
          <listitem id="ch0082s0000li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Hahn DL.</emphasis> 2009. Macrolide therapy in asthma: limited treatment, long-term improvement. <citetitle><emphasis>Eur Respir J</emphasis></citetitle> <emphasis role="strong">33:</emphasis>1239.</para>
          </listitem>
          <listitem id="ch0082s0000li0023" role="bibliographyEntry">
            <anchor id="ch0082s0000a0107"/>
            <para>23.<emphasis role="strong">Martin RJ, Kraft M, Chu HW, Berns EA, Cassell GH.</emphasis> 2001. A link between chronic asthma and chronic infection. <citetitle><emphasis>J Allergy Clin Immunol</emphasis></citetitle> <emphasis role="strong">107</emphasis><emphasis role="strong">:</emphasis>595–601.</para>
          </listitem>
          <listitem id="ch0082s0000li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Rehman S, Day J, Afshar B, Rowlands R, Billam H, Joseph A, Guiver M, Maddocks S, Chalker V, Beeton M.</emphasis> 2021. Molecular exploration for <citetitle><emphasis>Mycoplasma amphoriforme, Mycoplasma fermentans</emphasis></citetitle> and <citetitle><emphasis>Ureaplasma</emphasis></citetitle> spp. in patient samples previously investigated for <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> infection. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">27:</emphasis>1697.e1–1697.e5.</para>
          </listitem>
          <listitem id="ch0082s0000li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Taylor-Robinson D.</emphasis> 1996. Infections due to species of <citetitle><emphasis>Mycoplasma</emphasis></citetitle> and <citetitle><emphasis>Ureaplasma</emphasis></citetitle>: an update. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">23</emphasis><emphasis role="strong">:</emphasis>671–682.</para>
          </listitem>
          <listitem id="ch0082s0000li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Xiao L, Paralanov V, Glass JI, Duffy LB, Robertson JA, Cassell GH, Chen Y, Waites KB.</emphasis> 2011. Extensive horizontal gene transfer in ureaplasmas from humans questions the utility of serotyping for diagnostic purposes. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>2818–2826.</para>
          </listitem>
          <listitem id="ch0082s0000li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Deguchi T, Yoshida T, Miyazawa T, Yasuda M, Tamaki M, Ishiko H, Maeda S.</emphasis> 2004. Association of <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle> (biovar 2) with nongonococcal urethritis. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">31</emphasis><emphasis role="strong">:</emphasis>192–195.</para>
          </listitem>
          <listitem id="ch0082s0000li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Povlsen K, Bjørnelius E, Lidbrink P, Lind I.</emphasis> 2002. Relationship of <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle> biovar 2 to nongonococcal urethritis. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">21:</emphasis>97–101.</para>
          </listitem>
          <listitem id="ch0082s0000li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Zhang N, Wang R, Li X, Liu X, Tang Z, Liu Y.</emphasis> 2014. Are <citetitle><emphasis>Ureaplasma</emphasis></citetitle> spp. a cause of nongonococcal urethritis? A systematic review and meta-analysis. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">9:</emphasis>e113771.</para>
          </listitem>
          <listitem id="ch0082s0000li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Taylor-Robinson D, Jensen JS.</emphasis> 2011. <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle>: from Chrysalis to multicolored butterfly. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">24</emphasis><emphasis role="strong">:</emphasis>498–514.</para>
          </listitem>
          <listitem id="ch0082s0000li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Falk L, Fredlund H, Jensen JS.</emphasis> 2004. Symptomatic urethritis is more prevalent in men infected with <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> than with <citetitle><emphasis>Chlamydia trachomatis. Sex Transm Infect</emphasis></citetitle> <emphasis role="strong">80</emphasis><emphasis role="strong">:</emphasis>289–293.</para>
          </listitem>
          <listitem id="ch0082s0000li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Jensen JS, Bradshaw C.</emphasis> 2015. Management of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> infections—can we hit a moving target? <citetitle><emphasis>BMC Infect Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>343.</para>
          </listitem>
          <listitem id="ch0082s0000li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Björnelius E, Jensen JS, Lidbrink P.</emphasis> 2004. Conjunctivitis associated with <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> infection. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">39</emphasis><emphasis role="strong">:</emphasis>e67–e69.</para>
          </listitem>
          <listitem id="ch0082s0000li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Horner P, Donders G, Cusini M, Gomberg M, Jensen JS, Unemo M.</emphasis> 2018. Should we be testing for urogenital <citetitle><emphasis>Mycoplasma hominis, Ureaplasma parvum</emphasis></citetitle> and <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle> in men and women? A position statement from the European STI Guidelines Editorial Board. <citetitle><emphasis>J Eur Acad Dermatol Venereol</emphasis></citetitle> <emphasis role="strong">32:</emphasis>1845–1851.</para>
          </listitem>
          <listitem id="ch0082s0000li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Srinivasan S CL, Tapia KA, Hoffman NG, Munch MM, Morgan JL, Domogala D, Sylvan Lowens M, Proll S, Huang ML, Soge OO, Jerome KR, Golden MR, Hughes JP, Fredricks DN, Manhart LE.</emphasis> 2021. Urethral microbiota in men: association of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> and <citetitle><emphasis>Mycoplasma penetrans</emphasis></citetitle> with nongonococcal urethritis. <emphasis role="strong">Clin Infect Dis</emphasis> 73<emphasis role="strong">:</emphasis> e1684–e1693.</para>
          </listitem>
          <listitem id="ch0082s0000li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Doble A, Thomas BJ, Furr PM, Walker MM, Harris JRW, Witherow RO, Taylor-Robinson D.</emphasis> 1989. A search for infectious agents in chronic abacterial prostatitis using ultrasound guided biopsy. <citetitle><emphasis>Br J Urol</emphasis></citetitle> <emphasis role="strong">64</emphasis><emphasis role="strong">:</emphasis>297–301.</para>
          </listitem>
          <listitem id="ch0082s0000li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Krieger JN, Riley DE, Roberts MC, Berger RE.</emphasis> 1996. Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">34:</emphasis>3120–3128.</para>
          </listitem>
          <listitem id="ch0082s0000li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Jalil N, Doble A, Gilchrist C, Taylor-Robinson D.</emphasis> 1988. Infection of the epididymis by <citetitle><emphasis>Ureaplasma urealyticum. Genitourin Med</emphasis></citetitle> <emphasis role="strong">64</emphasis><emphasis role="strong">:</emphasis>367–368.</para>
          </listitem>
          <listitem id="ch0082s0000li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Grenabo L, Hedelin H, Pettersson S.</emphasis> 1988. Urinary infection stones caused by <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle>: a review. <citetitle><emphasis>Scand J Infect Dis Suppl</emphasis></citetitle> <emphasis role="strong">53:</emphasis>46–49.</para>
          </listitem>
          <listitem id="ch0082s0000li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Thomsen AC.</emphasis> 1978. Mycoplasmas in human pyelonephritis: demonstration of antibodies in serum and urine. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">8</emphasis><emphasis role="strong">:</emphasis>197–202.</para>
          </listitem>
          <listitem id="ch0082s0000li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Thomsen AC.</emphasis> 1975. The occurrence of mycoplasmas in the urinary tract of patients with chronic pyelonephritis. <citetitle><emphasis>Acta Pathol Microbiol Scand B</emphasis></citetitle> <emphasis role="strong">83:</emphasis>10–16.</para>
          </listitem>
          <listitem id="ch0082s0000li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Thomsen AC.</emphasis> 1978. Occurrence of mycoplasmas in urinary tracts of patients with acute pyelonephritis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">8:</emphasis>84–88.</para>
          </listitem>
          <listitem id="ch0082s0000li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Keane FE, Thomas BJ, Gilroy CB, Renton A, Taylor-Robinson D.</emphasis> 2000. The association of <citetitle><emphasis>Mycoplasma hominis, Ureaplasma urealyticum</emphasis></citetitle> and <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> with bacterial vaginosis: observations on heterosexual women and their male partners. <citetitle><emphasis>Int J STD AIDS</emphasis></citetitle> <emphasis role="strong">11</emphasis><emphasis role="strong">:</emphasis>356–360.</para>
          </listitem>
          <listitem id="ch0082s0000li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Plummer ELVL, Vodstrcil LA, Bodiyabadu K, Murray GL, Doyle M, Latimer RL, Fairley CK, Payne M, Chow EPF, Garland SM, Bradshaw CS.</emphasis> 2021. Are <citetitle><emphasis>Mycoplasma hominis, Ureaplasma urealyticum</emphasis></citetitle> and <citetitle><emphasis>Ureaplasma parvum</emphasis></citetitle> associated with specific genital symptoms and clinical signs in nonpregnant women? <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">73</emphasis><emphasis role="strong">:</emphasis>659–668.</para>
          </listitem>
          <listitem id="ch0082s0000li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Manhart LE, Critchlow CW, Holmes KK, Dutro SM, Eschenbach DA, Stevens CE, Totten PA.</emphasis> 2003. <citetitle><emphasis>Mucopurulent cervicitis</emphasis></citetitle> and <citetitle><emphasis>Mycoplasma genitalium. J Infect Dis</emphasis></citetitle> <emphasis role="strong">187</emphasis><emphasis role="strong">:</emphasis>650–657.</para>
          </listitem>
          <listitem id="ch0082s0000li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Taylor BD, Darville T, Haggerty CL.</emphasis> 2013. Does bacterial vaginosis cause pelvic inflammatory disease? <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">40</emphasis><emphasis role="strong">:</emphasis>117–122.</para>
          </listitem>
          <listitem id="ch0082s0000li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Miettinen A.</emphasis> 1987. <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> in patients with pelvic inflammatory disease. <citetitle><emphasis>Isr J Med Sci</emphasis></citetitle> <emphasis role="strong">23</emphasis><emphasis role="strong">:</emphasis>713–716.</para>
          </listitem>
          <listitem id="ch0082s0000li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Baczynska A, Friis Svenstrup H, Fedder J, Birkelund S, Christiansen G.</emphasis> 2005. The use of enzyme-linked immunosorbent assay for detection of <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> antibodies in infertile women serum samples. <citetitle><emphasis>Hum Reprod</emphasis></citetitle> <emphasis role="strong">20:</emphasis>1277–1285.</para>
          </listitem>
          <listitem id="ch0082s0000li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Haggerty CL.</emphasis> 2008. Evidence for a role of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> in pelvic inflammatory disease. <citetitle><emphasis>Curr Opin Infect Dis</emphasis></citetitle> <emphasis role="strong">21:</emphasis>65–69.</para>
          </listitem>
          <listitem id="ch0082s0000li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Falk L, Fredlund H, Jensen JS.</emphasis> 2005. Signs and symptoms of urethritis and cervicitis among women with or without <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> or <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> infection. <citetitle><emphasis>Sex Transm Infect</emphasis></citetitle> <emphasis role="strong">81:</emphasis>73–78.</para>
          </listitem>
          <listitem id="ch0082s0000li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Cohen CR, Manhart LE, Bukusi EA, Astete S, Brunham RC, Holmes KK, Sinei SK, Bwayo JJ, Totten PA.</emphasis> 2002. Association between <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> and acute endometritis. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">359</emphasis><emphasis role="strong">:</emphasis>765–766.</para>
          </listitem>
          <listitem id="ch0082s0000li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Lis R, Rowhani-Rahbar A, Manhart LE.</emphasis> 2015. <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> infection and female reproductive tract disease: a meta-analysis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">61</emphasis><emphasis role="strong">:</emphasis>418–426.</para>
          </listitem>
          <listitem id="ch0082s0000li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Farahani L, Tharakan T, Yap T, Ramsay JW, Jayasena CN, Minhas S.</emphasis> 2021. The semen microbiome and its impact on sperm function and male fertility: a systematic review and meta-analysis. <citetitle><emphasis>Andrology</emphasis></citetitle> <emphasis role="strong">9</emphasis><emphasis role="strong">:</emphasis>115–144.</para>
          </listitem>
          <listitem id="ch0082s0000li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Soni S, Alexander S, Verlander N, Saunders P, Richardson D, Fisher M, Ison C.</emphasis> 2010. The prevalence of urethral and rectal <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> and its associations in men who have sex with men attending a genitourinary medicine clinic. <citetitle><emphasis>Sex Transm Infect</emphasis></citetitle> <emphasis role="strong">86:</emphasis>21–24.</para>
          </listitem>
          <listitem id="ch0082s0000li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Lusk MJ, Konecny P, Naing ZW, Garden FL, Cumming RG, Rawlinson WD.</emphasis> 2011. <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> is associated with cervicitis and HIV infection in an urban Australian STI clinic population. <citetitle><emphasis>Sex Transm Infect</emphasis></citetitle> <emphasis role="strong">87</emphasis><emphasis role="strong">:</emphasis>107–109.</para>
          </listitem>
          <listitem id="ch0082s0000li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Sasaki Y, Honda M, Makino M, Sasaki T.</emphasis> 1993. Mycoplasmas stimulate replication of human immunodeficiency virus type 1 through selective activation of CD4+ T lymphocytes. <citetitle><emphasis>AIDS Res Hum Retroviruses</emphasis></citetitle> <emphasis role="strong">9</emphasis><emphasis role="strong">:</emphasis>775–780.</para>
          </listitem>
          <listitem id="ch0082s0000li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Napierala Mavedzenge S, Weiss HA.</emphasis> 2009. Association of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> and HIV infection: a systematic review and meta-analysis. <citetitle><emphasis>AIDS</emphasis></citetitle> <emphasis role="strong">23</emphasis><emphasis role="strong">:</emphasis>611–620.</para>
          </listitem>
          <listitem id="ch0082s0000li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Cassell GH, Davis RO, Waites KB, Brown MB, Marriott PA, Stagno S, Davis JK.</emphasis> 1983. Isolation of <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> and <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle> from amniotic fluid at 16-20 weeks of gestation: potential effect on outcome of pregnancy. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">10</emphasis>(Suppl)<emphasis role="strong">:</emphasis>294–302.</para>
          </listitem>
          <listitem id="ch0082s0000li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Chaim W, Horowitz S, David JB, Ingel F, Evinson B, Mazor M.</emphasis> 2003. <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle> in the development of postpartum endometritis. <citetitle><emphasis>Eur J Obstet Gynecol Reprod Biol</emphasis></citetitle> <emphasis role="strong">109</emphasis><emphasis role="strong">:</emphasis>145–148.</para>
          </listitem>
          <listitem id="ch0082s0000li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Novy MJ, Duffy L, Axthelm MK, Sadowsky DW, Witkin SS, Gravett MG, Cassell GH, Waites KB.</emphasis> 2009. <citetitle><emphasis>Ureaplasma parvum</emphasis></citetitle> or <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> as sole pathogens cause chorioamnionitis, preterm delivery, and fetal pneumonia in rhesus macaques. <citetitle><emphasis>Reprod Sci</emphasis></citetitle> <emphasis role="strong">16:</emphasis>56–70.</para>
          </listitem>
          <listitem id="ch0082s0000li0061" role="bibliographyEntry">
            <anchor id="ch0082s0000a0108"/>
            <para>61.<emphasis role="strong">Lowe J, Watkins WJ, Edwards MO, Spiller OB, Jacqz-Aigrain E, Kotecha SJ, Kotecha S.</emphasis> 2014. Association between pulmonary ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: updated systematic review and meta-analysis. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">33</emphasis><emphasis role="strong">:</emphasis>697–702.</para>
          </listitem>
          <listitem id="ch0082s0000li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Rohner P, Schnyder I, Ninet B, Schrenzel J, Lew D, Ramla T, Garbino J, Jacomo V.</emphasis> 2004. Severe <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> infections in two renal transplant patients. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">23</emphasis><emphasis role="strong">:</emphasis>203–204.</para>
          </listitem>
          <listitem id="ch0082s0000li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Meyer RD, Clough W.</emphasis> 1993. Extragenital <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> infections in adults: emphasis on immunosuppression. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">17</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S243–S249.</para>
          </listitem>
          <listitem id="ch0082s0000li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Johnson S, Sidebottom D, Bruckner F, Collins D.</emphasis> 2000. Identification of <citetitle><emphasis>Mycoplasma fermentans</emphasis></citetitle> in synovial fluid samples from arthritis patients with inflammatory disease. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>90–93.</para>
          </listitem>
          <listitem id="ch0082s0000li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Schaeverbeke T, Gilroy CB, Bébéar C, Dehais J, Taylor-Robinson D.</emphasis> 1996. <citetitle><emphasis>Mycoplasma fermentans</emphasis></citetitle>, but not <citetitle><emphasis>M penetrans,</emphasis></citetitle> detected by PCR assays in synovium from patients with rheumatoid arthritis and other rheumatic disorders. <citetitle><emphasis>J Clin Pathol</emphasis></citetitle> <emphasis role="strong">49</emphasis><emphasis role="strong">:</emphasis>824–828.</para>
          </listitem>
          <listitem id="ch0082s0000li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Schaeverbeke T, Renaudin H, Clerc M, Lequen L, Vernhes JP, De Barbeyrac B, Bannwarth B, Bébéar C, Dehais J.</emphasis> 1997. Systematic detection of mycoplasmas by culture and polymerase chain reaction (PCR) procedures in 209 synovial fluid samples. <citetitle><emphasis>Br J Rheumatol</emphasis></citetitle> <emphasis role="strong">36</emphasis><emphasis role="strong">:</emphasis>310–314.</para>
          </listitem>
          <listitem id="ch0082s0000li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Donta ST, Engel CC Jr, Collins JF, Baseman JB, Dever LL, Taylor T, Boardman KD, Kazis LE, Martin SE, Horney RA, Wiseman AL, Kernodle DS, Smith RP, Baltch AL, Handanos C, Catto B, Montalvo L, Everson M, Blackburn W, Thakore M, Brown ST, Lutwick L, Norwood D, Bernstein J, Bacheller C, Ribner B, Church LW, Wilson KH, Guduru P, Cooper R, Lentino J, Hamill RJ, Gorin AB, Gordan V, Wagner D, Robinson C, DeJace P, Greenfield R, Beck L, Bittner M, Schumacher HR, Silverblatt F, Schmitt J, Wong E, Ryan MA, Figueroa J, Nice C, Feussner JR, VA Cooperative #475 Group.</emphasis> 2004. Benefits and harms of doxycycline treatment for Gulf War veterans’ illnesses: a randomized, double-blind, placebo-controlled trial. <citetitle><emphasis>Ann Intern Med</emphasis></citetitle> <emphasis role="strong">141:</emphasis>85–94.</para>
          </listitem>
          <listitem id="ch0082s0000li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Tantengco OAG, De Jesus FCC II, Gampoy EFS, Ornos EDB, Vidal MS Jr, Abad CLR.</emphasis> 2021. Hyperammonemia syndrome associated with <citetitle><emphasis>Ureaplasma</emphasis></citetitle> spp. infections in immunocompromised patients and transplant recipients: a systematic review and meta-analysis. <citetitle><emphasis>Clin Transplant</emphasis></citetitle> <emphasis role="strong">35:</emphasis>e14334.</para>
          </listitem>
          <listitem id="ch0082s0000li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Bharat A, Cunningham SA, Scott Budinger GR, Kreisel D, DeWet CJ, Gelman AE, Waites K, Crabb D, Xiao L, Bhorade S, Ambalavanan N, Dilling DF, Lowery EM, Astor T, Hachem R, Krupnick AS, DeCamp MM, Ison MG, Patel R.</emphasis> 2015. Disseminated <citetitle><emphasis>Ureaplasma</emphasis></citetitle> infection as a cause of fatal hyperammonemia in humans. <citetitle><emphasis>Sci Transl Med</emphasis></citetitle> <emphasis role="strong">7:</emphasis>284re3.</para>
          </listitem>
          <listitem id="ch0082s0000li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Etienne N, Bret L, Le Brun C, Lecuyer H, Moraly J, Lanternier F, Hermine O, Ferroni A, Lecuit M, Pereyre S, Beven L, Lortholary O.</emphasis> 2018. Disseminated <citetitle><emphasis>Spiroplasma apis</emphasis></citetitle> infection in patient with agammaglobulinemia, France. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">24:</emphasis>2382–2386.</para>
          </listitem>
          <listitem id="ch0082s0000li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Farassat N, Reich M, Serr A, Küchlin S, Erwemi M, Auw-Hädrich C, Krastel H, Lagrèze WA.</emphasis> 2021. <citetitle><emphasis>Spiroplasma</emphasis></citetitle> species as a rare cause of congenital cataract and uveitis: a case series. <citetitle><emphasis>BMC Ophthalmol</emphasis></citetitle> <emphasis role="strong">21:</emphasis>434.</para>
          </listitem>
          <listitem id="ch0082s0000li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Bastian FO.</emphasis> 2014. The case for involvement of spiroplasma in the pathogenesis of transmissible spongiform encephalopathies. <citetitle><emphasis>J Neuropathol Exp Neurol</emphasis></citetitle> <emphasis role="strong">73</emphasis><emphasis role="strong">:</emphasis>104–114.</para>
          </listitem>
          <listitem id="ch0082s0000li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Jensen JS, Björnelius E, Dohn B, Lidbrink P.</emphasis> 2004. Comparison of first void urine and urogenital swab specimens for detection of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> and <citetitle><emphasis>Chlamydia trachomatis</emphasis></citetitle> by polymerase chain reaction in patients attending a sexually transmitted disease clinic. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">31</emphasis><emphasis role="strong">:</emphasis>499–507.</para>
          </listitem>
          <listitem id="ch0082s0000li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Pratt BC.</emphasis> 1991. Recovery of <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> from blood culture media. <citetitle><emphasis>Med Lab Sci</emphasis></citetitle> <emphasis role="strong">48:</emphasis>350.</para>
          </listitem>
          <listitem id="ch0082s0000li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Waites KB, Canupp KC.</emphasis> 2001. Evaluation of BacT/ALERT system for detection of <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> in simulated blood cultures. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>4328–4331.</para>
          </listitem>
          <listitem id="ch0082s0000li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Waites KB, Xiao L, Paralanov V, Viscardi RM, Glass JI.</emphasis> 2012. Molecular methods for the detection of <citetitle><emphasis>Mycoplasma</emphasis></citetitle> and ureaplasma infections in humans: a paper from the 2011 William Beaumont Hospital Symposium on Molecular Pathology. <citetitle><emphasis>J Mol Diagn</emphasis></citetitle> <emphasis role="strong">14</emphasis><emphasis role="strong">:</emphasis>437–450.</para>
          </listitem>
          <listitem id="ch0082s0000li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Truant AL, Tang Y-W, Waites KB, Bebear C, Rennie RP.</emphasis> 2016. Mycoplasma, p 195–213. <citetitle><emphasis>In</emphasis></citetitle> Truant AL (ed), <citetitle><emphasis>Manual of Commercial Methods in Clinical Microbiology</emphasis></citetitle>, 2nd ed. John Wiley and Sons, Hoboken, NJ.</para>
          </listitem>
          <listitem id="ch0082s0000li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Winchell JM, Thurman KA, Mitchell SL, Thacker WL, Fields BS.</emphasis> 2008. Evaluation of three real-time PCR assays for detection of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> in an outbreak investigation. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>3116–3118.</para>
          </listitem>
          <listitem id="ch0082s0000li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Dumke R, Schurwanz N, Lenz M, Schuppler M, Lück C, Jacobs E.</emphasis> 2007. Sensitive detection of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> in human respiratory tract samples by optimized real-time PCR approach. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>2726–2730.</para>
          </listitem>
          <listitem id="ch0082s0000li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Lodes MJ, Suciu D, Wilmoth JL, Ross M, Munro S, Dix K, Bernards K, Stöver AG, Quintana M, Iihoshi N, Lyon WJ, Danley DL, McShea A.</emphasis> 2007. Identification of upper respiratory tract pathogens using electrochemical detection on an oligonucleotide microarray. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">2:</emphasis>e924.</para>
          </listitem>
          <listitem id="ch0082s0000li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Loens K, Ieven M.</emphasis> 2016. <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle>: current knowledge on nucleic acid amplification techniques and serological diagnostics. <citetitle><emphasis>Front Microbiol</emphasis></citetitle> <emphasis role="strong">7:</emphasis>448.</para>
          </listitem>
          <listitem id="ch0082s0000li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Loens K, Ieven M, Ursi D, Beck T, Overdijk M, Sillekens P, Goossens H.</emphasis> 2003. Detection of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> by real-time nucleic acid sequence-based amplification. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>4448–4450.</para>
          </listitem>
          <listitem id="ch0082s0000li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Templeton KE, Scheltinga SA, Graffelman AW, Van Schie JM, Crielaard JW, Sillekens P, Van Den Broek PJ, Goossens H, Beersma MF, Claas EC.</emphasis> 2003. Comparison and evaluation of real-time PCR, real-time nucleic acid sequence-based amplification, conventional PCR, and serology for diagnosis of <citetitle><emphasis>Mycoplasma pneumoniae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>4366–4371.</para>
          </listitem>
          <listitem id="ch0082s0000li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Khanna M, Fan J, Pehler-Harrington K, Waters C, Douglass P, Stallock J, Kehl S, Henrickson KJ.</emphasis> 2005. The pneumoplex assays, a multiplex PCR-enzyme hybridization assay that allows simultaneous detection of five organisms, <citetitle><emphasis>Mycoplasma pneumoniae, Chlamydia</emphasis></citetitle> (<citetitle><emphasis>Chlamydophila</emphasis></citetitle>) <citetitle><emphasis>pneumoniae, Legionella pneumophila, Legionella micdade</emphasis></citetitle>i, and <citetitle><emphasis>Bordetella pertussis,</emphasis></citetitle> and its real-time counterpart. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43</emphasis><emphasis role="strong">:</emphasis>565–571.</para>
          </listitem>
          <listitem id="ch0082s0000li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Dumke R, Jacobs E.</emphasis> 2009. Comparison of commercial and in-house real-time PCR assays used for detection of <citetitle><emphasis>Mycoplasma pneumoniae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47</emphasis><emphasis role="strong">:</emphasis>441–444.</para>
          </listitem>
          <listitem id="ch0082s0000li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Touati A, Benard A, Hassen AB, Bébéar CM, Pereyre S.</emphasis> 2009. Evaluation of five commercial real-time PCR assays for detection of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> in respiratory tract specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>2269–2271.</para>
          </listitem>
          <listitem id="ch0082s0000li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Leal SM Jr, Totten AH, Xiao L, Crabb DM, Ratliff A, Duffy LB, Fowler KB, Mixon E, Winchell JM, Diaz MH, Benitez AJ, Wolff BJ, Qin X, Tang YW, Gonzalez M, Selvarangan R, Hong T, Brooks E, Dallas S, Atkinson TP, Zheng X, Dien Bard J, Waites KB.</emphasis> 2020. Evaluation of commercial molecular diagnostic methods for detection and determination of macrolide resistance in <citetitle><emphasis>Mycoplasma pneumoniae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>e00242-20.</para>
          </listitem>
          <listitem id="ch0082s0000li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Ratliff AE, Duffy LB, Waites KB.</emphasis> 2014. Comparison of the Illumigene Mycoplasma DNA amplification assay and culture for detection of <citetitle><emphasis>Mycoplasma pneumoniae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>1060–1063.</para>
          </listitem>
          <listitem id="ch0082s0000li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Deguchi T, Yoshida T, Yokoi S, Ito M, Tamaki M, Ishiko H, Maeda S.</emphasis> 2002. Longitudinal quantitative detection by real-time PCR of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> in first-pass urine of men with recurrent nongonococcal urethritis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>3854–3856.</para>
          </listitem>
          <listitem id="ch0082s0000li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Hardick J, Giles J, Hardick A, Hsieh YH, Quinn T, Gaydos C.</emphasis> 2006. Performance of the Gen-Probe transcription-mediated amplification research assay compared to that of a multitarget real-time PCR for <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> detection. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>1236–1240.</para>
          </listitem>
          <listitem id="ch0082s0000li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Jensen JS, Björnelius E, Dohn B, Lidbrink P.</emphasis> 2004. Use of TaqMan 5′ nuclease real-time PCR for quantitative detection of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> DNA in males with and without urethritis who were attendees at a sexually transmitted disease clinic. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42</emphasis><emphasis role="strong">:</emphasis>683–692.</para>
          </listitem>
          <listitem id="ch0082s0000li0092" role="bibliographyEntry">
            <anchor id="ch0082s0000a0109"/>
            <para>92.<emphasis role="strong">Jurstrand M, Jensen JS, Fredlund H, Falk L, Mölling P.</emphasis> 2005. Detection of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> in urogenital specimens by real-time PCR and by conventional PCR assay. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>23–29.</para>
          </listitem>
          <listitem id="ch0082s0000li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Svenstrup HF, Jensen JS, Björnelius E, Lidbrink P, Birkelund S, Christiansen G.</emphasis> 2005. Development of a quantitative real-time PCR assay for detection of <citetitle><emphasis>Mycoplasma genitalium. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>3121–3128.</para>
          </listitem>
          <listitem id="ch0082s0000li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Yoshida T, Deguchi T, Ito M, Maeda S, Tamaki M, Ishiko H.</emphasis> 2002. Quantitative detection of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> from first-pass urine of men with urethritis and asymptomatic men by real-time PCR. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>1451–1455.</para>
          </listitem>
          <listitem id="ch0082s0000li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Dupin N, Bijaoui G, Schwarzinger M, Ernault P, Gerhardt P, Jdid R, Hilab S, Pantoja C, Buffet M, Escande JP, Costa JM.</emphasis> 2003. Detection and quantification of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> in male patients with urethritis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">37</emphasis><emphasis role="strong">:</emphasis>602–605.</para>
          </listitem>
          <listitem id="ch0082s0000li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Bebear C, Waites KB.</emphasis> 2022. Detection of human mycoplasmas and ureaplasmas from clinical specimens by culture and nucleic acid amplification. <citetitle><emphasis>In</emphasis></citetitle> Laber AD, Burnham CAB (ed), <citetitle><emphasis>Clinical Microbiology Procedures Handbook</emphasis></citetitle>, 5th ed. ASM Press, Washington, DC.</para>
          </listitem>
          <listitem id="ch0082s0000li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Tabrizi SN, Costa AM, Su J, Lowe P, Bradshaw CS, Fairley CK, Garland SM.</emphasis> 2016. Evaluation of the Hologic Panther transcription-mediated amplification assay for detection of <citetitle><emphasis>Mycoplasma genitalium. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>2201–2203.</para>
          </listitem>
          <listitem id="ch0082s0000li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Van Der Pol B, Waites KB, Xiao L, Taylor SN, Rao A, Nye M, Chavoustie S, Ermel A, Kaplan C, Eisenberg D, Chan PA, Mena L, Pacheco S, Krishnamurthy S, Mohan R, Bertuzis R, McGowin CL, Arcenas R, Marlowe EM.</emphasis> 2020. <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> detection in urogenital specimens from symptomatic and asymptomatic men and women by use of the cobas TV/MG Test. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>e02124-19.</para>
          </listitem>
          <listitem id="ch0082s0000li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Lee SJ, Park DC, Lee DS, Choe HS, Cho YH.</emphasis> 2012. Evaluation of Seeplex® STD6 ACE detection kit for the diagnosis of six bacterial sexually transmitted infections. <citetitle><emphasis>J Infect Chemother</emphasis></citetitle> <emphasis role="strong">18</emphasis><emphasis role="strong">:</emphasis>494–500.</para>
          </listitem>
          <listitem id="ch0082s0000li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">de Salazar A, Espadafor B, Fuentes-López A, Barrientos-Durán A, Salvador L, Álvarez M, García F.</emphasis> 2019. Comparison between Aptima assays (Hologic) and the Allplex STI Essential assay (Seegene) for the diagnosis of sexually transmitted infections. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">14:</emphasis>e0222439.</para>
          </listitem>
          <listitem id="ch0082s0000li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Fernández G, Martró E, González V, Saludes V, Bascuñana E, Marcó C, Rivaya B, López E, Coll P, Matas L, Ausina V.</emphasis> 2016. Usefulness of a novel multiplex real-time PCR assay for the diagnosis of sexually-transmitted infections. <citetitle><emphasis>Enferm Infecc Microbiol Clin</emphasis></citetitle> <emphasis role="strong">34</emphasis><emphasis role="strong">:</emphasis>471–476.</para>
          </listitem>
          <listitem id="ch0082s0000li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Pereyre S, Camelena F, Henin N, Bercot B, Bebear C.</emphasis> 2021. Clinical performance of four multiplex real-time PCR kits detecting urogenital and sexually transmitted pathogens. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">28:</emphasis>733.e7–733.e13.</para>
          </listitem>
          <listitem id="ch0082s0000li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Yoshida T, Maeda S, Deguchi T, Miyazawa T, Ishiko H.</emphasis> 2003. Rapid detection of <citetitle><emphasis>Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma parvum</emphasis></citetitle>, and <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle> organisms in genitourinary samples by PCR-microtiter plate hybridization assay. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>1850–1855.</para>
          </listitem>
          <listitem id="ch0082s0000li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Mygind T, Birkelund S, Christiansen G.</emphasis> 1998. DNA sequencing reveals limited heterogeneity in the 16S rRNA gene from the rrnB operon among five <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> isolates. <citetitle><emphasis>Int J Syst Bacteriol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>1067–1071.</para>
          </listitem>
          <listitem id="ch0082s0000li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Baczynska A, Svenstrup HF, Fedder J, Birkelund S, Christiansen G.</emphasis> 2004. Development of real-time PCR for detection of <citetitle><emphasis>Mycoplasma hominis. BMC Microbiol</emphasis></citetitle> <emphasis role="strong">4:</emphasis>35.</para>
          </listitem>
          <listitem id="ch0082s0000li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Menard JP, Fenollar F, Henry M, Bretelle F, Raoult D.</emphasis> 2008. Molecular quantification of <citetitle><emphasis>Gardnerella vaginalis</emphasis></citetitle> and <citetitle><emphasis>Atopobium vaginae</emphasis></citetitle> loads to predict bacterial vaginosis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">47:</emphasis>33–43.</para>
          </listitem>
          <listitem id="ch0082s0000li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Férandon C, Peuchant O, Janis C, Benard A, Renaudin H, Pereyre S, Bébéar C.</emphasis> 2011. Development of a real-time PCR targeting the yidC gene for the detection of <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> and comparison with quantitative culture. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">17</emphasis><emphasis role="strong">:</emphasis>155–159.</para>
          </listitem>
          <listitem id="ch0082s0000li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Cunningham SA, Mandrekar JN, Rosenblatt JE, Patel R.</emphasis> 2013. Rapid PCR detection of <citetitle><emphasis>Mycoplasma hominis, Ureaplasma urealyticum</emphasis></citetitle>, and <citetitle><emphasis>Ureaplasma parvum. Int J Bacteriol</emphasis></citetitle> <emphasis role="strong">2013:</emphasis>168742</para>
          </listitem>
          <listitem id="ch0082s0000li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Kong F, Zhu X, Wang W, Zhou X, Gordon S, Gilbert GL.</emphasis> 1999. Comparative analysis and serovar-specific identification of multiple-banded antigen genes of <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle> biovar 1. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37</emphasis><emphasis role="strong">:</emphasis>538–543.</para>
          </listitem>
          <listitem id="ch0082s0000li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Harasawa R, Kanamoto Y.</emphasis> 1999. Differentiation of two biovars of <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle> based on the 16S-23S rRNA intergenic spacer region. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>4135–4138.</para>
          </listitem>
          <listitem id="ch0082s0000li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Kong F, Ma Z, James G, Gordon S, Gilbert GL.</emphasis> 2000. Species identification and subtyping of <citetitle><emphasis>Ureaplasma parvum</emphasis></citetitle> and <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle> using PCR-based assays. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>1175–1179.</para>
          </listitem>
          <listitem id="ch0082s0000li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Povlsen K, Jensen JS, Lind I.</emphasis> 1998. Detection of <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle> by PCR and biovar determination by liquid hybridization. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>3211–3216.</para>
          </listitem>
          <listitem id="ch0082s0000li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Kong F, Ma Z, James G, Gordon S, Gilbert GL.</emphasis> 2000. Molecular genotyping of human <citetitle><emphasis>Ureaplasma</emphasis></citetitle> species based on multiple-banded antigen (MBA) gene sequences. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>1921–1929.</para>
          </listitem>
          <listitem id="ch0082s0000li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Yi J, Yoon BH, Kim EC.</emphasis> 2005. Detection and biovar discrimination of <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle> by real-time PCR. <citetitle><emphasis>Mol Cell Probes</emphasis></citetitle> <emphasis role="strong">19</emphasis><emphasis role="strong">:</emphasis>255–260.</para>
          </listitem>
          <listitem id="ch0082s0000li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Xiao L, Glass JI, Paralanov V, Yooseph S, Cassell GH, Duffy LB, Waites KB.</emphasis> 2010. Detection and characterization of human <citetitle><emphasis>Ureaplasma</emphasis></citetitle> species and serovars by real-time PCR. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>2715–2723.</para>
          </listitem>
          <listitem id="ch0082s0000li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Cao X, Jiang Z, Wang Y, Gong R, Zhang C.</emphasis> 2007. Two multiplex real-time TaqMan polymerase chain reaction systems for simultaneous detecting and serotyping of <citetitle><emphasis>Ureaplasma parvum. Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">59</emphasis><emphasis role="strong">:</emphasis>109–111.</para>
          </listitem>
          <listitem id="ch0082s0000li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Cao X, Wang Y, Hu X, Qing H, Wang H.</emphasis> 2007. Real-time TaqMan polymerase chain reaction assays for quantitative detection and differentiation of <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle> and <citetitle><emphasis>Ureaplasma parvum. Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">57</emphasis><emphasis role="strong">:</emphasis>373–378.</para>
          </listitem>
          <listitem id="ch0082s0000li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Mallard K, Schopfer K, Bodmer T.</emphasis> 2005. Development of real-time PCR for the differential detection and quantification of <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle> and <citetitle><emphasis>Ureaplasma parvum. J Microbiol Methods</emphasis></citetitle> <emphasis role="strong">60:</emphasis>13–19.</para>
          </listitem>
          <listitem id="ch0082s0000li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Nilsson AC, Björkman P, Persson K.</emphasis> 2008. Polymerase chain reaction is superior to serology for the diagnosis of acute <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> infection and reveals a high rate of persistent infection. <citetitle><emphasis>BMC Microbiol</emphasis></citetitle> <emphasis role="strong">8:</emphasis>93.</para>
          </listitem>
          <listitem id="ch0082s0000li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Reznikov M, Blackmore TK, Finlay-Jones JJ, Gordon DL.</emphasis> 1995. Comparison of nasopharyngeal aspirates and throat swab specimens in a polymerase chain reaction-based test for <citetitle><emphasis>Mycoplasma pneumoniae. Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">14:</emphasis>58–61.</para>
          </listitem>
          <listitem id="ch0082s0000li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Waites KB, Bebear CM, Robertson JA, Talkington DF, Kenny GE (ed).</emphasis> 2001. <citetitle><emphasis>Cumitech 34, Laboratory Diagnosis of Mycoplasmal Infections.</emphasis></citetitle> American Society for Microbiology, Washington, DC.</para>
          </listitem>
          <listitem id="ch0082s0000li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Caliando JJ, McCormack WM.</emphasis> 1983. Recovery of mycoplasmas from blood and special tissues, p 27–36. <citetitle><emphasis>In</emphasis></citetitle> Tully JG, Razin S (ed), <citetitle><emphasis>Methods in Mycoplasmology, Diagnostic Mycoplasmology</emphasis></citetitle>, vol 2. Academic Press, New York, NY.</para>
          </listitem>
          <listitem id="ch0082s0000li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Boostrom I, Bala Y, Vasic JM, Gluvakov J, Chanard E, Barratt AH, Sands K, Portal E, Devigne L, Jones LC, Spiller OB.</emphasis> 2021. Evaluation of the MYCOPLASMA IST3 urogenital mycoplasma assay in an international multicentre trial. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">76:</emphasis>3175–3182.</para>
          </listitem>
          <listitem id="ch0082s0000li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Morris DJ, Jones LC, Davies RL, Sands K, Portal E, Spiller OB.</emphasis> 2020. MYCO WELL D-ONE detection of <citetitle><emphasis>Ureaplasma</emphasis></citetitle> spp. and <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> in sexual health patients in Wales. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">39:</emphasis>2427–2440.</para>
          </listitem>
          <listitem id="ch0082s0000li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">Pereyre S, Tardy F, Renaudin H, Cauvin E, Del Prá Netto Machado L, Tricot A, Benoit F, Treilles M, Bébéar C.</emphasis> 2013. Identification and subtyping of clinically relevant human and ruminant mycoplasmas by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>3314–3323.</para>
          </listitem>
          <listitem id="ch0082s0000li0126" role="bibliographyEntry">
            <anchor id="ch0082s0000a0110"/>
            <para>126.<emphasis role="strong">Moser SA, Mayfield CA, Duffy LB, Waites KB.</emphasis> 2006. Genotypic characterization of <citetitle><emphasis>Ureaplasma</emphasis></citetitle> species by pulsed field gel electrophoresis. <citetitle><emphasis>J Microbiol Methods</emphasis></citetitle> <emphasis role="strong">67</emphasis><emphasis role="strong">:</emphasis>606–610.</para>
          </listitem>
          <listitem id="ch0082s0000li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Xiao L, Crabb DM, Moser SA, Duffy LB, Glass JI, Paralanov V, Waites KB.</emphasis> 2011. Genotypic characterization of ureaplasma serovars from clinical isolates by pulsed-field gel electrophoresis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>3325–3328.</para>
          </listitem>
          <listitem id="ch0082s0000li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Zhang J, Kong Y, Feng Y, Huang J, Song T, Ruan Z, Song J, Jiang Y, Yu Y, Xie X.</emphasis> 2014. Development of a multilocus sequence typing scheme for <citetitle><emphasis>Ureaplasma. Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">33</emphasis><emphasis role="strong">:</emphasis>537–544.</para>
          </listitem>
          <listitem id="ch0082s0000li0129" role="bibliographyEntry">
            <para>129.<emphasis role="strong">Cousin-Allery A, Charron A, de Barbeyrac B, Fremy G, Skov Jensen J, Renaudin H, Bebear C.</emphasis> 2000. Molecular typing of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> strains by PCR-based methods and pulsed-field gel electrophoresis. Application to French and Danish isolates. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">124</emphasis><emphasis role="strong">:</emphasis>103–111.</para>
          </listitem>
          <listitem id="ch0082s0000li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Dégrange S, Cazanave C, Charron A, Renaudin H, Bébéar C, Bébéar CM.</emphasis> 2009. Development of multiple-locus variable-number tandem-repeat analysis for molecular typing of <citetitle><emphasis>Mycoplasma pneumoniae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47</emphasis><emphasis role="strong">:</emphasis>914–923.</para>
          </listitem>
          <listitem id="ch0082s0000li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Dorigo-Zetsma JW, Dankert J, Zaat SA.</emphasis> 2000. Genotyping of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> clinical isolates reveals eight P1 subtypes within two genomic groups. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38</emphasis><emphasis role="strong">:</emphasis>965–970.</para>
          </listitem>
          <listitem id="ch0082s0000li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Dumke R, Catrein I, Pirkil E, Herrmann R, Jacobs E.</emphasis> 2003. Subtyping of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> isolates based on extended genome sequencing and on expression profiles. <citetitle><emphasis>Int J Med Microbiol</emphasis></citetitle> <emphasis role="strong">292</emphasis><emphasis role="strong">:</emphasis>513–525.</para>
          </listitem>
          <listitem id="ch0082s0000li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Sasaki T, Kenri T, Okazaki N, Iseki M, Yamashita R, Shintani M, Sasaki Y, Yayoshi M.</emphasis> 1996. Epidemiological study of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> infections in japan based on PCR-restriction fragment length polymorphism of the P1 cytadhesin gene. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">34</emphasis><emphasis role="strong">:</emphasis>447–449.</para>
          </listitem>
          <listitem id="ch0082s0000li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Brown RJ, Holden MT, Spiller OB, Chalker VJ.</emphasis> 2015. Development of a multi-locus sequence typing scheme for the molecular typing of <citetitle><emphasis>Mycoplasma pneumoniae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>3195–3203.</para>
          </listitem>
          <listitem id="ch0082s0000li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Touati A, Blouin Y, Sirand-Pugnet P, Renaudin H, Oishi T, Vergnaud G, Bébéar C, Pereyre S.</emphasis> 2015. Molecular epidemiology of <citetitle><emphasis>Mycoplasma pneumoniae:</emphasis></citetitle> genotyping using single nucleotide polymorphisms and SNaPshot technology. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>3182–3194.</para>
          </listitem>
          <listitem id="ch0082s0000li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">Chalker VJ, Pereyre S, Dumke R, Winchell J, Khosla P, Sun H, Yan C, Vink C, Bébéar C.</emphasis> 2015. International <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> typing study: interpretation of <citetitle><emphasis>M. pneumoniae</emphasis></citetitle> multilocus variable-number tandem-repeat analysis. <citetitle><emphasis>New Microbes New Infect</emphasis></citetitle> <emphasis role="strong">7:</emphasis>37–40.</para>
          </listitem>
          <listitem id="ch0082s0000li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Férandon C, Peuchant O, Renaudin H, Bébéar C.</emphasis> 2013. Diversity of <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> clinical isolates from Bordeaux, France, as assessed by multiple-locus variable-number tandem repeat analysis. <citetitle><emphasis>BMC Microbiol</emphasis></citetitle> <emphasis role="strong">13:</emphasis>120.</para>
          </listitem>
          <listitem id="ch0082s0000li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">Jironkin A, Brown RJ, Underwood A, Chalker VJ, Spiller OB.</emphasis> 2016. Genomic determination of minimum multi-locus sequence typing schemas to represent the genomic phylogeny of <citetitle><emphasis>Mycoplasma hominis. BMC Genomics</emphasis></citetitle> <emphasis role="strong">17:</emphasis>964.</para>
          </listitem>
          <listitem id="ch0082s0000li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">Hjorth SV, Björnelius E, Lidbrink P, Falk L, Dohn B, Berthelsen L, Ma L, Martin DH, Jensen JS.</emphasis> 2006. Sequence-based typing of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> reveals sexual transmission. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>2078–2083.</para>
          </listitem>
          <listitem id="ch0082s0000li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Musatovova O, Herrera C, Baseman JB.</emphasis> 2006. Proximal region of the gene encoding cytadherence-related protein permits molecular typing of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> clinical strains by PCR-restriction fragment length polymorphism. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44</emphasis><emphasis role="strong">:</emphasis>598–603.</para>
          </listitem>
          <listitem id="ch0082s0000li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Ma L, Taylor S, Jensen JS, Myers L, Lillis R, Martin DH.</emphasis> 2008. Short tandem repeat sequences in the <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> genome and their use in a multilocus genotyping system. <citetitle><emphasis>BMC Microbiol</emphasis></citetitle> <emphasis role="strong">8:</emphasis>130.</para>
          </listitem>
          <listitem id="ch0082s0000li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">Waites KB, Talkington DF.</emphasis> 2004. <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> and its role as a human pathogen. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">17</emphasis><emphasis role="strong">:</emphasis>697–728.</para>
          </listitem>
          <listitem id="ch0082s0000li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">Alexander TS, Gray LD, Kraft JA, Leland DS, Nikaido MT, Willis DH.</emphasis> 1996. Performance of Meridian ImmunoCard Mycoplasma test in a multicenter clinical trial. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">34:</emphasis>1180–1183.</para>
          </listitem>
          <listitem id="ch0082s0000li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">Echevarría JM, León P, Balfagón P, López JA, Fernández MV.</emphasis> 1990. Diagnosis of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> infection by microparticle agglutination and antibody-capture enzyme-immunoassay. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">9</emphasis><emphasis role="strong">:</emphasis>217–220.</para>
          </listitem>
          <listitem id="ch0082s0000li0145" role="bibliographyEntry">
            <para>145.<emphasis role="strong">Lieberman D, Lieberman D, Horowitz S, Horovitz O, Schlaeffer F, Porath A.</emphasis> 1995. Microparticle agglutination versus antibody-capture enzyme immunoassay for diagnosis of community-acquired <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> pneumonia. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">14</emphasis><emphasis role="strong">:</emphasis>577–584.</para>
          </listitem>
          <listitem id="ch0082s0000li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Ozaki T, Nishimura N, Ahn J, Watanabe N, Muto T, Saito A, Koyama N, Nakane K, Funahashi K.</emphasis> 2007. Utility of a rapid diagnosis kit for <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> pneumonia in children, and the antimicrobial susceptibility of the isolates. <citetitle><emphasis>J Infect Chemother</emphasis></citetitle> <emphasis role="strong">13</emphasis><emphasis role="strong">:</emphasis>204–207.</para>
          </listitem>
          <listitem id="ch0082s0000li0147" role="bibliographyEntry">
            <para>147.<emphasis role="strong">Thacker WL, Talkington DF.</emphasis> 2000. Analysis of complement fixation and commercial enzyme immunoassays for detection of antibodies to <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> in human serum. <citetitle><emphasis>Clin Diagn Lab Immunol</emphasis></citetitle> <emphasis role="strong">7</emphasis><emphasis role="strong">:</emphasis>778–780.</para>
          </listitem>
          <listitem id="ch0082s0000li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Aubert G, Pozzetto B, Gaudin OG, Hafid J, Mbida AD, Ros A.</emphasis> 1992. Evaluation of five commercial tests: complement fixation, microparticle agglutination, indirect immunofluorescence, enzyme-linked immunosorbent assay and latex agglutination, in comparison to immunoblotting for <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> serology. <citetitle><emphasis>Ann Biol Clin (Paris)</emphasis></citetitle> <emphasis role="strong">50</emphasis><emphasis role="strong">:</emphasis>593–597.</para>
          </listitem>
          <listitem id="ch0082s0000li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Barker CE, Sillis M, Wreghitt TG.</emphasis> 1990. Evaluation of Serodia Myco II particle agglutination test for detecting <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> antibody: comparison with mu-capture ELISA and indirect immunofluorescence. <citetitle><emphasis>J Clin Pathol</emphasis></citetitle> <emphasis role="strong">43</emphasis><emphasis role="strong">:</emphasis>163–165.</para>
          </listitem>
          <listitem id="ch0082s0000li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">Beersma MF, Dirven K, van Dam AP, Templeton KE, Claas EC, Goossens H.</emphasis> 2005. Evaluation of 12 commercial tests and the complement fixation test for <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle>-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the “gold standard.” <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>2277–2285.</para>
          </listitem>
          <listitem id="ch0082s0000li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">Talkington DF, Shott S, Fallon MT, Schwartz SB, Thacker WL.</emphasis> 2004. Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> in human serum. <citetitle><emphasis>Clin Diagn Lab Immunol</emphasis></citetitle> <emphasis role="strong">11</emphasis><emphasis role="strong">:</emphasis>862–867.</para>
          </listitem>
          <listitem id="ch0082s0000li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Thacker WL, Talkington DF.</emphasis> 1995. Comparison of two rapid commercial tests with complement fixation for serologic diagnosis of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> infections. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>1212–1214.</para>
          </listitem>
          <listitem id="ch0082s0000li0153" role="bibliographyEntry">
            <para>153.<emphasis role="strong">Busson L, Van den Wijngaert S, Dahma H, Decolvenaer M, Di Cesare L, Martin A, Vasseur L, Vandenberg O.</emphasis> 2013. Evaluation of 10 serological assays for diagnosing <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> infection. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">76</emphasis><emphasis role="strong">:</emphasis>133–137.</para>
          </listitem>
          <listitem id="ch0082s0000li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">Csángó PA, Pedersen JE, Hess RD.</emphasis> 2004. Comparison of four <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> IgM-, IgG- and IgA-specific enzyme immunoassays in blood donors and patients. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">10:</emphasis>1094–1098.</para>
          </listitem>
          <listitem id="ch0082s0000li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Brown MB, Cassell GH, McCormack WM, Davis JK.</emphasis> 1987. Measurement of antibody to <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> by an enzyme-linked immunoassay and detection of class-specific antibody responses in women with postpartum fever. <citetitle><emphasis>Am J Obstet Gynecol</emphasis></citetitle> <emphasis role="strong">156</emphasis><emphasis role="strong">:</emphasis>701–708.</para>
          </listitem>
          <listitem id="ch0082s0000li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Brown MB, Cassell GH, Taylor-Robinson D, Shepard MC.</emphasis> 1983. Measurement of antibody to <citetitle><emphasis>Ureaplasma urealyticum</emphasis></citetitle> by an enzyme-linked immunosorbent assay and detection of antibody responses in patients with nongonococcal urethritis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">17</emphasis><emphasis role="strong">:</emphasis>288–295.</para>
          </listitem>
          <listitem id="ch0082s0000li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Lo SC, Wang RY, Grandinetti T, Zou N, Haley CL, Hayes MM, Wear DJ, Shih JW.</emphasis> 2003. <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> lipid-associated membrane protein antigens for effective detection of <citetitle><emphasis>M. hominis</emphasis></citetitle>-specific antibodies in humans. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">36:</emphasis>1246–1253.</para>
          </listitem>
          <listitem id="ch0082s0000li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Furr PM, Taylor-Robinson D.</emphasis> 1984. Microimmunofluorescence technique for detection of antibody to <citetitle><emphasis>Mycoplasma genitalium. J Clin Pathol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>1072–1074.</para>
          </listitem>
          <listitem id="ch0082s0000li0159" role="bibliographyEntry">
            <anchor id="ch0082s0000a0111"/>
            <para>159.<emphasis role="strong">Taylor-Robinson D.</emphasis> 1989. Genital mycoplasma infections. <citetitle><emphasis>Clin Lab Med</emphasis></citetitle> <emphasis role="strong">9</emphasis><emphasis role="strong">:</emphasis>501–523.</para>
          </listitem>
          <listitem id="ch0082s0000li0160" role="bibliographyEntry">
            <para>160.<emphasis role="strong">Møller BR, Taylor-Robinson D, Furr PM.</emphasis> 1984. Serological evidence implicating <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> in pelvic inflammatory disease. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">i:</emphasis>1102–1103.</para>
          </listitem>
          <listitem id="ch0082s0000li0161" role="bibliographyEntry">
            <para>161.<emphasis role="strong">Baseman JB, Cagle M, Korte JE, Herrera C, Rasmussen WG, Baseman JG, Shain R, Piper JM.</emphasis> 2004. Diagnostic assessment of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> in culture-positive women. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42</emphasis><emphasis role="strong">:</emphasis>203–211.</para>
          </listitem>
          <listitem id="ch0082s0000li0162" role="bibliographyEntry">
            <para>162.<emphasis role="strong">Kenny GE, Cartwright FD, Roberts MC.</emphasis> 1986. Agar dilution method for determination of antibiotic susceptibility of <citetitle><emphasis>Ureaplasma urealyticum. Pediatr Infect Dis</emphasis></citetitle> <emphasis role="strong">5</emphasis>(Suppl)<emphasis role="strong">:</emphasis>S332–S334.</para>
          </listitem>
          <listitem id="ch0082s0000li0163" role="bibliographyEntry">
            <para>163.<emphasis role="strong">Waites KB, Crabb DM, Duffy LB, Cassell GH.</emphasis> 1997. Evaluation of the Etest for detection of tetracycline resistance in <citetitle><emphasis>Mycoplasma hominis. Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">27</emphasis><emphasis role="strong">:</emphasis>117–122.</para>
          </listitem>
          <listitem id="ch0082s0000li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Waites KB, Canupp KC, Kenny GE.</emphasis> 1999. In vitro susceptibilities of <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> to six fluoroquinolones as determined by E test. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">43:</emphasis>2571–2573.</para>
          </listitem>
          <listitem id="ch0082s0000li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Dósa E, Nagy E, Falk W, Szöke I, Ballies U.</emphasis> 1999. Evaluation of the Etest for susceptibility testing of <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> and <citetitle><emphasis>Ureaplasma urealyticum. J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">43</emphasis><emphasis role="strong">:</emphasis>575–578.</para>
          </listitem>
          <listitem id="ch0082s0000li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">CLSI.</emphasis> 2011. <citetitle><emphasis>Methods for Antimicrobial Susceptibility Testing of Human Mycoplasmas; Approved Guideline CLSI Document M43-A.</emphasis></citetitle> Clinical and Laboratory Standards Institute, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0082s0000li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Beeton ML, Spiller OB.</emphasis> 2017. Antibiotic resistance among <citetitle><emphasis>Ureaplasma</emphasis></citetitle> spp. isolates: cause for concern? <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">72</emphasis><emphasis role="strong">:</emphasis>330–337.</para>
          </listitem>
          <listitem id="ch0082s0000li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB.</emphasis> 2009. Emerging macrolide resistance in <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> in children: detection and characterization of resistant isolates. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">28</emphasis><emphasis role="strong">:</emphasis>693–696.</para>
          </listitem>
          <listitem id="ch0082s0000li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Wolff BJ, Thacker WL, Schwartz SB, Winchell JM.</emphasis> 2008. Detection of macrolide resistance in <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> by real-time PCR and high-resolution melt analysis. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">52:</emphasis>3542–3549.</para>
          </listitem>
          <listitem id="ch0082s0000li0170" role="bibliographyEntry">
            <para>170.<emphasis role="strong">Peuchant O, Ménard A, Renaudin H, Morozumi M, Ubukata K, Bébéar CM, Pereyre S.</emphasis> 2009. Increased macrolide resistance of <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> in France directly detected in clinical specimens by real-time PCR and melting curve analysis. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">64:</emphasis>52–58.</para>
          </listitem>
          <listitem id="ch0082s0000li0171" role="bibliographyEntry">
            <para>171.<emphasis role="strong">Touati A, Peuchant O, Jensen JS, Bébéar C, Pereyre S.</emphasis> 2014. Direct detection of macrolide resistance in <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> isolates from clinical specimens from France by use of real-time PCR and melting curve analysis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>1549–1555.</para>
          </listitem>
          <listitem id="ch0082s0000li0172" role="bibliographyEntry">
            <para>172.<emphasis role="strong">Twin J, Jensen JS, Bradshaw CS, Garland SM, Fairley CK, Min LY, Tabrizi SN.</emphasis> 2012. Transmission and selection of macrolide resistant <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> infections detected by rapid high resolution melt analysis. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e35593.</para>
          </listitem>
          <listitem id="ch0082s0000li0173" role="bibliographyEntry">
            <para>173.<emphasis role="strong">Wold C, Sorthe J, Hartgill U, Olsen AO, Moghaddam A, Reinton N.</emphasis> 2015. Identification of macrolide-resistant <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> using real-time PCR. <citetitle><emphasis>J Eur Acad Dermatol Venereol</emphasis></citetitle> <emphasis role="strong">29:</emphasis>1616–1620.</para>
          </listitem>
          <listitem id="ch0082s0000li0174" role="bibliographyEntry">
            <para>174.<emphasis role="strong">Salado-Rasmussen K, Jensen JS.</emphasis> 2014. <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> testing pattern and macrolide resistance: a Danish nationwide retrospective survey. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">59:</emphasis>24–30.</para>
          </listitem>
          <listitem id="ch0082s0000li0175" role="bibliographyEntry">
            <para>175.<emphasis role="strong">Dionne-Odom J, Geisler WM, Aaron KJ, Waites KB, Westfall AO, Van Der Pol B, Xiao L.</emphasis> 2017. High prevalence of multidrug-resistant <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> in HIV-infected men who have sex with men in Alabama. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">66:</emphasis>796–798.</para>
          </listitem>
          <listitem id="ch0082s0000li0176" role="bibliographyEntry">
            <para>176.<emphasis role="strong">Morinaga Y, Suzuki H, Notake S, Mizusaka T, Uemura K, Otomo S, Oi Y, Ushiki A, Kawabata N, Kameyama K, Morishita E, Uekura Y, Sugiyama A, Kawashima Y, Yanagihara K.</emphasis> 2020. Evaluation of GENECUBE Mycoplasma for the detection of macrolide-resistant <citetitle><emphasis>Mycoplasma pneumoniae. J Med Microbiol</emphasis></citetitle> <emphasis role="strong">69:</emphasis>1346–1350.</para>
          </listitem>
          <listitem id="ch0082s0000li0177" role="bibliographyEntry">
            <para>177.<emphasis role="strong">Wagner K, Imkamp F, Pires VP, Keller PM.</emphasis> 2019. Evaluation of Lightmix Mycoplasma macrolide assay for detection of macrolide-resistant <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> in pneumonia patients. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> 25<emphasis role="strong">:</emphasis>383.e5–383.e7.</para>
          </listitem>
          <listitem id="ch0082s0000li0178" role="bibliographyEntry">
            <para>178.<emphasis role="strong">Tabrizi SN, Su J, Bradshaw CS, Fairley CK, Walker S, Tan LY, Mokany E, Garland SM.</emphasis> 2017. Prospective evaluation of ResistancePlus MG, a new multiplex quantitative PCR assay for detection of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> and macrolide resistance. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>1915–1919.</para>
          </listitem>
          <listitem id="ch0082s0000li0179" role="bibliographyEntry">
            <para>179.<emphasis role="strong">Le Roy C, Bébéar C, Pereyre S.</emphasis> 2020. Clinical evaluation of three commercial PCR assays for the detection of macrolide resistance in <citetitle><emphasis>Mycoplasma genitalium. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>e01478-19.</para>
          </listitem>
          <listitem id="ch0082s0000li0180" role="bibliographyEntry">
            <para>180.<emphasis role="strong">Le Roy C, Bébéar C, Pereyre S.</emphasis> 2021. Performance of three commercial molecular diagnostic assays for the simultaneous detection of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> and macrolide resistance. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>e00020-21.</para>
          </listitem>
          <listitem id="ch0082s0000li0181" role="bibliographyEntry">
            <para>181.<emphasis role="strong">Waites KB, Ratliff A, Crabb DM, Xiao L, Qin X, Selvarangan R, Tang YW, Zheng X, Dien Bard J, Hong T, Prichard M, Brooks E, Dallas S, Duffy L, Mixon E, Fowler KB, Atkinson TP.</emphasis> 2019. Macrolide-resistant <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> in the United States as determined from a national surveillance program. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>e00968-19.</para>
          </listitem>
          <listitem id="ch0082s0000li0182" role="bibliographyEntry">
            <para>182.<emphasis role="strong">Rothstein TE, Cunningham SA, Rieke RA, Mainella JM, Mutchler MM, Patel R.</emphasis> 2022. Macrolide resistance in <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle>, Midwestern United States, 2014 to 2021. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">66:</emphasis>e02432-21.</para>
          </listitem>
          <listitem id="ch0082s0000li0183" role="bibliographyEntry">
            <para>183.<emphasis role="strong">Meyer PM, Beeton ML, Uldum SA, Bossuyt N, Vermeulen M, Loens K, Pereyre S, Bébéar C, Keše D, Day J, Afshar B, Chalker VJ, Greub G, Nir-Paz R, Dumke R, ESGMAC–MyCOVID Study Team.</emphasis> <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> detections before and during the COVID-19 pandemic: results of a global survey, 2017–2021. <citetitle><emphasis>Euro Surveill</emphasis></citetitle> <emphasis role="strong">27</emphasis>:2100746.</para>
          </listitem>
          <listitem id="ch0082s0000li0184" role="bibliographyEntry">
            <para>184.<emphasis role="strong">Atkinson TP, Boppana S, Theos A, Clements LS, Xiao L, Waites K.</emphasis> 2011. Stevens-Johnson syndrome in a boy with macrolide-resistant <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> pneumonia. <citetitle><emphasis>Pediatrics</emphasis></citetitle> <emphasis role="strong">127:</emphasis>e1605–e1609.</para>
          </listitem>
          <listitem id="ch0082s0000li0185" role="bibliographyEntry">
            <para>185.<emphasis role="strong">Waites KB, Crabb DM, Duffy LB, Jensen JS, Liu Y, Paukner S.</emphasis> 2017. In vitro Activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China. Antimicrob Agents Chemother <emphasis role="strong">61:</emphasis>e02008-16.</para>
          </listitem>
          <listitem id="ch0082s0000li0186" role="bibliographyEntry">
            <para>186.<emphasis role="strong">Xiao L, Crabb DM, Duffy LB, Paralanov V, Glass JI, Hamilos DL, Waites KB.</emphasis> 2011. Mutations in ribosomal proteins and ribosomal RNA confer macrolide resistance in human <citetitle><emphasis>Ureaplasma</emphasis></citetitle> spp. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">37</emphasis><emphasis role="strong">:</emphasis>377–379.</para>
          </listitem>
          <listitem id="ch0082s0000li0187" role="bibliographyEntry">
            <para>187.<emphasis role="strong">Beeton ML, Chalker VJ, Maxwell NC, Kotecha S, Spiller OB.</emphasis> 2009. Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">53:</emphasis>2020–2027.</para>
          </listitem>
          <listitem id="ch0082s0000li0188" role="bibliographyEntry">
            <para>188.<emphasis role="strong">Meygret A, Le Roy C, Renaudin H, Bébéar C, Pereyre S.</emphasis> 2018. Tetracycline and fluoroquinolone resistance in clinical <citetitle><emphasis>Ureaplasma</emphasis></citetitle> spp. and <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> isolates in France between 2010 and 2015. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">73:</emphasis>2696–2703.</para>
          </listitem>
          <listitem id="ch0082s0000li0189" role="bibliographyEntry">
            <para>189.<emphasis role="strong">Jensen JS, Cusini M, Gomberg M, Moi H, Wilson J, Unemo M.</emphasis> 2022. 2021 European guideline on the management of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> infections. <citetitle><emphasis>J Eur Acad Dermatol Venereol</emphasis></citetitle> <emphasis role="strong">36</emphasis><emphasis role="strong">:</emphasis>641–650.</para>
          </listitem>
          <listitem id="ch0082s0000li0190" role="bibliographyEntry">
            <para>190.<emphasis role="strong">Machalek DA, Tao Y, Shilling H, Jensen JS, Unemo M, Murray G, Chow EPF, Low N, Garland SM, Vodstrcil LA, Fairley CK, Hocking JS, Zhang L, Bradshaw CS.</emphasis> 2020. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle>: a systematic review and meta-analysis. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">20:</emphasis>1302–1314.</para>
          </listitem>
          <listitem id="ch0082s0000li0191" role="bibliographyEntry">
            <para>191.<emphasis role="strong">Getman D, Jiang A, O’Donnell M, Cohen S.</emphasis> 2016. <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> prevalence, coinfection, and macrolide antibiotic resistance frequency in a multicenter clinical study cohort in the United States. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>2278–2283.</para>
          </listitem>
          <listitem id="ch0082s0000li0192" role="bibliographyEntry">
            <para>192.<emphasis role="strong">Berçot B, Charreau I, Rousseau C, Delaugerre C, Chidiac C, Pialoux G, Capitant C, Bourgeois-Nicolaos N, Raffi F, Pereyre S, Le Roy C, Senneville E, Meyer L, Bébéar C, Molina JM, Group AIS, ANRS IPERGAY Study Group.</emphasis> 2021. High prevalence and high rate of antibiotic resistance of <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> infections in men who have sex with men: a substudy of the ANRS IPERGAY Pre-exposure Prophylaxis Trial. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">73:</emphasis>e2127–e2133.</para>
          </listitem>
          <listitem id="ch0082s0000li0193" role="bibliographyEntry">
            <anchor id="ch0082s0000a0112"/>
            <para>193.<emphasis role="strong">Palich R, Gardette M, Bébéar C, Caumes É, Pereyre S, Monsel G.</emphasis> 2021. Initial failure of pristinamycin treatment in a case of multidrug-resistant <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> urethritis eventually treated by sequential therapy. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">48:</emphasis>e163–e164.</para>
          </listitem>
          <listitem id="ch0082s0000li0194" role="bibliographyEntry">
            <para>194.<emphasis role="strong">Duffy L, Glass J, Hall G, Avery R, Rackley R, Peterson S, Waites K.</emphasis> 2006. Fluoroquinolone resistance in <citetitle><emphasis>Ureaplasma parvum</emphasis></citetitle> in the United States. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>1590–1591.</para>
          </listitem>
          <listitem id="ch0082s0000li0195" role="bibliographyEntry">
            <para>195.<emphasis role="strong">Xiao L, Crabb DM, Duffy LB, Paralanov V, Glass JI, Waites KB.</emphasis> 2012. Chromosomal mutations responsible for fluoroquinolone resistance in <citetitle><emphasis>Ureaplasma</emphasis></citetitle> species in the United States. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>2780–2783.</para>
          </listitem>
          <listitem id="ch0082s0000li0196" role="bibliographyEntry">
            <para>196.<emphasis role="strong">Bébéar CM, Renaudin H, Charron A, Clerc M, Pereyre S, Bébéar C.</emphasis> 2003. DNA gyrase and topoisomerase IV mutations in clinical isolates of <citetitle><emphasis>Ureaplasma</emphasis></citetitle> spp. and <citetitle><emphasis>Mycoplasma hominis</emphasis></citetitle> resistant to fluoroquinolones. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">47:</emphasis>3323–3325.</para>
          </listitem>
          <listitem id="ch0082s0000li0197" role="bibliographyEntry">
            <para>197.<emphasis role="strong">Couldwell DL, Tagg KA, Jeoffreys NJ, Gilbert GL.</emphasis> 2013. Failure of moxifloxacin treatment in <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> infections due to macrolide and fluoroquinolone resistance. <citetitle><emphasis>Int J STD AIDS</emphasis></citetitle> <emphasis role="strong">24</emphasis><emphasis role="strong">:</emphasis>822–828.</para>
          </listitem>
          <listitem id="ch0082s0000li0198" role="bibliographyEntry">
            <para>198.<emphasis role="strong">Workowski KABL, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA.</emphasis> 2021. Sexually transmitted infections treatment guidelines, 2021. <citetitle><emphasis>MMWR Recomm Rep</emphasis></citetitle> <emphasis role="strong">70:</emphasis>1–187.</para>
          </listitem>
          <listitem id="ch0082s0000li0199" role="bibliographyEntry">
            <para>199.<emphasis role="strong">Glaser AM, Geisler WM, Ratliff AE, Xiao L, Waites KB, Gaisa M.</emphasis> 2019. Two cases of multidrug-resistant genitourinary <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> infection successfully eradicated with minocycline. <citetitle><emphasis>Int J STD AIDS</emphasis></citetitle> <emphasis role="strong">30</emphasis><emphasis role="strong">:</emphasis>512–514.</para>
          </listitem>
          <listitem id="ch0082s0000li0200" role="bibliographyEntry">
            <para>200.<emphasis role="strong">Bradshaw CS, Jensen JS, Waites KB.</emphasis> 2017. New horizons in <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> treatment. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">216</emphasis>(Suppl_2)<emphasis role="strong">:</emphasis>S412–S419.</para>
          </listitem>
          <listitem id="ch0082s0000li0201" role="bibliographyEntry">
            <para>201.<emphasis role="strong">Leal SMJ, Waites KB.</emphasis> 2022. <citetitle><emphasis>Mycoplasma</emphasis></citetitle> and <citetitle><emphasis>Ureaplasma. In</emphasis></citetitle> Cunha CB (ed), <citetitle><emphasis>Schlossberg’s Clinical Infectious Disease</emphasis></citetitle>, 3rd ed. Cambridge Universty Press, Cambridge, UK.</para>
          </listitem>
          <listitem id="ch0082s0000li0202" role="bibliographyEntry">
            <para>202.<emphasis role="strong">Soni S, Horner P, Rayment M, Pinto-Sander N, Naous N, Parkhouse A, Bancroft D, Patterson C, Fifer H.</emphasis> 2019. British Association for Sexual Health and HIV national guideline for the management of infection with <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle> (2018). <citetitle><emphasis>Int J STD AIDS</emphasis></citetitle> <emphasis role="strong">30</emphasis><emphasis role="strong">:</emphasis>938–950.</para>
          </listitem>
          <listitem id="ch0082s0000li0203" role="bibliographyEntry">
            <para>203.<emphasis role="strong">Tully JG, Taylor-Robinson D, Rose DL, Cole RM, Bove JM.</emphasis> 1983. <citetitle><emphasis>Mycoplasma genitalium</emphasis></citetitle>, a new species from the human urogenital tract. <citetitle><emphasis>Int J Syst Bacteriol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>387–396.</para>
          </listitem>
        </itemizedlist>
      </sect2>
    </sect1>
  </chapter>
